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Resumo 
 
Em 2018, o cancro colorectal (CRC) continua a ser o segundo tipo de cancro mais mortal, com 
881,00 mortes dos 1.8 milhões de novos casos. A deteção de estádios avançados tem mais 
probabilidade de desenvolver recorrências, mesmo após o tratamento, o que leva à necessidade 
de criar um novo sistema para a deteção de estádios iniciais. Assim, compreender a biologia e a 
descoberta de bio marcadores são etapas importantes na investigação do cancro. 
 Vários estudos sobre glicosilação associada ao cancro revelaram que a glicosilação aberrante é 
uma característica universal em várias fases da transformação maligna e progressão tumoral. A 
glicosilação aberrante está associada com tempos de sobrevivência inferiores, progressão tumoral 
e metástase, nomeadamente, a sobre expressão dos antigénios Thomsen-nouvelle (Tn)-, T-, e 
sialil-T (sT). Os principais portadores dos antigénios sT e sTn identificados são a mucina MUC1 
e a glicoproteina CD44v6. Por outro lado, os antigénios de Lewis e os seus derivados sialilados 
(Lex/sLex and Lea/sLeA) são os epitopos associados ao cancro mais proeminentes, em ambos as 
glicoproteínas e glicolípidos, já que a sua sobre expressão está relacionada com transformações 
malignas no CRC e pode levar a uma maior adesão e motilidade das células tumorais, resultando 
em metástase. 
O projeto tem como objetivos descobrir novos bio marcadores com potencial para a deteção 
precoce de CRC e avaliar o potencial terapêuticos de anticorpos contra antigénios associados ao 
CRC, nomeadamente contra antigénios de Lewis, Tn, T- e sT. Pela mesma razão, glicoproteínas, 
como a MUC1, CAE e CD44 vão ser estudadas para o desenvolvimento e produção de novos 
anticorpos monoclonais.  
Após a validação de bio marcadores, a tecnologia de hibridoma foi escolhida para produzir novos 
anticorpos contra sLe e/ou CD44, imunizando murganhos diretamente com proteínas de linhas 
celulares cancerígenas. O hibridoma contra CD44 mostrou marcação contra CD44 e sLex/a e foi 
realizada uma triagem adicional. A segunda linha de hibridoma contra antigénios sLe também 
mostrou positividade contra vários lizados celulares totais de células de CRC. Dois clones foram 
selecionados para caracterização adicional. Os clones irão ser validados para a deteção precoce 
ou, potencialmente, tratamento de CRC.  
Palavras-chave: Glicosilação, Cancro Colorectal, sialil Lewis, CD44, E-selectina, biomarcador 
tumoral, deteção precoce, anticorpos monoclonais, tecnologia de hibridoma, investigação 
translacional. 
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Abstract 
 
In 2018, colorectal cancer (CRC) remains the second deadliest kind of cancer with 881,00 deaths 
of the 1.8 million new cases. Late stages detection is more likely to develop recurrences, even 
after treatment, leading to the necessity to create a new system to early stages detection. Thus, 
understanding the biology of the cancer and biomarker discovery are important steps in cancer 
research. Several studies on cancer-associated glycosylation revealed that aberrant glycosylation 
is a universal feature in various steps of malignant transformation and tumour progression. 
Aberrant glycosylation is associated with poor survival, cancer progression, and metastasis, such 
as overexpression of Thomsen-nouvelle (Tn)-, T-, and sialyl-T (sT) antigens. Main carriers of sT- 
and sTn-antigens were identified as the mucin MUC1 and CD44v6. On the other hand, the Lewis 
antigens and their sialylated derives (Lex/sLex and Lea/sLeA) are the most prominent cancer-
associated epitopes on both glycoproteins and glycolipids, since their overexpression is related to 
CRC malignant transformations and may lead to increased tumour cell adhesion and motility, 
thereby resulting in metastasis. 
The project aims to discover new potential biomarkers for CRC early detection and to evaluate 
the therapeutic potential of antibodies against CRC-associated antigens, namely against Lewis 
antigens and Thomsen-nouvelle (Tn)-, T-, and sialyl-T (sT) antigens. For the same reason 
glycoproteins, such as MUC1, CAE and CD44 will be studied for the development of novel 
monoclonal antibody production.  
After biomarker validation, hybridoma technology has been chosen to produce novel antibodies 
against, sLe and/or CD44, immunizing the mice directly with cancer cell lines proteins. The 
hybridoma against CD44 show staining against CD44 and sLex/a and further screening must be 
performed. The second hybridoma line against sLe antigens also shows positivity against different 
total cell lysate of CRC cells.  Two clones have been selected for further characterization. The 
clones will be validated either for CRC early diagnosis or CRC treatment potential. 
Keywords: Glycosylation, Colorectal cancer, sialyl Lewis, CD44, E-selectin, cancer biomarker, 
early diagnosis, monoclonal antibodies, hybridoma technology, translational research 
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structure with the intent to reduce immune response and increase efficacy. d) humanization of 
the antibody sequence and e) creation of shorter fragments have been the most successful 
modification up to the date. ........................................................................................................ 48 
 Figure 3.1Colorectal cell lines calculation of doubling time, glycan dependent. Cell lines were 
equally distributed in culture and analysed at the same time of the day for 10 days. Dots represent 
day of harvest while continuous dotted lines show trend lines of growth. In A) HT29 and HT29 
transfected with FUT6 gene shows an increase of almost 2x of doubling time, contrasted by 
results in B) were differences between SW620 and SW620 FUT6 are almost null. In C) increase of 
doubling time from SW48 to SW48 ST6Gal1 is shown, while in D) decrease of cell growth between 
SW948 and SW948 St6Gal1 has been revealed. .......................................................................... 83 
 Figure 3.2 Comparing of CRC growth rating stage dependent. Analysis show that LS174T and 
SW948, of stage II, have a slower doubling time compared to HT29, SW48 and SW620 of stage 
III. ................................................................................................................................................. 84 
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 Figure 3.3 Representation of median fluorescence intensity (MFI) of different antigens 
extracellular expression. The antigen tested are sLex/a, Ley, Lex, Tn, sTn, CEA and CD44. Different 
colon cell lines (A-F) have been tested in order to look for a potential biomarker and to find 
correlation between cancer grades and antigens expression.  In A) normal colon CCD841Con 
presents high expression of CD44 but none of aberrant glycosylation. Grade 1 B) LS174T presents 
high level of CD44, of Tn and sLex/a antigens. In grade 1 C) HT29and its correlate FUT6 transfected 
cell lines, is maintained high expression in sLex/a antigens but a moderate expression of CD44 
antigen. In grade 3 D) SW948 and its corresponding ST6Gal1 transduced cell lines, shows high 
expression in CD44, in Lex and a relative low expression in CEA and sLex/a antigens. In E) SW48 and 
the transduced ST6Gal1 maintain a low signal in Lex and relatively low CD44. In F) grade 4 SW620 
and its relative FUT6 cell line displayed low CD44 expression contrasted by high sLex/a expression.
 ..................................................................................................................................................... 85 
 Figure 3.4 Correlation of (s)Lewis antigen expression in different stage-correlated cell lines. A-C) 
High expression of sLex/a is presented in most of the cell line studied LS174T (stage 2), HT29 and 
SW620 (stage 3). In D) lower expression of Lex is presented in SW948 (stage 2), while in E) no cell 
line responded to Ley signals. ....................................................................................................... 87 
 Figure 3.5 Differences in glycoprotein expression in different cancer stages. In A) SW948 shows a 
moderate-low expression of the CEA protein, while in B) the expression of CD44 is very high in 
CCD 841 Con and stage 2, LS174T and SW948, and is reduced in stage 3, SW48-HT29- SW620, cell 
lines. ............................................................................................................................................. 87 
 Figure 3.6 study of sLewisx/a antigens expression correlated with the CD44 glycoprotein. In the wt 
and mock HT29, sLex/a antigens are moderately expressed while the protein CD44 is almost 
absent. In the HT29 FUT6 transfected cell line, an expected increase of SLex antigens is correlated 
to a substantial increase of CD44 expression. ............................................................................. 88 
 Figure 3.7 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by HECA-452 
(1:1000). In A) LS174T presents two major bands, at >245kDa and 180>x>135; in B) HT29 FUT6 
present increase of sLex/a signal at ~135kDa and ~90 kDa and no almost signals is detected in wt 
and mock controls; in C) SW948 and 48 (wt, mock,St6Gal1) present smaller signals at ~100 kDa 
and at 75>x>55 kDa; in D) SW 48 (wt, mock, ST6Gal1) present smaller signals at ~100 kDa, at 
75>x>63 kDa; in E) SW620 wt and mock present the only band at ~100 kDa, while  FUT6 presents 
increase of expression at ~200 kDa, ~170 kDa and at ~90 kDa. .................................................. 89 
 Figure 3.8 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by anti-CD44-
hpan (1:1500. In A) LS174T presents two major bands at >135kDa and at ~90kDa, probably two 
glycosylated form. Same bands are found in HT29 wt, mock and FUT6. However, in HT29 FUT6 is 
presented a new band at ~130kDa, probably due to differences in glycosylation. In B) SW48 (wt, 
mock, ST6Gal1) reveal two bands at ~90kDa and ~75kDa, with lower signal intensity. Same 
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pattern is revealed in SW948 (wt, mock, ST6Gal1) with the exception of a consistent isoform at 
~135kDa. In D) SW620 (wt, mock) presents a band at ~50kDa probably no glycosylated. No bands 
are revealed in SW620 FUT6........................................................................................................ 90 
 Figure 3.9 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by anti-CD66e 
(1:1000). In A) LS174T presents one major band at ~200kDa, probably glycosylated. In B) HT29 
wt, mock one band at ~180kDa has been revealed but no signal is found in FUT6. In C) andD) 
SW948 and SW48 (wt, mock, ST6Gal1) reveal two bands between ~48-40 kDa, with lower signal 
intensity. In E) SW620 (wt, mock) presents a band at ~60kDa probably no glycosylated. No bands 
are revealed in SW620 FUT6........................................................................................................ 91 
 Figure 3.10 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by anti-CD15 
(1:1500). In A) LS174T presents smeared band from 180kDa down to ~50kDa. In B) HT29 (wt, 
mock) two bands at <48 kDa and one band at ~48kDa in found in FUT6. In C) SW948 and smeared 
band at 250>x>100 kDa are presented, validating results obtained by flowcytometry. In D) SW48 
(wt, mock, ST6Gal1) reveal two bands at ~180kDa and ~100kDa, with medium-high signal 
intensity. In E) SW620 (wt, mock, FUT6) no bands are revealed. ................................................ 92 
 Figure 3.11 Example of immunohistochemistry staining with different antibodies tested on same 
tissue cut from CRC patient. In tissue section in A) CEA presents high intensity and extension 
andCD44 present an intense membranal staining. In tissue section in B) Lex, sLex and sLea presents 
high extension and intensity, overlapping signals in A). In B) Ley and HECA-452 (sLex/a) present, 
respectively none and lower staining .......................................................................................... 96 
 Figure 3.12 Antigens scoring inter-correlations obtained by immunohistochemistry results of 
cohort of 40 CRC patients. Main significant correlations are found among CD15s, CA19.9 and 
HECA (**) ..................................................................................................................................... 97 
 Figure 3.13 Correlation studies between cancer staging and antigen expression. In A) increase in 
CD44 expression (extension x intensity) is correlated with significant (*) increase of cellular 
invasiveness (stages III/IV). Equally, in B) increase in Ley extension in expression is significantly (*) 
correlated with a more malignant phenotype. ............................................................................ 98 
 Figure 3.14 Correlation studies between cancer invasiveness (N) and antigen expression. In A) 
increase in CD15s (sLex) expression (extension x intensity) is correlated with significant (*) 
increase of cellular invasiveness (N>1). Equally, in B) increase in Ley extension in expression is 
significantly (**) correlated with a more malignant phenotype, in agreement with the 
aforementioned staging results. .................................................................................................. 98 
 Figure 3.15 Crosstab correlation between antigen expression and percentage of ganglion 
metastasis. In A) HECA-452 signal, which recognize sLex/a, is associated with an increase of 
ganglion metastasis.  In B) analysis of CD15s (sLex) confirmed increases of invasive behaviour in 
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62.1% of the cases. Chi-square tested confirmed significance of the test with A) p=0.03 (*) and B) 
p=0.013 (**)................................................................................................................................. 99 
 Figure 3.16 8-years overall patient survival. Expression of CD15 increase chances of OS with a 
significance of p=0.013 (**) ....................................................................................................... 100 
 Figure 3.17 Example of scratch wound assay performed with SW620 wt cell lines. The cells are 
positive for sLe antigens but have low expression of CD44 SW620 shows a most fully closure at 
the 7th day, while wounds maintained with anti-CD15s show delayed in stability. CD44 being 
mostly not expressed by the SW620, show similar closure to the negative control .................. 101 
 Figure 3.18 Comparison of wound closure of LS174T, SW48 and SW620, co-cultured with anti-
mouse II (Ctrl-), anti-CD15s (sLex) and anti-CD44-hpan (CD44). Antibodies were maintained in 
motion at 0.5µg/mL, until full wound closure or cell death.  In A) LS174T, high in sLe and CD44, at 
the 4th day show almost no closure compare to the negative control. In B) SW48 medium-low in 
sLex/a and CD44, show clear delay in closure after the 8th day. In C) SW620, low in sLe, has a 
delayed wound repair, compared not only to the negative control, but also to the samples co-
cultured with anti-CD44. In fact, this antibody appears not to affect cell migration when CD44 is 
mostly absent from cell expression............................................................................................ 102 
 Figure 3.19 Preliminary results of wound closure of LS174T  co-cultured with anti-mouse II (Ctrl-), 
anti-CA19.9 (sLea) and E-selectin-Ig (sLea/x) antibodies were maintained in motion at 0.5µg/mL, 
until full wound closure or cell death.  In A) LS174T, high in sLe, at the 4th day show almost no 
closure compare to the negative control. In B) LS174T co-cultured with E-selectin --Ig revealed 
proportional increase in wound distance, suggesting an active role of E-selectin in blocking cell 
migration. .................................................................................................................................. 103 
 Figure 3.20 Representative funnelling structure for antigen selection. In yellow are represented 
the different aberrant cancer-related glycans, in blue the glycoproteins involved in cancer 
profiling. CRC cells were tested by flow cytometry, western blot, immunohistochemistry and 
wound scratch assay. SLex/a and CD44 have been selected as the most promising biomarkers 
involved throughout different cancer stages. ............................................................................ 104 
 Figure 3.21 Schematic representation of immunoprecipitation (IP) technique. The different steps 
are described in figure. Final sample is recovered with glycine-low pH where both antibody and 
desired protein precipitate. In the final sample, pH is balanced by Tris-base solution at pH6.8 105 
 Figure 3.22 Example of IP results for HT29 FUT6 membrane protein extract. In A) precipitate with 
anti-CD44-hpan revealed two major bands in ~135kDa. IP flow through shows did not occur that 
recovery of all CD44 proteins. In B) E-selectin IP revealed two major bands at ~135kDa and a 
minor at ~100 kDa. .................................................................................................................... 105 
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 Figure 3.23 LC-MS/MS of LS174T and HT29FUT6 membrane protein E-selectin-Ig IP. In A) gel 
separation of the protein and division in 7 bands. In B) confidence of 100% CD44 human. 
Backbone of 82kDa. In C) correspondent sequence of peptides confidence. ............................. 106 
 Figure 3.24 Validation of CD44 IP as E-selectin ligand. In A) blot is stained with E-selectin Ig, and 
both CD44 IP and E-selectin-Ig IP presents signal at ~135 kDa. E-selectin-Ig IP has been used as a 
positive control. In B) qualitative signal intensity has been measured by imageJ. 135 kDa bands 
in IP CD44 and IP E-selectin, show similar intensity percentage................................................ 107 
 Figure 3.25 ELISA testing of CD44 IP. Although weak signal is revealed in the positive control (anti-
CD44-pan), positive signal for HECA-452 (sLex/a) is shown. Negative controls, respectively II anti-
mouse-HRP IgG for anti-CD44 and II anti-rat-HRP IgM, already subtracted from the absorbance 
intensity. .................................................................................................................................... 107 
 Figure 3.26 FRET representation between sLewis antigens and CD44 on LS174T cell line. In A) sLex 
donor-PE signal remained equal, while substantial increase is seen in CD44 Cy5-acceptor, 
suggesting presence of sLex on protein surface. In B) CD44-PE (donor) and sLea-PE (acceptor), 
showed increase in MFI PE-acceptor channel, indicating presence of sLea on the glycoprotein. MFI 
is normalized. ............................................................................................................................. 108 
 Figure 3.27 PNGase treatment of E-selectin-Ig IP from HT29 FUT6. In A) blot is stained with anti-
CD44-hpan and is possible to visualize a drop in signal and molecular weight from ~150 kDa to 
~120 kDa. In B) twin blot is stained with E-selectin-Ig and lost in signal is visible, confirming the 
correct enzymatic reaction. In C) relative quantification of CD44 signal is visible. Drop in intensity 
may be due to loss of glycosylation and thus antibody affinity. ................................................ 109 
 Figure 3.28 Sialidase treatment of E-selectin-Ig IP from HT29 FUT6. In A) blot is stained with anti-
CD44-hpan and is possible to increase in signal intensity. In B) twin blot is stained with E-selectin-
Ig and decrease in signal is visible. In C) relative quantification of CD44 signal is showed. Increase 
in intensity may be due to loss of glycosylation and thus antibody affinity. ............................. 110 
 Figure 3.29 Testing of LS174T supernatant for CD44 as soluble protein. Increase of supernatant 
concentration, correspond to a proportional increase in signal, correspondent to same molecular 
weight of the bands used as a control of total membrane protein LS174T. Bands are revealed at 
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 Figure 3.30Schematic representation of mice antigen immunizations. In A) CD44 IP of LS174T was 
run in native gel 8% in order to separate the protein from the antibody anti-CD44-hpan, co-
precipitated. western blot revelation was needed for identification of the correct band containing 
CD44. samples in polyacrylamide, diluted in PBS 1x, were directly injected in the mice, afterwards 
named miceCD44. in B) direct injection of LS174T total membrane lysate in the mice. antigen was 
selected based on the high expression of sLex/a glycans on Ls174T membrane. mice after 
immunization have been referred as miceLS174T ......................................................................... 112 
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 Figure 3.31 Timeline representing the different injections performed on mice during the 
immunization protocol. Two parallel protocols were performed with CD44 (A) or total membrane 
protein LS174T cells (B). Mice were immunized with CD44 extracted from LS174T mixed with 
polyacrylamide and adjuvants or immunized with total membrane extraction protein from 
LS174T. ...................................................................................................................................... 113 
 Figure 3.32 Results of mice serum tested for reactivity against CRC cell lysates. The presence of 
antibody titres of mouse sera was tested against the antigens coated and evaluated by ELISA. 
During the immunization three mouse groups were tested: Mice- (control mice with no 
immunization), MiceCD44 obtained from the mice immunized with CD44 extracted from LS174T 
cell line, and MiceLS174T immunized with LS174T total membrane protein. The coating was 
performed with LS174T (high in CD44 and E Selectin ligands), HT29 FUT6 (high in CD44) and 
SW620 wt (negative for CD44). During the different immunizations a high affinity for sera of 
MiceCD44 with HT29FUt6 and high signals with MiceLS17T were detected for the three coatings. 
Mice were sacrificed after the 5th immunization. In A) serum check at day 30; in B) serum check 
at day 60; in C) serum check at day 75; in D) serum check at day 90 and sacrifice ................... 115 
 Figure 3.33 ELISA testing of miceLS174T on E-selectin IP of LS174T cell line. Signal show positive 
reactivity against LS174T total membrane lysate, protein flow through and IP, suggesting 
presence of polyclonal specificity and aspecificity for E-selectin ligands. mice were sacrificed in 
order to detect monoclonal specific for E-selectin ligands. ....................................................... 116 
 Figure 3.34 representation of flowcytometry analysis of HT29 FUT6 and LS174T cell lines by serum 
of miceLS174T/CD44. In A) relative MFI have been plotted and shows positive reactivity by miceLS174T, 
but no visible staining was noted by serum of miceCD44. In B) flow cytometry histogram 
representation of difference in signal intensity by serum of miceLS174T/CD44. only polyclonal serum 
of miceLS174T shows partial binding. ............................................................................................ 117 
 Figure 3.35 Dot blot of miceCD44 against different concentration of total membrane protein 
(1.5/3/6 µg/µL) of: LS174T (high expression of CD44 and sLex), SW620wt (not expressing CD44) 
and HT29 FUT6 (high expression of CD44). Dot-blot showed proportional reactivity for LS174T and 
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 Figure 3.36 testing of 5 different clones obtained from miceCD44hybridoma fusion. The clones have 
been tested against LS174T (high in CD44 and E selectin ligand) and SW948 (low in CD44 and 
moderate in E-selectin ligands by ELISA). the wells were coated either by total membrane lysate 
(5 µg/mL) or with 90% confluency live cells. Membrane lysate were blocked 1% BSA; no blocking 
was performed on live cells. Results show higher binding of CD44.4 in LS174T and CD44.5 in 
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 Figure 3.37 testing of the 10 more stable clones against membrane protein lysates and 
commercial sLex/a/. In A) cell membrane lysates LS174T (high expression of CD44 and sLex), HT29 
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FUT6 (high expression of CD44), SW948 (low in CD44 and moderate in E-selectin ligands) and 
SW620wt (not expressing CD44) have been tested. Clones 2.15, 2.17, 2.24, 3.3, 3.5 show higher 
signal on LS174T membrane lysate coating rather the almost absent binding with the other cell 
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and .3, 2.4, 2.14, 2.15, 3.3, 3.5 positive for sLex/a.  In A) cell membrane lysates LS174T (high 
expression of CD44 and sLex), HT29 FUT6 (high expression of CD44), SW948 (low in CD44 and 
moderate in E-selectin ligands) and SW620wt (not expressing CD44) have been tested. clones 
2.17, 2.24, 3.3 displayed specificity for LS174T. 3.5 show binding for HT29 FUT6. In B) only 2.3 
clone show binding for sLex. In C) no clone show affinity for CD44 36kDa recombinant compared 
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LS174T (high expression of CD44 and sLex), HT29 FUT6 (high expression of CD44), SW948 (low in 
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Proportional binding of the serum is matching with CD44 expression in each cell lines. Morover, 
negative control miceCTRL serum shows no binding. On the right, serumt show intense binding with 
sLex and higher for sLea. Negative control miceCTRL serum shows no binding ............................ 123 
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total membrane lysate (5 µg/mL) or with 90% confluency live cells. Membrane lysate were 
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 Figure 3.43 The serum of miceLS174T series testing affinity for specific glycosylation. HECA-452 is 
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followed by weaker signals of clones 2, 29, 30 show high binding of LS174T (high expression of 
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AA Adenomatous polyps 
5-FU 5-fluorouracile 
Ab Antibody 
ADCC Antibody-dependent cell-mediated 
cytotoxicity 
AE1/AE3 Anti-cytokeratin 
Akt/PKB Protein kinase B 
APC Adenomatous polyposis coli 
APS Ammonium persulfate 
ATP Adenosine triphosphate 
  
 B 
  
Bcl-2 B cell lymphoma 2 
BEAMing Beads, Emulsion, Amplification and 
Magnetics 
BFB Chromosomal breakage-fusion-
bridge 
BSA Bovine serum albumin 
BSM Bovine submaxillary mucin 
  
 C 
  
C1GALT1 Β1,3-galactosyltransferase 
CA Carbohydrate antigen 
CAFs Cancer-associated fibroblasts 
CAM Cell-cell adhesion proteins 
CAR Chimeric antigen receptor 
CD Cluster of differentiation 
CDC Complement dependent cytotoxicity 
CDK Cyclin-dependent kinase 
cDNA Complementary Deoxyribonucleic 
acid 
CDRs Complementarity-determining 
regions 
CEA Carcinoembryonic antigen 
cfDNA Cell free DNA 
CIMP Cpg island methylator phenotype 
circRNAs Circular RNA 
CMS Consensus molecular subtypes 
COX2 Cyclooxygenase 2 
CRC Colorectal cancer 
CSCs Cancer stem cells cancer 
CT Computed tomography 
CTCs Circulating tumour cells 
 
CTL Cytotoxic T lymphocytes 
  
 D 
  
DAB 3,3’-diaminobenzidine 
DCBE Double contrast barium enema 
DDR DNA damage response 
DMSO Dimethyl sulfoxide 
  
 E 
  
E-Ig E-selectin-Ig 
EBV Epstein-barr virus 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EGF-R Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial to mesenchymal transition 
EpCAM Epithelial cell adhesion marker 
Eph Ephrins 
ER Endoplasmic reticulum 
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FAK Focal adhesion kinase 
FAP Familial adenomatous polyposis 
FBS Fetal bovine serum 
FC Flow cytometry 
FFPE Formalin-fixed, paraffin embedded 
FGF Fibroblast growth factor 
FIT Immunochemical faecal occult blood 
test 
FL-DNA Fluorescent long DNA 
FOBT Faecal occult blood test 
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FRET Förster resonance energy transfer 
FSC Forward scatter 
Fuc-TVIII Fucosyltransferases 8 
FUT Fucosyltransferases 
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G6PD Glucose-6-phosphate dehydrogenase 
GADPH Glyceraldehyde 3-phosphate 
dehydrogenase 
GalNAc N-acetylgalactosamine 
GALNT1 N-acetylgalactosaminyltransferases 
1 
GalT Galactosyltransferase 
GBPs Glycan binding proteins 
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GlcNAc N-acetylglucosamine 
GlcNAcTs Acetylglucosaminyltransferases 
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GnTs N-acetylglucosaminyltransferase 
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HAT Hypoxanthine-aminopterin-
thymidine 
HBP Hexosamine biosynthetic pathway 
HDI Human development index 
HER2 Human epidermal growth factor 
receptor 2 
HGPRT Hypoxanthine-guanine-
phosphoribosyl transferase 
HIF-1α Hypoxia-inducible factor 1- α 
HNPCC Hereditary nonpolyposis 
HS Heperan sulfate 
  
 I 
  
Ig Immunoglobulin 
IGF-1 Insulin-like growth factors 
IGF-1R Insulin-like growth factor 1 receptor 
IgG Immunoglobulin G 
IHC Immunohistochemistry 
IP Immunoprecipitation 
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LacNAc N-acetyllactosamine 
LC-ESI-MS/MS Liquid chromatography – 
electrospray ionization - tandem 
mass spectrometry 
LKB1 Liver kinase B1 
LTR Truncated long-terminal residues 
  
 M 
  
M2-PK Pyruvate kinase isoenzyme 2 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
mCRC CRC with metastasis 
MDSCs Myeloid-derived suppressor cells 
MET Epithelial transition 
MFI Median fluorescence intensity 
miRNA Micro RNA 
MMPs Matrix metalloproteinases 
mRNA Messenger RNA 
MS Mass spectrometry 
MSI-H Microsatellite instability 
MSS Microsatellite stability 
MTT 3-(4,5-Dimethylthiazol-2-yl-2,5-
Diphenyltetrazolium Bromide) 
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1.1. Cancer 
 
Cancer, also defined as noncommunicable disease, is the leading cause of the death worldwide. 
Thoroughly, it is the 1st or 2nd leading cause of death worldwide before the age of 70, in 91 of 
172 countries1. In the western countries, cancer premature mortality remains the highest, 
regardless the greatest advances in laboratory and clinical studies (Figure 1.1). The need for 
new strategic approaches, for the creation of personalized therapy, is driving the formation of 
a multidisciplinary environment and specialist cancer centres, with the mission to improve 
diagnostic, prognostic and therapeutic tools. 
 
 
1.1.1 Epidemiology and statistics 
 
Understanding cancer trends and statistics has become fundamental to comprehend pattern and, 
eventually, causes in cancer increase. Epidemiology programs are crucial for monitoring 
clinical data, projects and activities. Yet, collection of data worldwide is still requiring 
standardization of the process. At the date, each country provides their own data to the world 
health organization (WHO) and no unification of data was provided worldwide up to 20122. 
 
Figure 1.1 Global map ranking of cancer premature mortality worldwide up to 70 years, in 2015. The number of countries is 
included in the legend. Project GLOBOCAN 2018, adapted from World Health Organization (WHO) 
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For this reason, great efforts have been put in the collecting and re-organizing of statistical 
data, concerning cancer.  
Worth of consideration are thus the projects, GLOBOCAN and CONCORD-2. GLOBOCAN 
is an interactive web platform presenting incidence of mortality and prevalence of 36 types of 
cancers in 185 countries in the world; CONCORD-2 aims to register all cancer survival 
analysis of population-based registry data1,3. 
GLOBOCAN estimations declare that cancer incidence and mortality are rapidly growing 
worldwide with 18.1 new million cases with 9.6 million cancer deaths, in 2018, compared to 
the 14.1 cases of 2012, with 8.2 million deaths1.  
Major causes of cancer have been associated with aging, growth of population and, especially, 
socioeconomic development, defined using the human development index (HDI)1. HDI is a 
significant variable that considers the importance of national policy, in economic growth, in 
influencing development outcomes. Low-HDI are associated to developing countries and high-
HDI to developed ones. Analysis of the variable HDI on cancer data, confirmed that cancer 
incidence in high-HDI countries is 2-or 3- folds superior compared to low-HDI, but differences 
in mortality remain smaller, due to higher mortality chances in low HDI countries. Change in 
trends shows that low-HDI countries present increasing substitution of what-so-defined 
“poverty-related”/”infectious-related cancer” with cancer types ascribed to the westernization 
kind of life4,5. As a result, lung cancer remains the most diagnosed (11.6%) and the deadliest 
(18.4%) kind of cancer in both sexes worldwide, followed by breast (11.6%) and colorectal 
(10.2%), which however jumps on the second place as mortality cause with 9.2%1.  
These data suggest not only an improve in diagnostic and treatment in low-HDI, but 
also a homogenization of lifestyle worldwide. 
 
  
 3 
 
1.2. Heterogeneity  
 
Cancer is a dynamic disease and various changes can happen during tumour development. As 
a consequence, the tumour mass is often the result of a diverse collection of cells harbouring 
distinct molecular signatures with differential levels of sensitivity to treatment6. Thus, 
heterogeneity plays a major role in making cancer a major deadly disease.  
In the last 20 years, many studies have been focused in investigating the genesis of the 
heterogeneity and whether, it is the cause of cancer formation rather than a by-product of 
tumour progression. Hence, understanding the processes involved in transforming a normal 
cell into a malignant one could be the key for the creation of personalized diagnostic, 
prognostic and therapeutic tools. Here will be highlighted the tumour microenvironment and 
the hallmarks of cancer. 
 
1.2.1 The tumour microenvironment 
 
Cancer cells, through upregulation of oncogenes and downregulation of tumour suppressor, are 
the responsible entities of tumour initiation and progression. Different cells types are involved 
in cancer formation, transformation and malignancy and it is important to comprehend the 
contribution of each one of them in malignancy transformation. However, the great 
heterogeneity among same cancer types hardly explain so many sub-clonal populations.   
The personalized treatment and drug targeting are based into the recognition of crucial 
pathways and molecule recognition and it would not be possible without in-depth knowledge 
of the tumour microenvironment (TME). 
 Subsequently, the biology of a tumour can only be understood by studying the individual 
specialized cell types within it and their different behaviour7. 
 
I. Endothelial cells are the most studied class of cells in tumour environment: near the 
stroma is where the most heterogeneity is presented, and they are the cells responsible 
of tumour-associated vasculature. Many signalling pathways have been discovered 
responsible of their proliferation and differentiation among which Notch8, Neuropilin9, 
Robo10, Ephrin A/B11, Vascular endothelial growth factor (VEGF)12, angiopoietin13 and 
Fibroblast growth factor (FGF)14 signals. Most of the immunotherapies nowadays are 
based on anti -VEGF therapy. 
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II. Pericytes are mesenchymal type cells wrapped around the endothelial tubing of blood 
vessels and responsible in maintenance of a quiescent endothelium. They collaborate 
with endothelial cells to produce the vascular endothelial membrane, important for 
holding the blood pressure. 
Interestingly, it has been shown that the therapeutic inhibition of platelet-derived 
growth factor (PDGF) receptor expressed by tumour pericytes, affects pericytes and 
decreases tumour vascularization, while healthy pericytes are not affected by the 
therapy15. 
III. Cancer Stem Cells (CSCs) present in most of the tumours, may origin in different 
phases of cell development. They might be the cell-of-origin or a cell in a proliferative 
state, that undergo in tumour progression. In any case, multiple distinct classes of 
increasingly neoplastic stem cells form during cancer progression with their self-
renewal and tumour-initiating capabilities7. Their phenotypic plasticity can be the cause 
of such cellular variety in TME. As example, CSC can initiate a epithelial to 
mesenchymal transition (EMT), and be differentiated into mesenchymal, fibroblast-like 
cancer cells, behaving as cancer-associated fibroblasts (CAFs)16,17. CSCs are also 
chemotherapy resistant and they might be the reason of tumour recurrence after 
treatment. They may undergo a dormancy program, where tumour cells persist and 
suddenly erupts after years16.  
IV. Stem and progenitor cells of the tumour stroma can be recruited by the surrounding 
healthy tissue, but the bone marrow has also been identified as a key source. Some of 
the recruited cells from the bone marrow can persist in a partially-differentiate status 
exhibiting different function form the fully differentiate ones18.  
V. Cancer-associated fibroblast creates the support for the epithelial tissue. 
Reprogrammed variants of normal tissue-derived fibroblastic cells can enhance cancer 
cell proliferation, angiogenesis, and invasion and metastasis19. 
VI. Immune inflammatory cells are the most diverse type of cells in TME. They have 
shown a dual role of tumour antagonizing and tumour promoter, depending on which 
type of immune cells infiltrates the cancer mass. Cytotoxic T lymphocytes (CTLs) and 
natural killer (NK) cells are associated with tumour antagonizing abilities while 
macrophage subtypes, mast cells, and neutrophils, as well as T and B lymphocytes are 
proven to be tumour promoters20,21. They can release into the TME pro-tumour factors, 
such as epidermal growth factor (EGF), VEGF, FGF2, matrix-degrading enzymes and 
chemokines22.  
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1.2.2 Cancer evolution and Hallmarks of cancer 
 
Several theories have been proposed to explain cancer complexity and heterogeneity. 
In model of clonal evolution, sub sequential acquisition of genetic mutations and functions 
alterations, leads to a selection of sub-clones capable of co-existing in an altered tumour micro-
environment23. However, as depicted by Fouad et al. (2017), the clonal evolution theory is not 
able to explain why the alterations are undertaken in the first place24. 
In the model of stem cells, proposed by Tomasetti and Vogelstein (2015), is stated that only a 
minor number of cells, with self-renewable capacity, is capable of initiating and progressing 
tumour status25. These tumour cells have specific surface proteins (CD133, CD166, or CD44) 
and after chemotherapy have been shown to be more resistant, explaining relapse following 
treatments26.  
A third theory by Sottoriva et al. (2015), the big bang model, sustain that the fundamental 
mutations, happens early in cancer development, thus explaining why some tumour might 
overgrow without presenting metastasis and other small tumours present metastasis at early 
phases27.  
These three theories can be considered complementary one to each other and there is no doubt 
that the comprehension of tumour cell origin and heterogeneity is the key for cancer diagnosis 
and treatment.  
Subsequently, among these theories Hanahan and Weinberg (2000) followed by update in 
2011, proposed a new model, called the hallmarks of cancer 7,28.   
In their claim, cancer cells must go through 10 different transformation to form a malignant 
environment: they sustain that the passage from a normal to a malignant cell is the result of 
accumulation of defective traits, in a continuous evolution of the TME (Figure 1.2).  
In this sense, their theory has common points with the previously proposed clonal evolution.  
The hallmarks of cancers have represented the first big step towards cancer understanding and 
personalized therapy. Presently, being aware of how genetic and epigenetic alterations are 
associated with specific hallmarks of cancer, authors are completing the proposed model by 
correlating behaviour of different molecules, useful for diagnosis or treatment (i.e. miRNA29, 
targeted drug delivery30, the CRISPR generation31 and glycosylation32,33).  
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1.2.2.1 Self-Sufficiency in Growth Signals 
 
Normal cells maintain a quiescent mode until mitogenic growth signals (GS) move them into 
a proliferative status. Extracellular signals, intracellular transducer and intracellular pathways 
are the three main factors involved into cell proliferation mechanism. Alteration in any point 
can induce an uncontrolled growth. It has been shown that while normal cell cannot proliferate 
in absence of GS, tumour cells have adapted to mimic GS signals in an autocrine way: in 
glioblastomas and sarcomas, cancer cells produce PDGF and tumour growth factor  (TGF), 
two important differentiation and growth signals34. Cancer cell can also overexpress GF 
receptors often carrying tyrosine kinase property in the cytoplasmic domains, i.e. epidermal 
growth factor receptor (EGF-R-erbB) or human epidermal growth factor receptor 2 (HER2-
neu) in stomach tumours. In other occasion, cancer cells can activated a ligand-independent 
signalling by alteration of the structure of the receptor, such as the EGFR receptor cut in the 
cytoplasmic domain is always active35.  
Figure 1.2 The hallmarks of cancer.i) Sustain proliferative signals, ii) evading growth 
suppressor, iii) activating invasion and metastasis, iv) enabling replicative mortality) 
inducing angiogenesis and vi) resisting cell death represent the first six hallmarks 
theorized in 2000. In the revision of 2011, vii) deregulating cellular energetics and viii) 
avoiding immune destruction where added as emerging hallmarks. ix)Tumour 
promoting inflammation, x) genome instability and mutation are considered as tumour 
enabling characteristics. Image adapted from Hanahan and Weinberg (2011). 
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At the cytoplasmic level, tumour cells have been displayed an alteration in downstream 
pathways with SOS-Ras-Raf-MAPK (mitogen-activated protein kinase) cascade, responsible 
of activation of DNA cell proliferation signals. The alteration of the Ras protein into a 
constitutive activator of mitogenic and proliferative signals makes it a very powerful 
oncogene36. Ras can also interact directly with the survival promoter PI3 (Phosphoinositide 3-
kinase) enabling constitutive growth signals within the cells, including its key protein kinase 
B (Akt/PKB) signal transducer. When PTEN phosphatase, a catalyser of PI3 kinase product, 
phosphatidylinositol (3,4,5) trisphosphate (PIP3), is downregulated, generally by promoter 
hyper methylation, PI3K signalling is amplified inducing tumorigenesis37. The same happens 
when mTOR kinase, a coordinator of PI3K signalling, is inhibited in cancer cells38.  
TME and extracellular matrix (ECM) play an important role in activation of tumour signals. 
Successful binding of the integrins to the ECM promotes resistance to apoptosis and entrance 
to active cell cycle, while its unpairing can induce apoptosis and cell cycle arrest. Many cancer 
cells over express integrins on their cell surface39.  
A successful tumour is the one that cooperate with the microenvironment cells by inducing 
them to release growth factors28. Increase of oncogenic proliferative signals induces cell 
proliferation and tumour growth. However, it has been demonstrated that high levels of 
oncoprotein as RAS, RAF and MYC induce cellular senescence and /or apoptosis, as a 
defensive mechanism. Mice overexpressing these proteins, present cells with the typical 
senescent morphology: enlarged cytoplasm, the absence of proliferation markers 40. 
 
1.2.2.2 Insensitivity to antigrowth signals 
 
Cell machinery when in healthy status, lives in a perfect equilibrium where growth signals are 
equally important as the antigrowth signals. The antigrowth signal can act in two main point 
of a cell cycle: the G0, where the cell is forced out into a quiescent status, or the G1, where the 
cell in a post-mitotic state can proliferate or remain quiescent. Most of the antiproliferative 
signals are funnelled through the retinoblastoma protein (pRb) that in an hypo-phosphorylated 
status (Rb) can sequester the E2F transcriptional factors, fundamental to transit the cell from 
G1 to S phase28. Associated to pRb is the transforming growth factor ß (TGFß), which controls 
the phosphorylation and, thus, the activation of pRb. In some cell types, TGFß represses pro-
proliferative genes as c-myc gene and, concomitantly, activates the cyclin-dependent kinase 
(CDK) inhibitors, p15INK4B and p21 proteins: CDK is responsible to phosphorylate pRb41. 
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Alteration in any point of this cascade is responsible of inhibition of antigrowth signal and thus 
promoter of proliferation. TGFß can also activate a cell program named the EMT which confer 
the cell an high grade of malignancy42. Some cancer cell downregulate TGFß receptors by 
mutation or alteration of the structure43.Therefore, the role of the TGFß in cancer is still under 
investigation  
Protein in charge of signal transduction can be altered or downregulated in tumour cells, as 
happens with the protein Smda4 and the p15INK4B 44. Other proteins like the CDK4, can also 
change trough mutation and by not-recognition of the inhibitor p15INK4B can be constitutively 
activated, resulting in pRb constant hyperphosphorylation45. 
Proliferation by escaping of antigrowth signals can be induced into the cell before terminal 
differentiation. In this event, the protein Myc, which generally is bound to the protein Mad to 
induce differentiation, is paired to the Max protein, which complex is a proliferation inducer46. 
At the same level the inactivation of the Adenomatous Polyposis Coli (APC) /ß-catenin 
pathway is inactivated, blocking the entrance of the enterocyte to a differentiate post mitotic 
state47.  
Another aspect that leads to insensivity to antigrowth signals by cancer cells is the cell-to-cell 
contact inhibition. The tumour suppressor, Merlin, triggered by NF2 gene, is the responsible 
for coupling the E-cadherin to the tyrosine kinase receptors EGF. While straightening the bond, 
merlin is inhibiting the mitogenic signals. Thus the loss of NF2 gene in merlin functions leads 
to proliferation48. 
 
1.2.2.3 Evading apoptosis 
 
With apoptosis, cells control internal homeostasis and, in case of serious dysregulation and 
damage, promote cell death. The role of the apoptosis in cancer is still under discussion since 
in some cases has been proved to be induced by elevated levels of oncogenes signals, while, in 
cases of hyper-malignancy and resistance to therapy, it is attenuated7. It is induced by different 
signal ,which activate two main receptors: the inducers FAS and cytochrome C (present in the 
mitochondria), which activate respectively the ultimate effector of the apoptosis, the caspase-
8 and 9. Cytochrome C is activated by B cell lymphoma-2 (Bcl-2), a family of protein whose 
members are either pro (Bax, Bak, Bid, Bim) or  antiapoptotic (Bcl-2, Bcl-XL, Bcl-W)49.  
Bax and Bak share with the Bcl2-like proteins, the same BH3 motif for protein-protein 
interaction, leading to abnormal protein coupling and anti-/ and pro-apoptotic signals 
responsible of tumour development49. In a normal functioning cell, when p53 tumour 
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suppressor protein recognize a damage in the DNA, activates BH3-only protein such as Noxa, 
Puma and Bax that induce apoptosis. On the contrary, in cancer cells p53 is downregulated50.  
External survival factors such insulin-like growth factors (IGF-1) can force Bcl-2 upregulation 
and FAS death signal disruption. Other cancer cells have been shown to produce FAS ligand 
decoys in order to avoid downstream signalling51. Moreover, the PI3 kinase-AKT-PKB 
pathway in charge of antiapoptotic signals have been shown to be involved in the evasion52.  
Autophagy represents a cell-homeostasis controls mechanism, in which cellular organelles are 
broken down allowing the recycle of the metabolites. The degradation happens by the fusion 
of the autophagosome envelope vesicles with the lysosomes. It is a controlled pathway and 
PI3, AKT and mTOR kinase, stimulated by survival signals, are the responsible protein for 
blocking the autophagy program. Beclin-1 is also a very important protein, member of the 
BH3-pdomain proteins, and in stress-induced situations, such as reactive oxygen species 
(ROS), is uncouple from Bcl-2 and after liberation induces autophagy53. During radiotherapy, 
nutrient starvation and the use of cytotoxic drugs, induces high level of autophagy that 
paradoxically results in cancer-cells cytoprotection, by impaired death54.  
Necrosis have been investigated as a cancer deaths program: cells in necrosis increase 
cytoplasmic volume until membrane integrity loss. The debris liberated induce 
proinflammatory signals that recruit inflammatory cells specialized in removing the 
extracellular necrosis debris. Yet, in many tumour masses, inflammatory cells are activated by 
necrosis, promoting tumour growth angiogenesis and proliferation55. 
 
1.2.2.4 Limitless replicative potential  
 
Limitless replicative potential or cell immortalization has been evaluated has fundamental step 
in cancer malignancy.  
Cells are capable of a limited number of replicants, called doubles. A normal human cell can 
replicate from 60 to 70 times until it stops growing and begins a process called senescence. 
Curiously, when pRb and p53 tumour suppressor protein are silenced, fibroblast in culture 
avoid senescence and continue multiplying28. Yet, telomers, which are the repetition of short 
6bp at the end of each chromosome, are the key player in this mechanism. In fact, it has been 
proven that for each replication, each cell lose a part of the 3’ end of the DNA of telomers until 
the damage affects chromosomes function and bring the cell to death28. 
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Cancer cells, however, have developed different system to promote immortalization, by 
upregulating the enzyme telomerase that adds hexanucleotide at the end of the DNA. An 
alternative mechanism called alternative lengthening of telomeres, helps maintaining the 
telomerases ends by recombination-based inter-chromosomal exchange of information, named 
chromosomal breakage-fusion-bridge56,57.  
Recently, it has been associated a new telomere-independent functions and in particular its 
protein subunit telomerase reverse transcriptase (TERT). TERT can amplify the signalling 
cascade of the Wnt pathway, involved in cell migration and cancer progression, by serving as 
a cofactor of the β-catenin/LEF transcription factor complex, hence inducing proliferation and 
apoptosis resistance 58.  
 
1.2.2.5 Sustained angiogenesis 
 
Creation of new blood vessels contributes to maintain auto-sufficiency and to promote tumour 
growth. The development of the vasculature involves the birth of new endothelial cells and 
their assembly into tubes (vasculogenesis) in addition to the sprouting (angiogenesis) of new 
vessels from existing ones7. The vascularization process is controlled by balanced signals that 
can promote or silence its initiation59. One of the mechanisms is controlled by soluble factors 
and tyrosine kinase receptors on endothelial surface, where the initiating signals can be VEGF 
or FGF1/260,61. Endogenous inhibitor factors are present also in the angiogenesis process and 
they have been recognized in the trombospondin-1 (TSP-1), fragments of plasmin (angiostatin) 
and collagen 18 (endostatin)62. In most of tumour VEGF and FGF are up regulated, while the 
inhibitor factors such as trombospondin-1 and interferon ß are downregulated. P53 and Ras 
play main roles also in the vascularization processes: it has been documented that the 
downregulation of tumour suppressor p53 cause the drop of production of TSP-1 while Ras 
oncogene causes upregulation of VEGF63. Integrins, cell-matrix and cell–cell association also 
play critical roles. Interference in signals of integrins differently expressed on vascular and 
capillary surface can promote angiogenesis. Bone marrow-derived cells also contributes to 
tumorigenesis: cells of the innate immune system (macrophages, neutrophils, mast cells and 
myeloid progenitors) help in the angiogenetic switch of quiescent cells. It has been shown that 
the innate cells can contribute into the  protection of the vascular tissue from drugs targeting in 
endothelial tissue 64. 
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1.2.2.6 Tissue Invasion and Metastasis  
 
Tissue invasion and metastasis is the important final step common to all malignant tumours. 
The ability of malignant cells to detach form the primary tumour and invade new healthy sites 
in the body is the cause of the 90% of cancer death. 
The process invasion-metastasis cascade, that brings to the colonization of tumour cell into 
new tissues from the original tumour, begins with local invasion of tumour cells followed by 
intravasation of the cancer cells into the nearby lymphatic vessel. It ends with the 
extravasation/escape of the same cells from the vessel Lumina into the parenchyma of distant 
tissue and formation of micro-metastasis, which can grow into metastatic tumour. Three 
receptors are involved in this process: cadherin, integrins, lectins and cell-cell adhesion 
proteins (CAM).  
E-cadherin has the function of antigrowth signal by cell-cell interaction and activating the ß-
catenin transcription factor. Loss of E-cadherin and ß-catenin is thus a metastasis promoter. N-
cadherin which is activated in migrating neurons during embryogenesis, is upregulated in many 
invasive carcinomas65.Integrins, in charge of binding ECM, can have different function and in 
a metastasis carcinoma cells shifts the expression of integrins in favour of epithelial or stromal 
cells, rather than ECM. Upregulation and activation of protease in the ECM environment can 
cause detach from integrins and activate invasion by cancer cells in the nearby stroma, blood 
vessel and epithelial cell layers66,67. 
 Tumour cell surface lectins might be involved in cell-cell adhesion, cell attachment to 
substratum and metastasis. Selectins are a family of three “C-type” lectins that bind to 
sialofucosylated proteins or lipids in a calcium-dependent manner - E-selectin, P-selectin and 
L-selectin68. Several studies have pointed to a key role played by E-selectin-mediated 
endothelial adhesion in metastasis69.In fact, the binding efficiency of colon cancer cell lines to 
E-selectin is directly proportional to their respective metastatic potential70. 
The CAM family have been shown to be involved in a malignant transformation: N-CAM in 
cancer cells can switch from a more adherent to a less adhesive form in colorectal cancer71.  
An innovative concept raised up in the “hallmarks of cancer: the next generation” is the 
epithelial to mesenchymal transition (EMT). It refers to the capacity of epithelial tumour cells 
to acquire ability to invade, to resist apoptosis and to disseminate. The EMT transition has been 
found in most of the carcinomas and it can be activated permanently or in a transient way. The 
main transition factors responsible for the transitions are Snail, Slug, Twist and Zeb1/2: they 
 12 
 
cause the loss of adherent’s junctions with associated conversion from an epithelial to a 
fibroblastic morphology, induce resistance to apoptosis and induce the expression of 
degradation enzymes of the matrix72,73. Yet, it remains unclear the rules and the regulation of 
their expression. It appears that the transition is fundamental for the cell to proceed to 
metastasis and evidence have been shown that tumour cells and cells of neoplastic stroma 
interaction is crucial for the capability of invasive growth and metastasis74. More and more 
important is becoming the role of the immune system on the tumour growth: macrophages can 
supply matrix-degrading enzymes and stimulate EGF and be reciprocally stimulated by cancer 
cells with colony stimulating factor 1 (CSF-1), promoting an invasive behaviour20.  
The EMT transition can be reverted into mesenchymal to epithelial transition (MET) during 
initial invasion and metastasis dissemination. In fact, the adaptation of the transitioning cells 
to foreign tissue microenvironments results into successful colonization growth into macro-
tumours. However, some metastasis can remain dormant and they grow only after total 
resection of the primary tumour, suggesting a major role of the primary tumour in micro-
metastasis regulation75. Other reasons for metastasis dormancy have been directed to anti-
growth signal from the surrounding healthy cells76, tumour suppression by immune system77 
and high autophagy provoked by nutrient starvation78. It remains uncertain when and where 
the tumour acquires capacity of colonization of tissue. It may depend to selective pressure, 
where the most adapt cells survive or tissue specific colonization.  The anatomical-mechanical 
mechanisms explain the capacity of micro-metastasis of vascular and lymphatic drainage 
arresting non-specifically in the first organ encountered. On contrast, the theory of the seed 
and the soil sustain, that tumour cells have a preferable subsets of organs and their 
microenvironment24. 
 
1.2.2.7 Genome instability and mutation 
 
Genome instability has been well documented throughout the years of cancer research and 
study of mutation in the DNA has been used as promising biomarker for cancer detection. Most 
of cancer present different patterns of mutation, yet defects in the mechanisms of DNA 
maintenance and repair, as well as DNA methylation and histone modification have been 
resulted as the common feature. In general, the DNA maintenance genes, also named care-
taker of the genome, can act in three different points: repairing directly DNA damage, 
activating the repair machinery or inactivating mutagens before their effects on the DNA79. 
Loss of their function correspond to an increase in cancer manifestation and malignancy.  
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1.2.2.8 Immune escaping and tumour promoting inflammation  
 
Immunoediting is a dynamic process that describes the relation between the tumour cells and 
the immune system, and it comprises the elimination, equilibrium and escape phases 80. In the 
elimination phase tumour cells are mostly eliminated by the innate and adaptive immune 
responses to tumour cells. On the equilibrium, tumour cells that escaped the first phase do not 
present immunogenic antigens and various mutations increase overall resistance to immune 
attack. In the escaping phase tumour cells continue to grow and expand in an uncontrolled 
manner and may eventually lead to malignancies80. 
The role of the immune system in tumour progression is still under discussion. The double role 
of the immune system towards the tumour microenvironment originated two new hallmarks of 
cancer: the immune escaping mechanism of cancer cells to evade immune activation and the 
tumour promoting inflammation by the same immune cells. 
It has been shown in fact that the infiltration of immune cells in tumour environment has the 
purpose of tumour eradication. For example, colon cancer patients with a high level of 
infiltration of CTLs and NKs has been shown a better tumour prognosis and outcome81. 
 In vivo experiments in immunocompromised mice, lacking development or function of CD8+ 
CTLs, CD4+ Th1 helper T cells, or NK, had an increase tumour incidence77. At the same time, 
tumour microenvironment acquire mechanism to escape the immune system such as the 
expression of the programmed death ligand-1 (PD-L1) which inhibit the activation of T 
lymphocytes by binding the programmed death-1 receptor (PD-1)82. Stromal cells and tumour 
derived exosome can secrete immune suppressor factors by upregulation of immune suppressor 
molecules24. Other cancer cells are able to secrete TGFß, a potent immunosuppressor, which 
can paralyse CTLs and NK infiltration, or they can recruit immunosuppressive immune cells, 
such as regulatory T cells (Tregs) and myeloid-derived suppressor cells83,84. Highly 
immunogenic cells are constantly eliminated by the immune system (immunoediting) while 
weakly immunogenic cancer cells, barely recognized, are free to grow and expand into solid 
tumours, following a Darwin clone selection mechanism. 
Unexpectedly, it has been demonstrated the role of inflammation in most of tumour progression 
by supplying active biomolecule in cancer microenvironment: growth factors that sustain 
proliferative signalling, survival factors that limit cell death, proangiogenic factors, 
extracellular matrix-modifying enzymes that facilitate angiogenesis, invasion, and metastasis, 
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and inductive signals that lead to activation of EMT85. Moreover, immune cells can release 
reactive oxygen species(ROS) well known for their mutagenic potential55.  
 
1.2.2.9 Reprogramming energy metabolism 
 
Glucose and glutamine are the main nutrients and pool of carbons, fundamental for energy 
production inside the cell24.The production of energy inside the cells is conducted by firstly the 
glycolysis (or scission of the glucose molecule) in the cytoplasm, with the production of two 
molecules of pyruvate. If the reaction is conducted in aerobic condition, the pyruvate is 
converted in the mitochondria into carbon dioxide and water; if the reaction is happening in 
anaerobic conditions the pyruvate is converted into lactate or acetic acid, through 
fermentation86. The last hallmarks of cancer, also known as the “Warburg effect” is identified 
in the choice of cancer cells to conduct a glycolysis process also in anaerobic conditions, with 
high rates of glucose consumption and lactic acid production, leading to cellular acidosis87,88. 
To compensate the lower efficiency in adenosine triphosphate (ATP) production, the complex 
organic molecule that provide energy to drive many processes in living cells, the cancer cells 
upregulates the glucose transporters, i.e. GLUT1, increasing the glucose intake. This has been 
shown to be associated with activated oncogenes, i.e. RAS, MYC, and mutant tumour 
suppressors, i.e. p5389. In hypoxia condition cells upregulate the glucose transporters and 
increase the production of glycolytic pathways enzyme and this can be one of the reasons why 
cancer cells chose this mechanism of energy production. 
Cancer cell have also shown to increase the lipid production with upregulation of major 
components of fatty acyl chain synthesis, probably to favour membrane formation in a high 
proliferative environment. In this case, glutamine is captured by mitochondria and converted 
into glutamate which can be used directly or converted into α-keto-glutarate, a glucose 
alternative to produce citrate or share in fatty acid synthesis under unfavourable conditions90. 
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1.3 Colorectal cancer 
 
In 2018, colorectal cancer (CRC) remains the second deadliest kind of cancer with 881,00 
deaths of the 1.8 million new cases worldwide. The burden of colorectal cancer is supposed to 
increase up to 2.2 new million cases with 1.1 million death by 203091. The world health 
organization (WHO) has predicted an increase in diagnosed cases of 77% and increase of death 
by 80% by 2030, making CRC one of the leading burdens after cardiac diseases and lung 
cancer. 
Although the mortality rates are equivalent in low and high HDI countries, its incidence is 2-
/3- time superior in high HDI states, suggesting high correlation between lifestyle and cancer 
arisen. As support of this hypothesis, it has been shown an improvement of survival rates when 
best practice of dietary patter and life style are adopted in the developed countries92. Obesity, 
exceed in red meat consumption, smoking and low physical exercise have been correlated with 
high colorectal cancer incidence92–95. Colorectal cancer develops from the transformation of a 
normal colonic mucosa to an invasive cancer cell. This transformation can take from 10 to 15 
years and for this reason for non-hereditary kind of colorectal cancer the diagnostic routine for 
the so-called average risk population is every 10 years from 40-50 years old and every 5 years 
after 50. Age remains the major responsible of CRC carcinogenesis but in general the 70%-
80% of CRC formation are sporadic, while the rest 20%-30% have hereditary basis, of which 
familiar adenomatous polyposis (< 1%), non-polyposis hereditary CRC also known as Lynch 
syndrome (1%-5%) and MYH-gene associate polyposis (<1%) are the most characterized96. 
Three are the main pathways involved in CRC formation: the chromosomal instability which 
consists in the accumulation of mutation in oncogene e suppressor genes, that leads to 
neoplastic transformation97. The second involves defects in the DNA reparation mechanisms 
and the consequent accumulation of mutations, which occur in particular in the DNA 
microsatellites98. The third pathways involves epigenetics and hyper methylation of DNA 
nucleotides in the promoters gene, also known as CpG island methylator phenotype (CIMP)99. 
 
1.3.1 Diagnosis and biomarkers 
 
It is well documented that a good screening program combined with sensitive diagnostic 
method is the key for a reduction in CRC mortality and increase of overall survival (OS). 
Detecting CRC at the first stages correspond to an increase of 5-year survival up to the 90%, 
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significantly higher compared to the 15% when detected in the advanced stages. For this 
reason, many detection methods have been studied and tested in clinics for their specificity and 
sensitivity100. The main screening methods in use can be divided into two groups: analysis of 
biological samples, by liquid or tissue biopsy, where the doctors are looking for indicative CRC 
biomarkers and endoscopic techniques, where the identification of advanced adenomatous 
polyps (AA) pre-neoplastic lesion formation before cancer transformation is crucial for the exit 
of CRC treatment96. Main biological samples test in use are performed in faecal samples (faecal 
occult blood test, FIT: faecal (FOBT), faecal immunochemical test, faecal (FIT), faecal DNA 
and RNA, proteins), in blood/plasma (DNA, RNA, protein) and urine (Figure 1.3). 
 
 
1.3.1.1 Fecal occult blood test and fecal immunochemical test 
 
The faecal blood occult test is a non-invasive test and up-to the date is the most in use. The 
guanic (g)FOBT, based on guaiac resin, is based on the identification of the enzymatic activity 
of the peroxidase in the haemoglobin heme subunit. In fact, polyps, AA and neoplastic 
formation, leads to lesion in the internal mucosa and the identification of residual blood in the 
faeces may be an indicator of abnormal growths101. However, diet, such as red meat, could 
influence the test outcome and is important to follow dietary restrictions days before the test102.  
Figure 1.3. Schematic representation of all the alternatives test available for colorectal cancer prevetion, screening, diagnosis, 
prognosis and treatment. The red line separate symptomatic from asymptomatic patients; in green is represented the stages 
of CRC. FOBT: fecal occult blood test, FAP: familial adenomatous polyposis, HNPCC: hereditary nonpolyposis CRC. Image 
adapted from Binefa et al. (2015) 
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The test has been shown to help in mortality reduction up to 33% in cohorts of patients tested 
every year for 13 years. The identification of pre-neoplastic lesion can in fact be treat 
immediately by surgical removal, helping fighting cancer formation by early stages detection. 
gFOBT sensitivity can go from 6.2% up to 83.3% while the specificity remains more constant 
at 80%103. 
Immunochemical faecal occult blood test, in contrast with gFOBT, not only is able to give 
semi-quantitative results but is also haemoglobin specific and does not need any dietary 
restriction before the use. The FIT is based on the use of monoclonal or polyclonal specific 
antibodies against human haemoglobin and it is performed with immunoassays. Although it 
has a better sensitivity that could reach the 98%, it could have very little sensitive down to 
5.4%104. In general, the specificity remains high with a range of 77-99%104. 
 
1.3.1.2 DNA and RNA 
 
CRC can have high mitotic activity and low adhesion index, that allows the identification of 
DNA analysis of the gene alterations involved in CRC, such as the KRAS gene and hyper 
methylation. The analysis of DNA in stools (sDNA) has not shown high sensitivity since the 
amount of human DNA in the sample is around 0.01%105. Moreover, most of the sample 
contains natural inhibitors of the polymerase chain reaction (PCR), technique in use for DNA 
amplification and study106. On the other hand, the methylation status of many genes displayed 
a remarkable diagnostic accuracy for CRC and AA. A new recent technique is the fluorescent 
long DNA (FL-DNA) which allows the identification of longer segments the DNA (>150-200 
bp). These segments are generated by cancer cells avoiding the normal apoptotic pathway and 
generating longer fragments of DNA; the technique have showed a sensitivity of 80%107.   
DNA CRC markers have been searched also in the plasma/blood samples. In order to remove 
enzymes present in the blood, that could inhibit the PCR, the sample must be pre-treated108,109. 
In general, two components are studied in DNA analysis, genes mutation and/or hyper 
methylation. Many mutations have been recognized in CRC formation and among these, the 
APC and KRAS genes being the most present and the earliest formation in the tumorigeneses. 
90% of sporadic colon cancer occurs after APC mutations, and they are detected through DNA 
in plasma up to the 73% specificity110,111. 
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Other genes, such as Septin 9, are hyper methylated during colon cancer formation and the 
methylation analysis detects CRC up to 96% with a specificity range that goes from 86% up to 
100%112,113. 
RNA is also becoming more and more important in CRC diagnosis, with circular RNA 
(circRNAs) messenger RNA (mRNA) and micro RNA (miRNA). A study identified 257 new 
circRNA species of which 67 circRNAs were missing in colorectal cancer (CRC) patients 
compared with those in healthy controls. Moreover, upregulation of serum circ-KLDHC10 was 
able to distinguish CRC patients from healthy subjects, suggesting that could be promising 
non-invasive biomarker for the early detection and screening of CRC 114.  
miRNA can be downregulated or upregulated in the CRC. A study of 88 CRC identified five 
most expressed miRNAs (miRNA-10a-5p, -21-5p, -22-3p, -143-3p, and -192-5p), among a 
pool of 523 miRNAs, with good potential as diagnostic tools115. Further studies, identified 
upregulation of miRNA92a and miRNA29a and downregulation of miRNA 16-1 associated 
with CRC profile17,116. In particular, miRNA 16-1 plays a role in the epithelial-mesenchymal 
transition, contributing to the metastasis capacity of the CRC cells17.  
Combination of miRNA and mRNA gene expression could correctly distinguish high 
microsatellite instability (MSI-H) versus microsatellite stability (MSS) in colon cancer 
samples. The work suggests that the this technique may represent a general approach for 
improving bio-molecular classification of human cancer117. 
 
1.3.1.3 Proteins 
 
Proteins are considered an important biomarker, due to their stability both in faeces and blood 
sample.  
In the stool of patients are detected protein such as the pyruvate kinase isoenzyme 2 (M2-PK), 
an isoform overexpressed during cell proliferation, the S100 calcium protein and the 
metallopeptidase inhibitor 1: they have shown to have sensitivity up to 80% with a specificity 
up to 95%118,119. 
In the plasma, carcinoembryonic antigen (CEA) have been studied as a diagnostic biomarker 
for colorectal cancer, but it has not shown enough sensitives. Also, the carbohydrate antigen 
CA19.9 have been investigated with CA 50, CA 72.4 and CO29.11 with not acceptable 
diagnostic performances120. 
The study of autoantibodies is very equally relevant in CRC diagnosis (epithelial cell adhesion 
molecule, p53, p62, CEA, HER-2/neu, Ras, topoisomerase Ⅱ-alpha, histone deacetylase 3 and 
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5, ubiquitin L3, tyrosinase, tropomyosin, cyclin B1), that can be detected by 
immunoassays121,122.  
 
1.3.1.4 Cell free DNA and circulating tumour cells 
 
Innovative forms of cancer detection involve also the circulating tumour cells (CTCs) and cell 
free DNA. The latter is released by cancer cells during the cell turnover, can be isolated from 
the plasma or other biological fluids. They allow detection of cancer mutations through non-
invasive techniques.  Emulsion PCR techniques, such as the Droplet Digital PCR and the 
Beads, Emulsion, Amplification and Magnetics (BEAMing) are able to identify genomic 
alterations ranging from 0.01 to 0.001%123. 
The study of CTCs has been challenging due to difficulty in detection. In metastasis formation, 
Wnt signalling and EMT confer chemotherapeutic resistance to CTCs. Until now, CTCs are 
isolated through positive selection for an epithelial cell surface marker, epithelial cell adhesion 
marker (EpCAM), overexpressed in cancer cells. However, when the cells undergo to epithelial 
to mesenchymal (ETM) the sensitivity of the detection, decreases. New studies have revealed 
the potential of the carbohydrate sTn, for positive selection and isolation of CTCs123–126. 
 
1.3.2 Second phase of diagnosis 
 
The use of instruments to detect abnormal cellular mass is still crucial for a correct CRC 
diagnosis. In fact, after the identification of altered levels of CRC biomarkers the clinician 
performs colonoscopy (or sigmoidoscopy, if performed on the distal-left colon) and proceeded 
to tissue collection for the final tissue diagnosis, performed by the pathologist100. 
The machines used in CRC diagnostic are in order of importance and specificity: colonoscopy, 
sigmoidoscopy, computed tomography (CT) colonography and Double Contrast Barium 
Enema (DCBE)127. 
Colonoscopy is the endoscopic machine performed throughout all the intestine length. It is an 
invasive technique that require sedation, a specific diet for bowl preparation and might lead to 
secondary complications, such as perforation or bacterial infection. However, up to the date, is 
the most effective in detecting polyps >6 mm with specificity up to 98% and sensitivity up to 
99%.  
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It has been shown that a screening every 10-year performed by colonoscopy can reduce 
mortality and incidence up to 65% and 67%96. Likewise, the sigmoidoscopy is becoming of 
important use in CRC diagnostic: it is a colonoscopy performed only on the distal part of colon, 
known also as left colon96. 
Colonoscopy and sigmoidoscopy have been exhibited not only to be invasive techniques but 
they can also cause severe infection by multi-drug resistant Escherichia coli and Klebsiella 
species, with rates of 7-day post endoscopic infections varied widely, ranging from 0 to 115 
per 1000 procedures for screening colonoscopy, 0 to 132 for non-screening colonoscopy128.  
For this reason, other techniques have been experimented for CRC such as CT colonography 
and DCBE. CT colonography, remains quite invasive technique and its specificity to detect 
neoplasm is 82% but for polyps >10mm which is still inferior to the colonoscopy while the 
DCBE has shown even lower results with 48% specificity in polyps>10 mm; both the 
techniques remains expensive and they are used as complementary tests129,130.  
 
1.3.3 Colorectal cancer and stages classifiers 
 
Throughout the sample histologic analysis, it is defined the cellular origin of the tumour, the 
stage and the grade. The pathologist’s diagnosis by tissue biopsy is crucial the decision for a 
correct treatment. CRC is a very heterogeneous disease and can develop form different cellular 
subsets, however more than 99.5% are carcinomas of which 92% adenocarcinomas originating 
from the epithelial stratum of colon mucosa131. Subsequently, the pathologist defines the 
cellular grade of the cancer, which consist in the level of differentiation of the tumour cells 
from its origin, and the stage, which define the level of invasiveness of cancer. Original staging 
system is composed by stage I, where the polyps appear, stage II/III where the tumour is 
spreading and stage IV, where the tumour has started metastasis. Another important 
classificatory, named TNM, helps to for a better description of the cancer, with T describing 
the mass of the tumour, N the invasion to the lymph nodes and M eventual metastasis present. 
The TNM system contributes also to the definition of other parameters: the grade (G), the 
elevation of serum tumour markers (S), the completeness of a resection of the tumour (R), 
invasion at lymphatic vessel (L) and invasion into the veins (V)132. All the factors helps for a 
better identification of the cancer, yet other aspects of host-tumour interaction are crucial for 
the tumour microenvironment progression such as extracellular matrix, supporting stromal 
cells, and immune cells interactions131,133.  
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Broussard et al. (2011) suggested to include in the TNM scoring an evaluation of the immune 
cells in the tumour mass. In fact, they have correlated an higher infiltration of cytotoxic CD8+ 
T cell in the tumours with higher disease-free and overall survival rates133. New diagnosed 
lesions during the course of the follow-up of patients is often necessary in order to confirm the 
recurrence of the disease125,132. 
 
1.3.4 New algorithms for staging and diagnosis 
 
Because of the great heterogeneity in colorectal cancer study results, researchers have proposed 
new algorithms to find correlation among the different markers in cancer development and 
progression, useful for the choice of proper treatments. The markers would include gene 
mutation, gene expression, up-/downregulation of proteins, immune infiltration, 
hypermethylation, Chromosomal instability and drug resistance. This is how Guinney et al. 
(2015) regrouped the data by forming four consensus molecular subtypes (CMS) with 
distinguishing features. As represented in Figure 1.4, CRC has been divided in: 
CSM 1 (14%), MSI immune, characterized by an overexpression of genes involved with 
immune infiltrate combined with a strong activation of immune evasion pathways associated 
with higher MSI.  
CSM2 (37%), the canonical, shows an elevated SCNA with an upregulation of WNT and MYC 
protooncogenes activation.  
CSM3 (13%), the metabolic, with mutations in KRAS, presents an heterogeneous MSI 
associated with high metabolic activity.  
CSM4 (23%), the mesenchymal, with the worst outcome, presents activation of TGF-, 
angiogenesis and an upregulation of factors involved in the  EMT, necessary for migration and 
infiltration134. Nevertheless, a 5th subgroup containing the 13% of unclassified cases of CRC 
was later identified, suggesting the necessity of ulterior refinement of the CRC-CSMs, 
including new variables such as post-transcriptional and epigenetic factors134. 
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Trinh et al. (2016) validated the prognostic value of CRC subtyping by identifying a robust 
IHM assay for different markers, that will help to identify molecular CRC subtypes and 
uncover subtype-specific therapeutic benefit. A microarray stained for five markers (CDX2, 
FRMD6, HTR2B, ZEB1 and KER) was used. CSM1 was selected by the MSI status and the 
CSM2/3 by CDX2, a marker highly expressed in epithelial-like tumour. CSM4 were selected 
with HTR2B and FRMD6 expressed in mesenchymal like cells. To confirm the ETM 
transition, the marker ZEB1 and an anti-cytokeratin (AE1/AE3) was used to normalize for 
epithelial content. The experiment permitted to confirm the stratification of CRC groups and 
verify the therapeutic benefit for each subtype135. 
In order to find out the most valuable biomarkers and pathways for diagnosis and prognosis in 
colorectal cancer (CRC) Zangh et al. (2018) have created a CRC biomarkers database, based 
on all the publications found on CRC. The CRC biomarkers were closely related to the CRC 
initiation and progression. As a results, correlation of multiple protein biomarker of KRAS-
PTEN-STAT3-CD44-ZEB1-ZEB2-S1PR1 reveals to have most significant role in CRC 
diagnosis, such as molecular functions and cellular composition of the protein biomarkers are 
involved in CRC diagnosis, therapy and prognosis136. 
 
 
 
Figure 1.4. Molecular consensus subtypes regrouped data of algorithm analysis for CRC classification.  For each 
group is listed the percentage of frequency, genetic and epigenetic features that characterizes each subgroup. Image 
adapted from Guinney et al. (2015). 
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1.3.4 Colorectal cancer and treatment 
 
The choice of the treatment is based on cancer location, staging and identification of its 
biomarkers. When possible, colon cancer is always treated surgically, with R0 tumour mass 
resection (R0), which correspond the entire remission and removal, improving long-term 
survival from 20% up the 50% of the patients with metastasis100. R1 to microscopic residual 
tumour, R2 to macroscopic residual are also operated whenever possible137. As a prognostic 
biomarker, level of CEA is checked for cancer total remission138,139. In rectum is more difficult 
to obtain a cut with adequate distal and circumferential margins (at least 1 cm), due to the 
absence of serosa and proximity to other pelvic organs. For this reason, pre- or/post- 
chemotherapy is used as adjuvant treatment in order to increase the 10 years’ overall survival 
(OS) and progression-free survival (PFS). Conventional chemotherapeutic includes 5-FU, 
capecitabine (one fluorouracil oral prodrug), Leucovorin (5-FU and folinic acid), FOLFOX (5-
FU, folinic acid and oxaliplatin-inhibits DNA repair-), FOLFIRI (5-FU, folinic acid and 
irinotecan-topoisomerase inhibitor-) and FOLFOXIRI (5-FU, folinic acid and oxaliplatin and 
irinotecan)100,140,141. 
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1.4. Glycosylation  
 
Glycosylation is one of the most important post-translational modification on proteins and 
lipids and it influences most of the biological processes, such as  protein folding, cell adhesion, 
molecular trafficking/clearance, receptor activation, signal transduction and endocytosis146. 
The study of glycans that compose a certain cell or tissue, or glycome, has become more 
influencing with the discovery of the glycocalyx in the mid of the 20th, conferring a new role 
to the carbohydrates, known to be involved in energy generation and metabolism147. The 
glycocalyx is an assemble of glycoproteins, glycolipids and receptors-binding-glycan and it 
covers the surface of mammalian cells, as well as most of the extracellular molecules. Among 
the functions are included mechano-transduction, homeostasis, signalling and blood cell–
vessel wall interactions148. The word glycan comprehend oligosaccharide, polysaccharide, and 
carbohydrates; the structural diversity of glycans depends on several factors, namely 
differences in monosaccharide composition, glycosidic linkage, branching, the presence of 
non-carbohydrate substituted components (phosphorylation, sulfation, acetylation, etc.) and 
linkage to their aglycones (peptide, lipid, etc.)149.  
Nine monosaccharides are used in the enzymatic process of glycosylation in mammals which 
are recovered from conserved biosynthetic pathways that provides the monosaccharides150. It 
has been difficult to predict glycan’s sequences since are not directly translated from the DNA. 
In other words, glycan diversification exclusively depends on regulation, translation and 
activity of glycoenzymes. These enzymes, responsible of glycosylation processes, are divided 
into glycotransferases which synthetize sugar chains and glycosidases, which hydrolyses sugar 
bonds in the glycans structures. Both enzymes contribute to the final sugar structure and the 
paradigm one sugar one enzyme is most of the times respected; yet, glycosyltransferases can 
also act as isozymes, transferring different types of sugar to the chain.  Different enzyme can 
also compete for the same acceptor substrate and add diverse sugars with different linkages. 
Glycans can be found attached to proteins and lipids. The glycosylation process occurs in the 
lumen of the endoplasmic reticulum (ER) and in the Golgi apparatus in co-translational or post-
translational processes. Some bulky sugar is formed in the cytoplasmic and flipped inside of 
the ER, but most of the growing chain happens directly inside the ER or Golgi. The 
glycosylation process follows precise rules, where not all the monosaccharides can bind all 
lipid and protein (Figure 1.5) and the expression of many glycans has specific functions: thus, 
glycans are as universal in nature as nucleic acids, proteins, lipids and metabolites151.   
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Glycans can be attached to lipids in order to generate glycolipids, such as glycosphingolipids 
(GSLs) (Figure 1.6)152. GSLs is the major product of lipids glycosylation and include the sialic 
acid-bearing gangliosides. 50–70% of the serum proteins are also glycosylated153. Protein 
glycosylation includes N-glycans, O-glycans and glycosaminoglycans, or proteoglycan (Figure 
1.6)152. O-glycan and N-glycan is the major class of protein glycosylation and their aberration 
has vastly documented been involved with malignancy in tumour progression. For this reason, 
N- and O- glycosylation will be the major focus of this thesis. 
 
Figure 1.5 Representation of the possible linkages between sugar donors (on the left) and their respective 
protein and lipid acceptors (up-left) or/and their saccharide acceptors (up-right).α and ß correspond to the 
type of glycosidic bondage of the sugars depending on the anomeric position of the stereocenter linked though 
position 1-2. Numbers from 2 to 6 identify position on the acceptor saccharide. Image adapted from Ohtsubo 
et Marth (2006). 
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1.4.1 N-glycans 
 
N-glycans binds to the asparagine of protein by recognizing the Asn-X-Ser/Thr motif. It is 
estimated that two thirds of this consensus sequences present on the protein databased is N-
glycosylated. Some exception has been proved to be also in the Asn-X-Cys motif, given the 
cysteine present in a reduced form. All the N-glycans share a common penta-saccharides core 
region and can be divided in three main classes: i) high mannose type, in which only mannose 
residues are attached to the core, ii) the complex-type, in which “antennae” initiated by N-
acetylglucosaminyltransferases (GlcNAcTs) are attached to the core and iii) the hybrid-type, 
in which only mannose residues are attached to the Manα1–6 arm of the core and one or two 
antennae are on the Manα1–3 arm154 (Figure 1.7).  
 
Figure 1.6 Common classed of glycoconjugates in mammalian cells. N-glycans, O-glycans, GPI-anchored glycoproteins and 
glycosaminoglycans are the major class of protein linked to glycans; differs for preferences in aminoacidic linkage and 
structures. Hyaluronic acid belongs to the glycosaminoglycans family but is found free in the ECM. Glycosphingolipids 
(GSLs) are the major class of glycans bound to lipids. on the bottom-right is the coloured legend of monosaccharide 
components. image adapted from Pinho et Reis (2015) 
Figure 1.7 Three main types of N-Glycans. 
Oligomannose, complex and hybrid, share the same 
pentasaccharides core but differs for the elongation. 
Image adapted from Essential of glycobiology (2009).  
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No evidence proved that N-glycans can occur on cytoplasmic or nuclear proteins nor on the 
cytoplasmic portions of membrane proteins. The transfer happens in the luminal side of the ER 
membrane while the protein is translated on ribosomes and translocating in the ER 
membrane150. In the trans-Golgi occurs the final sugar addition: i) sugar additions to the core, 
ii) elongation of branching N-acetylglucosamine residues by sugar additions, and iii) “capping” 
or “decoration” of elongated branches. The role of different glycoenzymes is critical for the 
final differentiation of N-glycans chains (Figure 1.8). This converts the limited repertoire of 
hybrid and branched N-glycans into an extensive array of mature, complex N-glycans154.  
 
 
1.4.2 O-GalNAc glycans 
 
O- Glycans are attached to the hydroxyl oxygen of serine and threonine residues on mammal 
proteins. O-glycans are mostly covalently α-linked via an N-acetylgalactosamine (GalNAc) 
moiety to the -OH of serine or threonine by an O-glycosidic bond155. Other types of O-glycans 
include those attached via O-mannose, and the β-N-acetylglucosamine, which tend to be more 
present in the intra-cellular protein156. Mucin are the glycoproteins carrying the greatest 
number of O-GalNAc glycans, and therefore, this type of modification is also called mucin 
type O-glycan. The GalNAc can be extended with galactose, N-acetylglucosamine, fucose, or 
sialic acid, but not mannose, glucose, or xylose residues.  
 
Figure 1.8 Example of different N-glycans with specific glycoenzymes, responsible for each linkage (in blue). 
Sialyltransferases, such as α-galactoside α-2,6-sialyltransferase I (ST6Gal-I), α2,3-sialyltransferases (ST3Gal-Ts); 
fucosyltransferases 8 (Fuc-TVIII); N-acetylglucosamine (GlcNAc) transferases (GnTs); galactosyltransferase 
(GalT). Image adapted from Pinho et Reis (2015) 
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There are eight GalNAc core structures, of which the first four (core1 to 4, the most common) 
and the mucin O-Glycan can be branched or modified with O-acetylation of sialic acid and O-
sulfation of galactose and N-acetylglucosamine150. Most of mucin O-glycan are antigenic 
(Table 1.1 O-GalNAc glycans different cores and antigenic epitopes of mucins. image adapted 
from Essential of glycobiology (2015)).  
 
 
 
Most of the glycosylation occur in the secretory pathway (ER and Golgi), and therefore almost 
all membrane and secreted proteins are glycosylated. However, it has been found many nuclear 
and cytoplasmic protein can be O-glycosylated155. O-glycosylation may serve for the viability 
of many mammalian cell types perhaps by acting as a nutrient sensor, preventing protein 
phosphorylation, or regulating protein turnover155.  
Table 1.1 O-GalNAc glycans different cores and antigenic epitopes of 
mucins. image adapted from Essential of glycobiology (2015) 
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The simplest O-glycan is called Tn and it consist of the single GalNAc bond to the serine or 
threonine, and when is sialylated is called sialyl Tn (sTn). The core 1, name T antigen, is 
composed by Galβ1-3GalNAc- and it forms the core of many longer and complex O-glycan 
structures. Equally the core 1 can be sialylated and it take the name of sialyl T (sT). When the 
core one is attached to a branching N-acetylglucosamine is called core 2 and it is found on 
most of mucin and glycoproteins; linear core 3 and branched core 4 are found only is specific 
mucin and tissue (Figure 1.9). Core 5-8 are most rare and are reported to be bound to specific 
mucins; in particular Bovine submaxillary mucin (BSM) is found containing core 7 structure. 
One of the important complex O-glycans carries antigens, such as the ABO and Lewis blood 
group determinants, on core 1-4 and 6155.  
 
The terminal structures of O-GalNAc glycans may contain fucose, galactose, N-
acetylglucosamine, sialic acid in α-linkages, N-acetylgalactosamine in both α- and β-linkages, 
and sulphate. Many of this sugar are antigenic and they are recognized by the lectins, receptor 
recognizing glycans. In particular, the sialylated and sulphated Lewis antigens are ligands for 
selectins: increase of sialylation and binding of aberrant Lewis antigens has been proved to 
play a major role in cancer invasion and metastasis. 
Figure 1.9 O-glycans core structure assembling pathway. Different glycoenzymes (in blue) are involved in the catalysis. 
Sialyltransferases, such as α-GalNAc ST6Gal-I (ST6GalNAc-I),α2,3-sialyltransferases (ST3Gal-Ts); fucosyltransferases 8 (Fuc-TVIII); 
N-acetylglucosamine (GlcNAc) transferases (GnTs); galactosyltransferase (GalT). Image adapted from Pinho et Reis (2015) 
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1.4.3 Function of glycosylation 
 
Glycosylation has important roles that spans from affecting  protein structure and function to 
cell signalling, and migration157.  
Glycosylation is very important in regulating cell-cell communication by promoting or 
inhibiting molecular binding. For example, the adhesion molecule, NCAM, is known to be 
negatively charged by a poly-sialic structure in order to inhibit homotypic NCAM protein-
protein binding151.  
Glycosylation function is regulated by glycans' receptor, named lectins. Lectins can recognize 
different sequences-motifs and are defined as C-type lectins, S-type lectins, P-type lectins, and 
the Siglecs158,159. Lectins have generally low affinity but high avidity, due to its multivalence 
allowing different sugar to bind the same lectin. Some lectins also have specificity for specific 
protein, suggesting a participation in protein recognition during lectin selective binding151. 
In general, glycans are very important in controlling different cellular mechanisms such as cell 
adhesion, self/non-self-recognition, receptor activation, molecular trafficking and endocytosis. 
In cell-cell adhesion one of the most key lectin is the selectin. Selectins bind the Sialyl-Lewisx/a 
(SLex/a) antigens on the endothelium of the vasculature and on the leucocytes, contributing to 
the immune system trafficking responses160. Selectin are single chain transmembrane protein 
and they share the calcium dependent C-lectin/N-terminal and the epidermal growth factor 
(EGF)-like domains. Their subtypes are divided into E-selectin (endothelial), P-selectin 
(platelet) and L-selectin (lymphocytes), where the first is expressed by immune cells and 
endothelial cells, the second by platelets and endothelial cells and the third mostly by 
leukocytes68. 
Glycans are beneficial in self/non-self-recognition as it happens in the activation of the toll-
like receptor on immune system cells by binding of specific pathogens glycan.  
An important example of molecular trafficking is the glycoprotein turnover promoted by the 
Asialoglycoprotein lectin which bind and internalize glycoproteins lacking or bearing 
insufficient sialic acid linkages. Asialoglycoprotein receptors can be expressed in endothelial 
cells, dendritic cells and macrophages161. Sometimes glycosylation can contribute to the 
intracellular regulation. For instance, O-fucosylation of notch receptor is in charge to control 
its trafficking, ligand-binding and activation. Similarly, the receptors MHC, EGF, TGF-β (on 
epithelial cells), the IgM B cell antigen receptor (BCR) and the glucose transporter 2 
glycoprotein (on pancreatic β cells) are shown to be highly regulated by glycosylation. In fact, 
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glycans expressed on these receptors have demonstrated to contribute to the endocytosis and 
consequent internalization162,163.   
Glycosylation appears, thus, to be involved not only in all the main cellular functions, but also 
in receptors regulation and cells-cells communication. Hence, any disruption in the 
mechanisms can cause serious alterations in cellular homeostasis. This abnormal behaviour is 
often seen and studied in tumour microenvironments. 
1.5. Hallmarks of cancer glycosylation 
 
Alteration in glycosylation pathways, in glycoenzymes expression or in glycan sequences is 
involved in many diseases. Aberrant glycosylation, associated with regulation of cell adhesion, 
migration and proliferation, has been connected with the acquisition of cancer capabilities and 
suggested to be considered as new hallmark of cancer32,33. Efforts have been spent in finding 
cancer-characteristic glycans that could be used in early diagnosis and drug targeting.  
Alteration in glycotransferases and glycosidases can origin at different levels: epigenetic, 
transcription, post-transcription, altered glycosidase activity, altered expression of 
glycoconjugate acceptor, altered sugar nucleotide transporter activity and improper function of 
the Golgi structure164.  
Overall, sialylation and fucosylation are the major typical terminal modification of proteins 
and they are involved with cancer formation and progression.  
Sialylation is in charge of many cellular functions such as cell-cell communication and protein 
targeting; modification in total sialic acid and sialoprotein has been reported contributing to 
tumour progression152. Two enzymes, sialidase and sialyltransferase (ST), are responsible for 
controlling the sialic acid cellular contents. As the amount of sialic acid in tumour depends on 
many different STs, they have been considered promising potential biomarker for cancer early 
diagnosis, treatment and tumour prognosis165.  
Fucosylation is a modification which involve the addition of the fucose sugar unit by the 
fucosyltransferases (FUT) enzymes. FUT enzymes, expressed in many tissues, incorporates 
fucose to reducing end of complex glycans in the linkage specific manner. The fucose 
homeostasis is controlled by a lysosomal enzyme called α-L-fucosidase, which catalyse the 
hydrolytic cleavage of the terminal fucose. Fucoprotein are glycoproteins which contain fucose 
and have been reported useful in cancer prognosis and diagnosis. Alteration in FUT genes 
or/and proteins expression has been suggested involved in cancer formation164.  
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Furthermore, different types of FUTs and STs are involved in the formation of Lewis antigens, 
which over or altered expression is involved in cancer malignant phenotypes and recognised 
as tumour antigens (Table 1.2).   
 
 
Incomplete O-glycosylation pathways is linked with the formation of T- (Thomsen–Friedreich 
antigen or unmodified core 1 structure), Tn- (Thomsen-nuovelle antigen) and SLex/a antigens 
which has been linked with tumorigenesis and bad prognosis166. The decrease in E-cadherin 
and increase in SLex/a expression, with a correspondent overexpression in E-selectin, favourites 
the movement of cancer cells to distant organs, creating the basis for metastatic tumour 
formation167. Loss of E-cadherin increases, also, the Matrix metalloproteinases (MMPs) 
expression, enzymes involved in the degradation of the extracellular matrix65. In parallel, 
different class of tyrosine kinase, including EGFR, Her2-neu, insulin-like growth factor 1 
receptor (IGF-1R) and c-Met are able to induce the EMT by inhibiting E-cadherin 
adhesion168,169.  
Glycosylation and, in particular, sialylation has been demonstrated to be involved in apoptosis 
evasion by the hyper-sialylation of the Fas receptor, which inhibits the recognition of Fas 
ligand and thus apoptosis activation170. In addition, glycoproteins such as mucins (MUC) 
produced by epithelial cancer cells or the MUC-like-glycoproteins like carcinoembryonic 
antigen (CEA)125, CEA19–9, CEA15–3, CEA72–4, are involved with tumour progression and 
are considered very important in study of early detection. For instance, MUC1 overexpression 
is involved with E-cadherin function disruption in adherents junctions in cancer cell 171.  
Table 1.2 Association of different fucosyltranfersases (FUTs) and sialyltranferase (STs) in glycan tumour 
antigens formation. Table adapted from Vajaria and Patel (2016) 
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Following the classification of the different hallmarks of cancer, different authors have 
proposed glycosylation as a missing hallmarks of cancer, integrating the role of aberrant 
glycans in each step of tumorigenesis (Figure 1.10)32,164,172. 
 
 
1.5.1 Sustaining proliferative signalling 
 
O-glycosylation of proteins can regulate cell cycle signals, including the transcription factor 
forkhead protein M1(FoxM1), cyclin D1 and cMyc173,174. For instance, incorrect glycosylation 
can contribute to oncogenesis by stabilizing the cMyc protein and competing with 
phosphorylation. Moreover, in ovarian cancer cells, the knock-down of the enzyme Cosmc, the 
molecular chaperon fundamental for a correct O-glycosylation, results in an increase of T- and 
Tn- antigen and their sialylated counterparts (sT- and sTn-), which are tumour-associated 
carbohydrates, not usually present in peripheral tissues and blood cells175. 
Degrees of branching in N-glycosylation are also involved in modulating proliferative signals, 
including EGFR, FGFR, PDGF, MET and IGFR32,176. 
Figure 1.10 Association of expression of aberrant glycans for each cancer 
hallmark. General increase in O-GlcNAc is mostly common to all steps. 
Increase of Le, sLe, sTn is mainly involved with invasion and metastasis, 
tumour-promoting inflammation and immune escape. Image adapter from 
Peixoto et al (2019) 
Hallmarks of cancer 
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Further role of glycosylation has been associated within the ECM: it facilitates the integrin 
dependent growth factor signalling to promote cell growth and survival and modify the 
function and signalling of the multifunctional cell surface molecule CD44177,178. 
 
1.5.2 Evading Growth suppressors 
 
O-GlcNAcylation regulates the two main suppressors of proliferation, p53 and RB. In 
particular, when p53 is O-GlcNAcylated on ser 149, ubiquitin-dependent proteasome 
degradation is blocked, maintaining the p53 function activated. On the other hand, when O-
GlcNAcase (OGA) is overexpressed, it is induced the activation by phosphorylation of MDM2, 
resulting in p53 degradation179.  
Similarly, RB is positively controlled by glycosylation and, in particular by O-GlcNAc in phase 
G1, by preventing phosphorylation and promoting binding of E2F-1 transcription factor. 
During final G1 cell cycle, phosphorylation prevails on glycosylation leading to the release of 
E2F and the entering in the S phase of cell cycle and thus promoting cell proliferation180. 
 
1.5.3 Deregulating cellular energetics 
 
As previously described, one of the main hallmarks of cancer cells is the passage from the 
oxidative phosphorylation towards the aerobic glycolysis, also known as ‘Warburg effect’88. 
In this hypoxic context, Hypoxia-inducible factor 1- α (HIF-1α) upregulates the expression of 
glucose transporters-1 and 3 (GLUT1, GLUT3), allowing the intracellular uptake and 
phosphorylation of glucose. This passage can influence most of metabolic pathways, such as 
the hexosamine biosynthetic pathway (HBP). The final product of the HPB pathway is the 
UPD-GlcNAc responsible for O-GlcNAcylation, critical metabolite in O- and N-
glycosylation181. It has been shown that O-GlcNAcylation is involved in cancer-associated 
metabolic reprogramming: Glucose-6-phosphate dehydrogenase (G6PD), an enzyme of the 
pentose phosphate pathway (PPP) is O-GlcNAcylated in response to hypoxia and is involved 
with cell cancer proliferation182. O-GlcNAcylation at the serine 149 of the phosphofructokinase 
1 (PFK1) has proven linkage with cell proliferation183. Moreover, O-GlcNac can regulate 
transcription factors activity and c-Myc stability, confirming the main role that Hyper-O-
GlcNAcylation contributes to oncogenicity, frequently accompanied by cell dedifferentiation 
and acquisition of mesenchymal characteristics89,174. 
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1.5.4 Resisting cell death 
 
Glycosylation plays a major role in controlling the function of death receptors as Fas (CD95) 
and TNFR1; cancer cells use the glycosylation machinery to regulate apoptosis by disrupting 
ligand-receptor interactions, modulating the formation of signalling complexes and influencing 
ligand secretion from effector cells. For instance, the lectin galectin-3 binds the Fas ligand 
repressing the apoptotic signal and increase tumour survival184. Likewise, the addition of sialic 
acids by ST6Gal-I in an α2-6 linkage to the N-glycans of Fas provides protection against Fas-
mediated apoptosis in colon carcinoma cells185.  
Other glycosyltransferases, as N-acetylgalactosaminyltransferases 1 (GALNT1) has been 
reported responsible for glycosylation at integrin α3β1 which modify its conformation and 
induces focal adhesion kinase (FAK) activation in bladder cancer cells186. Inhibition or de-
phosphorylation of FAK is indeed an apoptotic inducer and has been shown to inhibit also the 
PI3K/AKT signalling, suggesting a role in the downstream apoptotic regulation187.  
O-GlcNAcylation has proved a main role in resisting cell death: both NF-κB p65 subunit and 
its upstream kinases IKKα/IKKβ are O-GlcNAcylated. Reduction in O-GlcNAcylation reduces 
NF-κB activity and target gene expression188. 
 
1.5.5 Enabling replicative immortality  
 
The ability of cancer cell to reactivate the human telomerase reverse transcriptase (hTERT) 
and activation of telomerase, is the main mechanism to overcome senescence. There are still 
no direct proves of the linkage between glycosylation and telomerase activation, yet the role of 
c-MYC, direct activator of TERT, is discussed. In fact, c-MYC is a glycosylated protein and it 
has been shown to be stabilized by O-GlcNAc and with it, high level of O-GlcNAcylation has 
been shown in cancer cells174,189.  
 
1.5.6 Angiogenesis 
 
Glycans are involved in many steps of angiogenesis (sprouting) and vasculogenesis (new tubes) 
and a distinct set of glycosylation genes have been associated into the cascade.  
Important key inducer of angiogenesis is the VEGF and its correspondent receptor VEGFR: 
glycosylation of both is associated in angiogenesis. Heperan sulphate (HS) proteoglycans can 
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modulate angiogenesis by effecting the bioavailability and interaction of VEGFs with VEGFRs 
or interacting with endostatin, an anti-angiogenic factor190,191. The upregulation of O-
GlcNAcylation on VEGF and aberrant glycosylation on VEGFR modulates the interaction with 
galectins192,193. For instance, galectin-1 (Gal-1) binds β1-6GlcNAc branched N-glycans present 
on VEGFR2 in endothelial cells surface to activate a VEGF-like signalling194. The interruption 
of the β1-6GlcNAc branching led to converted refractory tumours into anti-VEGF-sensitive, 
which suggest the main role of glycosylation in tumour therapy when treated with anti-VEGF 
treatments194. It has been also proved to impact angiogenesis through EGF receptor signalling 
and influencing the expression of angiogenic cytokines, in ovarian cancer195.  
O-glucose, O-GlcNAc, and O-GalNAc have shown to regulate angiogenesis by affecting Notch 
signalling, responsible for stabilization of arterial endothelial fate and angiogenesis 196,197. 
 
1.5.7 Activating invasion and metastasis 
 
The ability of glycans to activate invasion and influence metastatic conditions in cancer cells 
has been well documented. The role shown by glycosylation seems dual: from a side reduces 
adhesion of cancer cells, thus inducing CTCs formation, but from the other side promotes 
adhesion of cancer cells, inducing nesting of metastatic cells33,124,160. High levels of sialylated 
glycans present on tumour cells surface increase local negative charges that physically disrupt 
cell-cell adhesion and promote detachment from the tumour mass through electrostatic 
repulsion198. High level of sialic acid is indeed correlated with malignancy and bad prognosis. 
Likewise, the presence of truncated O-glycan, as sTn, due to inhibition of the COSMC 
chaperone or increase in ST6GalNAc1enzyme, has been associated with cancer cell growth 
and invasion175,199. More overexpression of glycosyltransferases, such as GnT-V, induce 
β1,6GlcNAc branching of N-glycans on E-cadherin, leading to non-function adherent junction 
and misleading cell-cell adhesion. GnT-III catalyses the addition of bisecting GlcNAc to 
complex N-glycans and is thought to influence interactions with galectins. Downregulation of 
GnT-III has been associated with  increase of cell migration and metastasis200. 
SLewis antigens are instead associated with the tumour cells capability of promoting adhesion. 
The sLex/a antigen is overexpressed in most of tumour and promotes adhesion of tumour cells 
by interaction with selectins on the endothelial surface201. Addition of a sulphate group at the 
sixth position of GlcNAc generates 6-sulfo-sLex, a ligand for L-selectin and E-selectin in 
bladder cancer202. In agreement, cell lines overexpressing Lex have revealed an increase of 
FUT6 and FUT7 fucosyltransferases, two enzymes involved in the catalysis of sLex 203. 
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Sialyltransferase ST6GalNAc2 has a role in metastasis in breast cancer: loss of the enzyme 
corresponds to alteration of O-glycans, leading to an increase in metastasis204. 
 Galetin-1 binding to CD44 or CD326 can promote attachment to the ECM and endothelial 
cells205.  
 
1.5.8 Genome Instability and mutations 
 
As previously mentioned, p53 is glycosylated by O-GlcNAc and O-phosphate modifications 
which increase its stability. On the other hand, p53 plays the major role as DNA sentinel in 
maintaining its stability206. The protein kinase ataxia-telangiectasia mutated (ATM), a key 
regulator of DNA damage response (DDR), is also glycosylated: O-GlcNAc and 
phosphorylation play major roles in regulation of the DNA damage pathway207.  
 
1.5.9 Tumour promoting inflammation and tumour escape 
 
The dual role of the immune system in cancer development is supported also from glycan 
change in the tumour system. The selectin proteins (E-, P- and L-) are important for the entry 
of circulating lymphocytes into peripheral lymph nodes and leukocyte emigration into inflamed 
tissues through binding of sialylated and fucosylated glycans68.  
Glycosylation is able to influence NF-kb and cyclooxygenase 2 (COX2), important 
proinflammatory molecules188,208. Other tumours have shown stroma containing several pro-
inflammatory cytokines, as IL-1β and IL-6, which regulate the expression of biosynthetic 
glycosyltransferases to increase the expression sialylated antigens, as SLex/a 209. 
On the other hand, glycans can interfere in immune cell recognition, leading to the emergency 
of cancer cells resistant. In general, hyper-sialylation phenotype has been associated with the 
mechanisms of immune evasion. 
Lectins have a main role in tumour escaping surveillance: galectins and siglecs (sialic acid-
binding immunoglobulin-type lectins) are thought to be involved in immune evasion. In 
particular, siglecs can induce an antigen-specific tolerogenic programming, enhancing Treg 
cells and reducing the generation and propagation of inflammatory T cells, as happens in the 
binding of the macrophage siglecs-15 with sTn- inducing the TGF-ß secretion210. sTn can be 
also act on the membrane of MUC1 and CD44 by promoting DC maturation inducing 
tolerogenic mechanism211; MUC-sT on breast cancer cells, recognize siglecs-9 on 
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macrophages initiate inhibitory immune signalling through the activation of the MAPK/ERK 
pathway212. N-glycosylation of the immune checkpoint molecule PD-L1 can reduce 
proteasomal degradation which increase its immunosuppressive activity over T- cells213.  
Moreover, also the fucosylated group on Lewis antigens, bound to the C-type of lectins on the 
macrophages, induces a tolerogenic response by activation of cytokines IL-10 and IL-27, with 
consequent activation of TH2, T follicular helper (TFH) or Treg cells214. 
 
1.6. Colorectal cancer and glycosylation 
 
Aberrant glycosylation on colorectal cancer progression have been significantly reported in the 
last 15 years. Incomplete and aberrant synthesis of glycans have been revealed in all the stages 
of CRC and two mechanisms can explain functional consequences: i) a direct alteration of 
function and structures of protein and lipids or ii) a shift in glycan binding proteins (GBPs) 
through galactose-binding proteins (galectins), sialic acid-binding immunoglobulin-type 
lectins (siglecs), and selectins153. Nevertheless, glycosylation revealed to be a challenging topic 
to investigate, being its regulation highly dependent on the context and on epigenetic signals. 
Consequently, many techniques have been applied in glycosylation studies in order to find 
patterns in carcinogenesis events. 
CRC cell lines, tissues and biological sample from patients are analysed by gene expression 
(gene mutation, miRNA and mRNA expression), binding assay (antibodies/lectins used in 
enzyme-linked immunosorbent assay [ELISA], Flow cytometry, microarrays, 
immunofluorescent microscopy, immunohistochemistry and western blot), glycoenzyme 
modification (with synthetic enzymes, or knock-in knock-down and knock-out experiments) 
and mass spectrometry techniques, which allow the identification and characterization of 
glycan structures. The use of different samples and of multiple techniques is useful to overcome 
eventual bias that a single analysis may bring in the interpretation of glycan structures and 
behaviours. General alterations in N-, O- and GSL- glycans, fucosylation, sialylation, sulfation 
and (sialyl) Lewis antigens has been reported in CRC (Figure 1.11).  
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In CRC, N-glycans alterations show a general intensification of high-mannose type structures 
as well as higher branching and core-fucosylation. The increase of high mannose type has been 
correlated in CRC tissue and cell lines with metastasis215. A hypothesis suggest that this 
increase is due to a precursor accumulation to incomplete maturation during N-glycan 
biosynthesis216.  
Core-fucosylated high- mannose glycans as well as truncated versions with or without fucose, 
also called pauci-mannosidic structure, were identified in tumours. This increase of core-
fucosylation in cell lines was correlated with the upregulation of fucosyltransferase FUT8, 
responsible for the addition of α1,6-core-fucose on the innermost GlcNAc of the N-glycan 
core. Increasing of FUT8 expression have been associated with malignancy in CRC217.  
Upregulation of N-acetylglucosaminyltransferase V (GnT-V) is responsible for the extended 
β1,6-linked GlcNAc branching. The increase of the GnT-V has shown loss of contact 
Figure 1.11 Alteration of glycan structure in different phases of CRC 
formation and progression. A general increase in SLe antigens, sialylation 
and fucosylation is common throughout the different steps. Image adapted 
from Holst et al. (2015) 
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inhibition, increased cell motility, and morphological transformation, and in correlation, 
increase in higher branching have been associated with increase in invasion and metastasis218. 
The same branching can be extended by (poly-)N-acetyllactosamine (LacNAc), whose higher 
expression is associated with cancer progression, metastasis, and poor survival219. 
O-glycosylation is heavily present on the MUC membrane protein surfaces and their alteration 
have been studied. In general, an increase in core 1 structures which are generally truncated, 
sialylated and fucosylated facilitation tumour progression and metastasis. In colon cancer tissue 
the upregulation of core 1 β1,3-galactosyltransferase (C1GALT1, T-synthase) correspond to 
an increase in Thomsen-Friedenreich (T)-antigen leading to poor survival and metastasis220. 
Equally, the down regulation of C1GALT1 brings to a diminution in Thomsen-nouvelle (Tn)-
, T-, and sialyl-T (sT) antigens and might be used in target therapies153. 
Overexpression of T-, O-acetylated sTn- as well as Tn-antigens have been associated also with 
tumorigenesis and progression, in the early events of malignant transformation. Main carriers 
of sT- and sTn-antigens were identified as the mucin MUC1 and CD44v6221,222. Sialylation of 
the T- antigen is performed by α2,6-sialyltransferase gene (ST6GalNAc2), while an increase 
in sTn- corresponded to an upregulation of the sialyltransferase ST6GalNAc1. Interestingly, in 
colon cancer carcinomas the enzyme core 2 β1,6-N- acetylglucosaminyltransferase (C2GnT), 
responsible for conversion of the T- and Tn-antigen to core 2 structures, is upregulated 
allowing the biosynthesis of sialyl Lewisx/a, proved cancer antigens223. Correspondently, the 
enzyme β1,4-galactosyltransferase, responsible for type 2 chains (precursor for SLex) is 
upregulated and the β1,3-galactosyltransferases forming type 1 chains are downregulated224. 
Overall, an increased in density of O-glycan has been associated with tumour malignancy and 
progression. 
Holst et al (2013) have investigated modifications in GSL-glycans, reporting a general pattern 
in colorectal cancer formation: (i) increased fucosylation, (ii) decreased acetylation, (iii) 
decreased sulfation, and (iv) reduced expression of globo-type glycans, as well as (v) disialyl 
gangliosides225. 
A general increase of fucosylation on glycans attached on lipids and proteins have been 
reported on N-, O- and GSL-glycans, by the action of various fucosyltransferases. In particular, 
FUT3, 4, 5, 6, 7, and 9 on antennary N-glycans are elevated in CRC and their upregulation 
brings elevated expression of cancer-associated blood group Lewis antigens153. It has been 
hypothesised that fucosylation plays a major role in early stages of the cancer, while a process 
of de-fucosylation is promoted in more advanced stages. 
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Sialylation plays important duties in healthy cells and sialic acid decorates the end position of 
glycans of proteins and lipids. The most common is the negatively charged N-acetylneuraminic 
acids (NeuAc), while adult humans lack the expression of another variant of sialic acids, 
N-glycolylneuraminic acid (NeuGc). However, adult tumour environment not only shows a 
general increase in sialylation but also appearing of NeuGc expression226.  
Dysregulation of silalyation is due to sialyltransferase and/or glycosidases or enhanced 
possible sialylation sites. In detail, increase in α2,6-linked sialic acids on N-glycans and α2,3-
linked sialic acid have been associated with poor prognosis and metastatic profiles. In 
accordance, the α2,6-sialyltransferase ST6Gal1 is upregulated in colon tumours, as well as 
increased expression of α2,3-sialyltransferases with cancer cell migration and metastasis227. 
Further studies have to be performed in order to understand the role and the up regulation of 
the two type of sialic acid linkage, but hypothesis attribute main role in early stages cancer 
development to the α2,6-linked sialic acids, and critical role in metastasis with regard of 
epithelial–mesenchymal transition of the α2,3-linked sialic acid153. 
Decreases in sulfation have been observed, however contradictory results in cancer progression 
show the urge to further investigate the subject. It has been suggested that the negative charge 
of sulfation plays a critical role in protease resistance and interaction with functional molecules. 
On the contrary, the blood related group (sialyl) Lewis antigens X and A have been deeply 
investigating and are responsible of increased malignancy, poor prognosis and increased 
metastasis for creation of new ligands. The Lea on the contrary diminish in cancer progression. 
Supposedly, incomplete synthesis of 6-sulfo sLex and disialyl Lea cause the accumulation of 
sLex/a. Equally, neosynthesis by changes in glycosyltransferases have been ascribed to 
accumulation of the antigen228. In hypoxia conditions, overexpression of FUT7 leads to 
increase of (s)Lex and of ST3Gal1 to Lea/x. FUT3 and FUT6 responsible for sLea and sLex, 
respectively, are used as tumour markers, being overexpressed in metastatic conditions229. In 
general, FUT3, 4, 5, 6, and 9 as well as α2,3-sialyltransferases are involved in neosynthesis of 
Lewis antigens229. However, FUT 1 and 2 play a major role in converting Lex/a into antigens 
Lewis Y (Ley) and Lewis B (Leb) by addition of a fucose to the galactose of this motif230. Study 
reveals increase expression of these epitopes and their respective enzymes in colon tumour and 
carcinomas. An increase of FUT4 has been also observed and possibly related to an enhanced 
expression of LeY231. 
In conclusion, incomplete synthesis or neosynthesis is the common ground for aberrant 
glycosylation formation. Alteration in glycosyltransferases or sialidases brings to 
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tumorigenesis and formation of new ligand binding recognitions, most of the times responsible 
for malignant transformation and metastasis. Although many studies must be performed in 
order to fully understand the glycosylation role in cancer formation, it is undeniable its 
potential for targeted therapies. Among the all aberrant glycan just described, O-glycans and 
Lewis antigens, shows the most important role: not only they are, in most of the cases, cancer 
specific but also expressed from the early to the late stages of cancer. This is an important 
factor, that need to be exploited in biomarker discovery and targeted therapies. Also, 
Sialylation being responsible of malignant transformation and present in the final part of 
glycans structure, represents a good objective for cancer treatment.   
 
1.7. Glycoproteins and biomarker discovery 
 
Treatment in Colorectal cancer has higher chances to be effective during early stages of the 
disease, with chances up to 90% during the 5-year rate survival232. Consequently, most of the 
studies are driven towards the discovery of new and effective early detection biomarkers.  
A good molecular biomarker must be sensitive and specific to the disease: detection of 
malignancy at first stages of the cancer and use of non-invasive tools are the central focus in 
biomarker discovery nowadays. As a matter of fact, it has been noted an increase in testing 
population when screening exams are quick and less invasive. Biomarker can be of different 
origin, including altered DNA, RNA, proteins, glycosylation and immune cells. 
Up to the date, colonoscopy followed by tissue biopsy is the main technique adopted for CRC 
diagnosis and prognosis. However, use of human specimen and testing of liquid biopsy is also 
increasing. Each type of biomarker can be detected with different techniques and the use of 
diverse types of biomarker helps for a correct diagnosis and prognosis. Proteins are considering 
excellent biomarkers not only because important for cellular mechanisms (i.e. cell growth, cell 
signalling, protein metabolic process and cell motility) but also for their stability.  
Moreover, some upregulated protein when glycosylated can also carry aberrant glycosylation 
even when secreted, revealing promising potential as liquid biomarker.  
As mentioned, glycan profiles of proteins can be affected by of glycosyltransferases and 
glycosidases and by the availability of environmental factors (e.g., glucose, growth factors) 
and sugar nucleotides leading to alterations of glycan structures153. Some glycoproteins are 
already in use in clinics, such as CEA and CA19.9 as good prognostic factor.233 Levels of CEA 
are checked after total resection of tumour and decreasing of its level in the blood correspond 
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to proper remission of the tumour100. CEA and CA19.9 have been in use also for diagnostic 
proposes, however, they lack specificity precluding them to be used as early detection tools. 
Increase in core-fucosylation in serum protein in pancreatic cancer have been shown and 
fucosylated haptoglobin has been also proposed as new biomarker234. The measure of aberrant 
glycans variation has diagnostic tool have been proposed. Increased levels of sLex and sLea in 
serum of CRC patients were highly associated with distant metastasis201. Likewise, Tn antigen 
and its sialylated form, sTn, have shown great specificity in cancer detection. Wei et al (2016.) 
reported  6 O-glycoproteins carrying Tn (Keratin 8, Keratin 18, Decorin, Sorbin, SORBS1 and 
CD44 antigen) to correlate with the initiation and progression of CRC235.  
Nowadays, many glycoproteins have been already investigated for CRC and in the next 
paragraphs will be highlighted the most discussed. 
 
1.7.1 TIMP1 
 
Tissue inhibitor metalloproteinases (TIMPs) is a glycoprotein that contributes to the inhibition 
of MMPs, which have been implicated with tumour invasion and metastasis by degradation of 
the ECM. 
However, in colon cancer TIMP-1 is upregulated compared to their normal counterparts, 
eventually increasing the growth of cancers. It induces cell growth and inhibit apoptosis. 
Moreover, TIMP-1 promotes colon cancer progression and accumulation of CAFs (Cancer 
Associated Fibroblasts) in colon cancer 236. TIMP-1 has been identified has a new early-stage 
biomarker with blood plasma sample having significantly elevated TIMP-1 levels compared 
with healthy individuals237. In CRC, TIMP-1 is aberrantly glycosylated with enhanced β1,6-
branching in CRC238. The aberrant glycosylation decreases the inhibition power of the MMP2 
and 9, causing increase in cell motility and metastatic phenotype.  
The pro-tumoral activity, the upregulation and the presence of characteristic aberrant 
glycosylation make TIMP-1 a novel potential target for cancer therapy. 
 
1.7.2 MUC1 
 
Mucin is a class of high molecular weight glycoproteins expressed on epithelial tissue. In 
general, mucins are highly covered in glycans. Mucin can be classified as secreted gel forming 
mucins (MUC2, MUC5AC, and MUC6), transmembrane mucins (MUC1) and other types. 
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MUC1 is found on the apical part of most epithelial surface, yet during tumorigenesis, 
expression of specific mucins may be reduced or the organ specificity lost and new mucins 
may be expressed aberrantly239. MUC1 one can contribute in tumour growth by activation of 
ß-catenin trough binding of siglecs-9 and aberrant O-glycosylation expressed on MUC1 
surface240. In metastasis, the expression of T-antigen on MUC1 serves as a binding of galectin-
3, which promotes cell surface polarization of MUC1 and consequent exposure of E-selectin, 
increasing adhesion of cancer cells241. MUC1 was found playing a role also in immune 
modulation. The Tn-antigen on its surface interacts with macrophage galactose lectin (MGL) 
and instruct the DC to activate a Type 2 T helper cells (TH2)-mediated responses, which is not 
implied in tumour eradication242. Likewise, MUC1 can interact with NK cells and inactivate 
NK cell-mediated cytotoxicity243. A metanalysis from Zeng et al. (2015) not only confirmed a 
great correlation between CRC and MUC1 expression, but also suggested it as a good potential 
diagnostic tool in predicting status of metastasis. However, the use of different monoclonal 
antibodies to test the MUC1 can bias the specificity in MUC1 recognition, with ranging from 
20% up to 92.7%, for this remains very important the creation of tools for specific and sensible 
recognition of the marker244.  Vaccine against MUC1 tumour-associated antigens (MUC1-
TAA) have been designed. Kimura et al. (2013) have reported high immunogenicity in  
~ 50% of patient with colon adenocarcinoma tested. High levels of anti-MUC1 
immunoglobulin G (IgG) and long-lasting immune memory was not associated with significant 
toxicity, suggesting an important role of this vaccine for cancer prevention245. 
 
1.7.3 Carcinoembryonic antigen  
 
The carcinoembryonic antigen (CEA) is a glycoprotein of molecular weight ≤200 kDa and 
belongs to the immunoglobulin’s superfamily 246. CEA is well known to be a serum protein 
biomarker and has been acting as cell adhesion mediator for cancer cells.  Many drugs are in 
use or in trail with target CEA, of which most have action on controlling tumour development 
in colon cancer patients. CEACAM5 exhibiting an aberrant glycosylation which is recognized 
by C-type lectin receptors expressed on dendritic cells (DCs) and modulates the innate and 
adaptive tumour immune response247. Expression of Lewis antigens on CEA and CEACAM1 
proteins impairs DC maturation and increases the secretion of immuno-suppressive cytokine 
interleukin-10 (IL-10)248. Thus, CEA produced by tumour cells is not recognized by the 
immune system, for this reason have been developed new strategies to enhance immune 
reactions against CEA. Vaccines against CEA have been designed and under clinical trial, 
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whose porpoise is the activation of the immune system against cells overexpressing CEA. 
Recent studies showed that the CEA expression is directly linked and increases with cancer 
stage  249. Yet, it has been calculated a low sensitivity and specificity in screening cancer early 
stages I-II 250. However, it has been identified that its receptor, CEAR, mediates CEA  pro-
metastatic activity to other organs, thus it would probably play an important role in drug 
development for cancer treatment251. CEA increase in metastatic cancer that develop liver and 
spontaneous pancreatic and lung metastasis. Zhao et al. (2018), using lectin staining  revealed 
higher expression levels of fucose, mannose and T antigen on CEA in the tumour tissues 
relative to the tumour-adjacent normal tissues; sufficient to distinguish CRC tumour tissues 
from healthy tissues with high sensitivity and specificity252. These results suggest that the use 
of combinatorial lectins and detection of aberrant glycosylation on CEA could be used as 
potential effective and non-invasive biomarker. 
 
1.7.4 CA 19-9 
 
Carbohydrate antigen (CA) 19.9, correspond to the carbohydrate sLewisa and is used in clinic 
as prognosis biomarker with the CEA. CA 19.9 name has been defined by a monoclonal 
antibody produced by hybridoma of mice immunized with CRC cell line, SW 1116. Sensitivity 
and specificity to detect CRC are still under discussion since is less effective than CEA. 
However, when used in combination with CEA it increases up 71.7%139. These suggest the 
sensitivity of this combination  increases significantly 139, suggesting that even though it cannot 
be considered a good single biomarker but could be a great booster in diagnosis and prognosis 
when combined. Other carbohydrate antigens, such as CA 50, CA 195, CA 242, CA M26, CA 
M25, CA M43 and CA 72.4, have been tested but excluded due to their reduced sensitivity, 
stage dependency and specificity253. Although testing of carbohydrate antigens reveals a dwell 
in specificity and sensitivity, the combined use with glycoprotein discloses an interesting raise 
in sensitivity, which could be use in early detection. 
 
1.7.5 CD44 
 
CD44 is a ubiquitous multifunctional glycoprotein. Main duties involve cell-cell and cell-
matrix adhesion and interaction with growth factor and extracellular ligands for signal 
transduction and cytoskeleton rearrangements254. CD44 is also involved in lymphocytes 
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homing haematopoiesis, cell migration and adhesion, tumour invasion and metastasis. It is a 
single chain molecule composed by a distal extracellular domain, a membrane-proximal 
region, a transmembrane-spanning domain, and a cytoplasmic tail. Its molecular weight may 
vary from 85-230kDa as a consequence of the many isoforms originated by alternative splicing 
and the heavy glycosylation255. CD44 gene is located in the short arm of the 11th chromosome 
and consist of 19 exons of which 1–16 encode the extracellular domain, exon 17 encodes the 
highly conserved transmembrane domain, and exons 18 and 19 encode the intracellular 
domain. Azevedo et al. (2018) performed an in-silico study of the possible mRNA transcript 
and results possible 21 combinations of which just 8 are proved experimentally256. Analytical 
difficulties are aggravated by the glycosylation, and possible glycosylation sites present on the 
splicing sites: glycans often present a non-templated and context-dependent nature, increasing 
molecular diversity and functionality256. The known 8 isoforms are gp116 and gp85, 
glycoproteins named after their molecular weight, CD44H and E observed on hematopoietic 
and epithelial cells respectively, HCELL a CD44 hematopoietic cell E-/L-selectin ligand 
mostly implicated with tumour progression and metastasis, CD44v3, CD44v6, CD44v9, named 
after their monoclonal antibodies recognition, involved with cancer, including chemoresistance 
and prognosis. Being the study of this protein very complex due to the different isoforms, roles 
and possible posttranslational modifications, Azevedo et.al (2018) pointed out the necessity 
for a better characterization of the glycosylation of this protein, having specific cancer-
associated isoforms, which have a great potential as tumour biomarker256. The role of CD44 as 
a diagnostic and prognostic tool is still under discussion since results remains controversial. 
Recently, Wang et al. (2019) have performed a metanalysis of 48 studies with total CD44 
isoforms overexpression: as results the expression of CD44 was showing direct correlation 
with worse OS of CRC patients and was associated with lymph node metastasis, distant 
metastasis, poor differentiation, and CD44v6 with tumour size257. However, other studies high 
levels of CD44 mRNA was associated with benign outcome survival rate of gastric tumour258. 
In intestinal CSCs, the variants 4-10 are found the most abundant, however other isoforms are 
mostly abundant. In breast cancer, the CD44v4 is responsible to mediate cell adhesion to 
endothelial monolayer259. Soluble isoform of CD44 is also available. Proteolytic cleavage 
release CD44 from the membrane by detaching the cytoplasmatic tail. In has been found serum 
concentration at 2 µg/ml in mouse and in tumour-bearing strains increase up to approximately 
10 µg/ml. Immunodeficient mice have low concentrations of 0.5 µg/m indicating that 
malignant activities can induce release from cell surface CD44222,260. 
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1.8. Antibodies 
 
The immune system plays an everyday central role in maintaining cellular homeostasis by 
fighting non-self-agents. The immune response is defined innate when the immune cells do not 
rearrange their receptors and therefore are not affected by previous interaction with infectious 
agents. In contrast, the acquired immune response is when the immune cells suffer genetic 
rearrangement on their receptor genes and its effectiveness can be greatly improved after 
contact. A central role in the acquired immune system is played by the antibodies, or 
immunoglobulins (Igs). They are glycoproteins produced specifically by B lymphocytes, 
which expose on the cell surface an antibody with a unique antigen binding site, that is used as 
receptor or secreted. In fact, antibodies have the ability to recognize with high sensitivity and 
specificity a particular sequence (epitope) of an antigen262.  
The remarkable multifunctionality of the antibodies, is given by its structure. The “Y” shape is 
formed by a constant part, Fc, which correspond to the lower part, and a variable part composed 
by two antigen-binding fragments, Fab, at the top. The Fab portion is composed by a heavy 
and a light chain both in the constant and variable part (CH, CL/VH, VL) (Figure 1.12a). The 
antigen specificity is created through continuous genetic recombination of the hypervariable 
complementarity-determining regions (CDRs) present both in the light and heavy chain262. The 
Fc constant part is instead responsible of the effector function of the antibody, activating 
effector molecules and stimulating the cells of the immune system. There are five classes of 
immunoglobulins named IgG, IgM, IgA, IgD and IgE which maintain the four-chain antibody 
structure but differ for the constant region of the heavy chain (Figure 1.12b) and function263. 
For instance, IgM, as monomeric form is a cell surface receptor on B lymphocytes, and as a 
pentameric form is the first class of antibodies secreted by B lymphocytes once activated, i.e. 
plasma cells. Upon specific stimuli, the plasma cells can suffer class switching and then express 
other class of antibodies, but with the same antigen specificity and differentiate into memory 
B cells. After the primary response, and due to point mutations, the plasma cells may express 
antibodies with higher affinity. The IgG can activate several mechanism of action as antibody 
dependent cell cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), 
phagocytosis, or blockage of the action of specific molecules(Figure 1.12b).264. 
In detail the ADCC is activated by the engaging of Fc receptor on Natural Killer (NK) cells, 
leading to their activation and exocytosis of the cytolytic granule complex perforin/granzyme 
and thus activation of apoptosis. The CDC is a cytolytic cascade mediated by a series of 
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complement proteins (C1–C9) that are abundantly present in the serum: C1q binds to the Fc 
region of IgM or IgG bound to antigens, which triggers a cascade of signal ending with the 
lysis of the targeted cell. Other soluble antibodies can function as decoy for signal homeostasis 
or cross-linking of receptors that are connected to mediators of cell apoptosis to induce cell 
death262. Antibodies are present in the serum in a polyclonal form and different clones in fact 
can recognize different epitopes on the same antigen. However, each B cell clone can produce 
only one antibody. The antibody and the antibodies produced by one B cell clone is then called 
monoclonal. Nowadays, monoclonal antibodies are one of the most important tools used in 
research for characterization and in therapy as leaders of the development of personalized 
treatment.  
 
 
1.8.1 Production of monoclonal antibodies  
 
The first monoclonal antibody was generated in 1975 and fully licenced in 1986. Since then, 
the market and the production of monoclonal antibodies has raised, becoming fundamental in 
research and in clinics265. After 40 years, around 47 monoclonal antibodies have been approved 
Figure 1.12 Broad overview of antibody structure and diversity. a) structure of an immunoglobulin G (IgG) antibody’s 
molecule is composed by constant (C) and variable (V) domains for each light (L) or heavy (H) chain. The heavy chain 
comprises three constant domains (CH) and one variable (VH), and the light chain contains one constant (CL) and one 
variable (VL) domain. Specificity of an antibody is determined by its complementarity-determining regions (CDRs). b) 
IgG can switch different subtypes depending on the Fc effector function. c) switch in class of antibody improves the 
effector function of the antibody and increases its ability to eliminate the pathogen that induced the response. 
engineering of antibodies comprehends the different modification to the Y structure with the intent to reduce immune 
response and increase efficacy. d) humanization of the antibody sequence and e) creation of shorter fragments have 
been the most successful modification up to the date. 
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in EU or USA for treatment of many different diseases266. Major problems in antibody 
production is to obtain a highly specific antibody, obtain high yield in production and guarantee 
the less immunogenicity or secondary effect, as possible, in therapies. For this reason, 
advancing in genetic sequencing and biotech techniques as led to efficient modification of 
antibodies constructing for example short fragments antibodies like single chain variable 
fragment (scFv) with reduced size and immunogenicity267. Engineering the Fc region in 
modulation of its interaction with the neonatal Fc receptor (FcRn) promotes IgG half-life 
extension (Figure 1.12e)268. Likewise, the glycosylation of the antibodies can modify and 
modulate the Fc effector functions of antibodies269. To promote efficacy, monoclonal 
antibodies can also be modified by conjugation of coupling effectors such as, plant/bacterial 
toxins, enzymes, radionuclides, cytotoxic drugs etc265,270.  
Three are the main techniques to produce monoclonal antibodies: hybridoma technology (the 
oldest), immortalized B cells and phage display265. 
 
1.8.1.1 Hybridoma technique  
 
Hybridoma technique was used to produce the first monoclonal antibody in 1975. The 
generation of this cells begins with immunization of a particular animal species, with the 
epitope or antigen target and collection of the B cells from the spleen of the sacrificed animal. 
The polyclonal mix of B cells is fused by using chemicals, by electrofusion or virus-assisted,  
with an immortal myeloma cell line lacking the hypoxanthine-guanine-phosphoribosyl 
transferase (HGPRT) gene271. The fused or hybridoma cells are then cultured in hypoxanthine-
aminopterin-thymidine (HAT) selection medium in which only the hybridoma cells are able to 
survive and proliferate since they have inherited immortality conferred by the myeloma cells 
and capacity to survive in culture medium in the presence of aminopterin conferred by B cells. 
Aminopterin blocks the principal pathway for the synthesis of nucleotides and unfused 
myeloma cells cannot produce nucleotides by the salvage pathway as they lack the enzyme 
HGPRT272. The selection is about two weeks long and after the cells, which are selected in a 
polyclonal environment, are then separated usually by limiting dilution cloning techniques. 
The cell medium supernatant of single clone cell is then tested, usually by ELISA, to select the 
specific clone producing the desired antibody. The selected hybridomas can then be stored 
away in liquid nitrogen273. Drawbacks of this technique consist in a non-stable production of 
clones, but mostly the creation of murine antibodies that are then recognized as non-self by the 
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immune system when used in therapy (HAMA effect). For this reason, Winter et al. (1988) 
initiated the method of humanization of the Fc and Fv framework regions by replacing the 
murine sequences with human germline amino acids, revolutionized the field of antibody 
therapeutics (Figure 1.12d)274. Nonetheless, difference in species in the sequence remains very 
important in research, which take advantage of the diversity in complex immunoassays studies. 
 
1.8.1.2 Immortalized B cells 
 
B cells from peripheral blood of a donor can also be immortalized with the help of the Epstein-
barr virus (EBV), which belongs to the herpes family and has the ability to efficiently 
immortalize in vitro nearly all human B cells. The B cells with the desired antibody, are 
selected and expanded before immortalization due to the low frequency of the cells. After 
immortalization although they are able to produce continuously the antibody, the EBV-
transformed cells cannot grow indefinitely since they do not have the phenotype of malignant 
cells275. These cells are also difficult to grow and do not produce the antibody with a high yield. 
However, when the B cell is extracted from the patient it allows the production of antibodies 
with unique specificity against neoantigens. In order to increase its production and stability, 
techniques of cell fusion have been applied also to these cells276. 
 
1.8.1.3 Phage display 
 
Phage display is a technique invented in 1985 to overcome the problems of immunogenicity of 
full antibodies produced in animals. In fact, with the phage display is possible by sequencing 
the variable fragments to produce short fragments antibody (scFv) which consist only of the 
heavy and light chains variable parts of the antibody (Fig12e)267. The first step in phage display 
is the production of phage libraries, created by isolating B-lymphocytes from the blood of 
humans and then isolating the mRNA and converting it into cDNA using PCR to amplify all 
the VH and VL segments. Once the segments are cloned into a vector next to the protein pIII 
of the phage genome, the phage are expanded by infection of E. coli in order to generate a 
library containing approximately 1010 cells by inoculating the library with an additional helper 
phage. The linkage to the pIII allows the VH and VL to be exposed on the outer surface of 
phage which is then tested against different antigens. After several cycles of binding of the 
phage with the targeted epitope, the selected phage is expanded a second time through infection 
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of the E. coli, the phage expressing the desired scFv isolated and the nucleotide sequences of 
the scFv VH and VL sequenced, enabling the useful creation of different antibodies166. The 
tricky part in phage display is to obtain a proper library against the desired antigen. In fact, 
different libraries can be tested more times and the process of selection is quicker, due to the 
absence of immunization and sacrifice of animals. However, without a good phage library 
becomes very hard to produce the desired antibody. Phage display is particularly indicated 
when toxic agents must be used (not suitable for animal immunisation) or when the molecule 
are very small (not immunogenic). For this reason one of the successful scFv antibody against 
Tn has been produced by Kubota et al.277 
 
1.8.2 Monoclonal antibody in cancer 
 
In the last 20 years the use of monoclonal antibody in cancer and solid tumour treatment has 
revealed to be one the most successful therapy strategy. The selection of the target for 
monoclonal antibody treatment required a deep knowledge in cancer dynamic and 
immunoglobulin activity. In early days the use of murine antibodies provoked the development 
of immune response HAMA (antibody anti-mouse antibodies) which reduced drastically their 
clinical utility (Figure 1.12d-e)278. However, with humanization in transgenic mice of the Fc 
and Fv sequences, by Winter and the production of short fragments by phage display, have 
helped reducing drastically the side immune response274. The mechanism of killing the cells 
by antibody, can occur directly by receptor blockade or agonist activity, induction of apoptosis, 
or delivery of a drug, radiation, or cytotoxic agent; immune-mediated cell killing mechanisms; 
regulation of T cell function; and specific effects on tumour vasculature and stroma. As 
previously mentioned, the Fc is fundamental in the activation of the ADCC and CDC 
systems262. Up to 2012, 12 antibodies have been approved by FDA for solid and hematologic 
cancers278. The most successful includes the one belonging to the ErbB family, to which belong 
VEGF and EFGR. In colorectal cancer, the use of anti-EGFR is effective in wildtype KRAS 
patients, while is considered not useful with mutated KRAS143. For this reason, many clinical 
trials have been developed around the molecular tumour characterization of the patients and 
the effectiveness of the monoclonal antibodies in combination with the classic chemo and radio 
therapies. Furthermore, the use of monoclonal antibodies can help T cell activation. T cells 
targeting to the tumour is improved by antibody-mediated blockade of T cell inhibitory check 
points (e.g., CTLA4 and PD1)279,280. In general, many tumours associated antigens have been 
 52 
 
identified, among which glycoprotein cluster of differentiation (CD) CD20, CD30, CD33, 
CD44 and CD52, growth factors including CEA and EGR and vascular growth factors 
including VEGF143,169,222,281. 
Finally, the introduction of the CAR-T cells in tumour treatment has become on central role in 
antigen discovery and antibody production. In fact, CARs (Chimeric Antigen Receptor) are 
fusion proteins of a selected single-chain fragment variable from a specific monoclonal 
antibody and one or more T-cell receptor intracellular signalling domains. The modification 
can occur by CRISPR-CAS or direct transfer in vivo of mRNA by electroporation. CAR-T cells 
are based on the genetic modification of patient's autologous T-cells to express a CAR specific 
for a tumour antigen, following by ex vivo cell expansion and re-infusion back to the patient. 
The CAR-T would then be able to redirect and activate the immune system against tumour 
cells282,283. Clinical trials have shown a recovery up to the 92% Acute Lymphocytic Leukaemia. 
 
1.8.3 Glycan-binding monoclonal antibodies and lectins 
 
Monoclonal antibodies and lectins have been used in research as important tools to characterize 
glycan expression, on protein and cell surfaces. Many of the lectins used are extracted from 
plants or animals, while antibodies are generated by immunization of the animal with antigen 
carrying the desired glycan or Glycan-protein conjugates (glycans coupled to carrier proteins 
such as bovine serum albumin [BSA] or keyhole limpet hemocyanin [KLH])166. 
In glycan identification, antibodies and lectins have different advantages. In fact, while lectins 
recognize specifically general ligands, such as α2-6-linked sialic acid and α1-2-linked fucose, 
monoclonal antibodies can recognize specifically other certain antigens, as sLea284. However, 
in case of antigens such Lex and sLea is not possible to distinguish N-glycans, O-glycans or 
glycolipids with neither of them. In other situations, some lectins can recognize just the N-
glycan from the O-glycans: the plant lectin Concanavalin A (ConA) does not bind mucin-type 
O-glycans in animal cells but binds only to some specific classes of N-glycans284. Most of the 
lectins and antibodies are used for glycan purification, either with affinity chromatography or 
affinity binding and immunoprecipitation (using protein A or G for non-covalent binding with 
the antibody) or lectin-induced precipitation. The same antibody and lectins are used in western 
blot experience or in cell characterization experiments, through flow cytometry, 
immunohistochemistry and ELISA. The use of glycosyltransferases and glycosidases in 
combination with antibodies and lectins is optimal for glycan characterization and function 
assays. 
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The production of monoclonal antibodies against glycans that could be use in therapy is also 
becoming a central focus in research. As previously described, the glycan tumour profiling 
shows constant alteration compared to healthy tissue and overexpression of tumour-associated 
carbohydrate antigens (TACAs), as a result of aberrant glycosylation in tumours, is usually 
correlated with poor prognosis and survival of cancer patients285. TACAs are associated both 
with inducing cancer metastasis and invasiveness and using TACAs for immunotherapy 
targeting, could play a major role, not only as diagnostic targets, but in also in preventing 
tumour metastasis and thus increasing OS. Several criteria have been chosen for selection of 
anti-tumour mAbs: i) the antibody binds the cell tumour surface ii) with high affinity, iii) the 
antibody recognize a specific tumour marker that has a limited expression in healthy tissue, iv) 
the mAb must be potent immune-mediated with non-immune-mediated cytotoxicity effects, v) 
and the antibody could directly kills tumour cells and/or vi) the mAb internalises into target 
cells so it can delivery toxic agents285. 
In 2015, Dinutuximab a mAb against GD2, a disialoganglioside overexpressed in 
neuroblastomas and melanomas, have been approved as a good mAb for cancer treatment. In 
therapy, combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), 
interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), has been shown in a phase III trial an 
effective therapeutic agent in children with high risk of neuroblastoma. Its action induces cell 
lysis via ADCC and CDC286.  
Another monoclonal antibody against Ley, named BR96, have shown to induce ACDD and 
CDC directed against tumour cells. When conjugated with BR96 was conjugated to 
doxorubicin and docetaxel (also known as SGN-15), showed remission power in advanced 
non-small-cell lung cancer patients287. In order to reduce HAMA effects, a humanized mAb 
(hu3S193) against Ley have been also created. It contains only 3%-5% mice content and in 
phase one have shown minimal toxicity in 15 patients with different tumours. In MCF-7 
xenografts mice have demonstrate capability to reduce tumour mass compared to a placebo 
treatment288.  
Monoclonal antibodies against sLea have been also produced and tested. KM231 is a murine 
anti- sLea antibody which have been shown to react against human gastrointestinal cancer and 
detection in patient serum. It have been also conjugated with ricin A chain immunotoxin and 
tested on xenograft: the KM231-ricin significantly inhibited the growth of established 
subcutaneous tumours suggesting tumour toxicity efficacy289. 5B1 (IgG1) and 7E3 (IgM) are 
also mAbs anti- sLea produced by KLH conjugated vaccine immunization. Both have shown 
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great CDC activation290. NCCT-ST-421 (IgG3) is a murine mAb which recognize Lea and 
induces ADCC and CDC to antigen-positive gastric cells. FG88 are internalizing murine 
antibody, which recognize Lea-c-x glycans. A subclone FG88.2 have shown great binding 
associated with poor outcome in the colorectal sample cohort, suggesting good potential as 
diagnostic and therapeutic tools in most aggressive colon cancers285. Other antibodies against 
sTn have been produced: B72.3, TKH2, 3F1 and 3P9. Some of these were test in clinics with 
few successes. However, 3P9 have demonstrated inhibit proliferation and migration of STn-
expressing cells as well as on tumour growth by CDC and apoptosis. A new monoclonal 
antibody against sTn have been produced, L2A5. The results demonstrated the high sensitivity 
of L2A5 mAb to detect tumour tissue with higher extension, in a sialic acid-dependent binging, 
compared to the widely used anti-STn antibodies. Loureiro et al. (2018) have proved that LA25 
have a great potential not only as diagnostic tool but also effective targeting and blocking of 
cancer-associated antigens involved in mechanisms underlying tumour progression in multiple 
types of cancer199. 
In conclusion, nonetheless the difficulties, great progression has been made in monoclonal 
antibody production against cancer-aberrant glycans. The advances in clinical trial suggest a 
great potential of monoclonal antibodies as tools for diagnosis, prognosis and treatment. 
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Rationale and aims of the thesis 
 
CRC is considered the second deathliest cancer-type and one of the most common human 
malignant diseases. Due to its localization in the body, it is still very difficult to be detected in 
the early stages, when treatment is more effective. CRC detected at late stages is more likely 
to develop recurrences, even after treatment, leading to the necessity to create a new system to 
early stages detection. Colonoscopy is the main technique used to obtain tissues, to be used for 
diagnosis, followed by molecular analysis, supporting both diagnosis and prognosis. However, 
there is still a necessity for more reliable biomarkers.   
The understanding of the pathological molecular pathways has contributed not only to 
molecular diagnosis and allowed the identification of novel targets for treatment. Nowadays, 
two targeted antibodies, Cetuximab (Erbitux), an anti-epidermal growth factor receptor 
monoclonal antibody (anti-EGFR) and Bevacizumab (Avastin), a vascular endothelial growth 
factor monoclonal antibody (anti-VEGF), are in use as treatment to all the CRC stages and for 
liver and lung metastasis. Although these treatments have been successfully used combined 
with chemotherapies, they are not efficient for all patients and have associated toxicity, because 
the targets are not cancer specific as their main function is the inhibition of cell proliferation 
processes and angiogenesis.   
Nevertheless, understanding the biology of the cancer and biomarker discovery are important 
steps in cancer research; it is essential to develop new sensitive, low cost, minimally invasive 
and accurate blood test to meet clinical needs and to improve cancer detection. 
Many modifications have been found and investigated during the stages of CRC. Many 
carriers, such as the mucin MUC1 CD44v6 and CEA, have been already identified carrying T- 
sT- (sialylated/Thomsen-Friedenreich (T)-antigen) and sTn-antigens (sialylated-Thomsen-
nouvelle (Tn)-antigen). This aberrant glycosylation is associated with poor survival, cancer 
progression, and metastasis. On the other hand, the Lewis antigens and their sialylated 
derivatives (Lex/sLex and Lea/sLea) are the most prominent cancer-associated epitopes on both 
glycoproteins and glycolipids, since their overexpression is related to CRC malignant 
transformations and may lead to increased tumour cell adhesion and motility and, thereby, 
result in metastasis.  
Therefore, the project aimed to two main goals: discovering of new biomarkers for CRC early 
detection and producing specific antibody against the new identified target. 
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 This thesis has been focussed in validating Lewis antigens as well as others E-selectin ligands 
expression in each stages of the cancer progression. In fact, the role of E-selectin ligands, such 
as sLex/a and glycoprotein CD44, has been reinforced in cancer progression and metastasis by 
several basic researches, thus studies of E-selectin ligands behaviour could be of great utility 
in biomarker research. For the same reason glycoproteins, such as CEA and CD44 have been 
studied for the development of novel monoclonal antibody production. Biomarker validation 
was performed using crossed experiments on CRC cell lines and on CRC patients’ tissue. For 
the development of the project, three main method of screening have been adopted in order to 
look for new biomarkers for Colorectal cancer (CRC): Flow cytometry, western blot and 
immunohistochemistry. In flow cytometry, live cells of CRC have been screened for the 
principal glycoproteins known to be involved in cancer progression and for the most prominent 
aberrant glycans present in CRC tissues. From this experiment, four mayor antigens have been 
selected for western blot-total cell lysate analysis: carcinoembryonic antigen (CEA), CD44, 
Lewis (Le) and sialyl Lewis (sLe). In parallel, screening of CRC tissues with a panel of the 
same antibodies used in flow cytometry have been performed. As a results of the screening 
CD44 and sLewisx/a have been selected has potential antigens for new antibodies productions. 
From the biomarker validation with immunoassay, CD44 decorated with aberrant sLex/a 
resulted to be the most promising biomarkers. Thus, monoclonal antibodies have been 
produced with the use of hybridoma technology against these targets. Novel antibodies against 
sLex/a and CD44 have been produced and validated for antigens recognition. Two clones have 
been selected for further characterization either for early diagnosis and/or CRC treatment 
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2.1 Cell lines  
 
2.1.1 Stock 
 
During the development of the project, different colorectal cancer cell (CRC) lines were 
handled. All the cell lines were genetically profiled in order to guaranty cell line authentication. 
Profiling of human cells was performed by Microsynth company, who analysed specific 
polymorphic short tandem repeat loci (STRs). STR loci were amplified using the PowerPlex® 
16 HS System (Promega). Fragment analysis was done on an ABI3730xl (Life Technologies) 
and the resulting data were analysed with Gene Marker HID software (Softgenetics). Cell line 
samples matching at ≥80 % of alleles across the eight reference loci were said to be related. 
 
Follow the list of cell lines used during the PhD project: 
 
1. CCD 841 CoN (ATCC® CRL-1790™) cell line established from normal tissue from 21 
weeks’ gestation female fetus.  
2. LS174T (American tissue and cell collection reference: ATCC®CL-188TM) cell line 
was established from Dukes’ type B adenocarcinoma of colon from a 58-year-old 
Caucasian female. Grade I- Stage 2 
3. HT29 (ATCC®HTB-38TM) derived from an adenocarcinoma of colon from a 44-year-
old Caucasian female. Grade I- Stage 3 
4. SW948 (ATCC®CCL-237TM) was established from Dukes’ type C, adenocarcinoma 
of colon from an 81-year-old Caucasian female. Grade III- Stage 2 
5. SW48 (ATCC®CCL-231TM) derived from Dukes’ type C, adenocarcinoma of colon 
from an 82-year-old Caucasian female. Grade III  IV – Stage 3 
6. SW620 (ATCC®CCL-227TM) cell line derived from a Dukes’ type C metastatic 
adenocarcinoma from colon in lymph node from a 51-year-old Caucasian male. Grade 
IV-Stage 3 
7. HEK293 T (ATCC® CRL-1573™) cell line derived from embryonic kidney from 
epithelial tissue. 
8.  JY1 [LASJY1] (ATCC® 77441™) non-adherent lymphoblastoid releasing IL-6 in the 
supernatant. Cells gently handled by Prof. Sandra van Vliet from VUMC, The 
Netherlands. 
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I. HT29 mock and HT29 FUT6. Transfected with void plasmid or plasmid containing 
human Fuc-TVI cDNA, with G418 resistance. 
II. SW948 mock and SW948 ST6GAL1. Transduced with void plasmid or plasmid 
containing human ST6Gal1 cDNA, with blastacidin resistance. 
III. SW48 mock and SW48 ST6GAL1. Transduced with void plasmid or plasmid 
containing human ST6Gal1 cDNA, with blastacidin resistance. 
IV. SW620 mock and SW620 FUT6. Transfected with void plasmid or plasmid containing 
human Fuc-TVI cDNA, with G418 resistance. 
 
2.1.2 Cell culture of colon cell lines 
 
All cell lines were adherent and were grown in T25 and T75 culture flasks (SARSTEDT), in a 
37°C incubator (Panasonic) with a humidified atmosphere and 5% CO₂. SW48, SW948 and 
SW620 cell lines were cultured in L-15 Leibowitz’s medium (Lonza) supplemented with 10% 
of Fetal Bovine Serum (FBS) (Gibco), 1% 200mM L-glutamine (Gibco) and 1% 10,000 U/mL 
Penicillin/Streptomycin (Gibco). 
LS174T cell lines were cultured in MEM (Biowest) supplemented with 10% FBS (Gibco), 1% 
200mM L-glutamine (Gibco), 1% 10,000 U/mL Penicillin/Streptomycin (Gibco), 1% 100X 
Non-Essential Amino acids (Gibco) and 1% 100mM Sodium Pyruvate (Gibco); HT29 (wild 
type and transfected), HEK293 T, CCD 841 CoN and LY ebv transformed (source of IL-6 for 
hybridoma stability) (ATCC® 77441™) cell lines were cultured with DMEM (Gibco) 
supplemented with 10% FBS (Gibco), 1% 200mM L-glutamine (Gibco) and 1% 10,000 U/mL 
Penicillin/Streptomycin (Gibco); SW48, SW948 and SW620 cell lines were cultured with L-
15 (Lonza) were supplemented with 10% FBS (Gibco), 1% 200mM L-glutamine (Gibco) and 
1% 10,000 U/mL Penicillin/Streptomycin (Gibco) in closed tap T-flasks. In fact, cells growing 
in L-15 (Lonza) medium don't need the use of CO2. 
Regardless specific experiments medium was substituted maximum every four days, respecting 
the stability time of the components. In normal passages, cells were harvested at 80/90% of 
confluency, washed with 1X phosphate buffered saline (PBS) and detached with 0.05% 
Trypsin-EDTA (TE) (Gibco) for cells-depended variable time 1'-5'. Trypsinization of cells 
must be require the minimum time possible not to intact glycosylation. Centrifugation 
(Eppendorf) at 200x g for 5 min and cultured according to the desired dilution and cells 
behaviour. All cell lines resuspended in culture medium and 10% (v/v) of dimethyl sulfoxide 
(DMSO) (Sigma) for storage at -80°C. 
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2.1.3 Cell growth curve 
 
Cell growth curves were tested for doubling times and cells behaviour. Growth curved were 
tested for a maximum of 15 days. Cells were maintained in starvation (0% FBS) for 24h and 
then distributed in T25 flasks (SARSTEDT). 20˙000 cells were seeded in 15 T25 Flasks 
(SARSTEDT). Medium was changed every 4 days for 15 days. Pictures were taken every 24h 
hours. Cells were counted with Neubauer Chamber diluted in Trypan blue (Invitrogen).  
The curves were then constructed using the Log10 value and analysed in Excel (Microsoft). 
 
2.1.4 Influence of confluency in glycosylation expression 
 
In order to test changing in glycosylation depending on cell confluency, cells at time 0 (24h 
starvation to synchronize cell cycle) were seeded at 50%, 40%, 30%, 20%, 10%. Concentration 
were calculated by proportion of 100% confluency/cm2, revealed from cell growth curves 
(paragraph 2.1.3). Depending on doubling time (24h, 36h and 48h). cells were harvested and 
tested by flow cytometry (paragraph 2.3.1) for SLewisx/a (HECA-452 clone, Biolegend), 
SLewisx (CD15s -CSLEX1 clone, BD Pharmigen), SLewisa (CA19.9-203 Abcam), STn (B72.3 
from hybridoma supernatant), CD44 (2C5, R&D). 
 
2.1.5 IC50 5-FluoroUracil  
 
SW620 wild type (wt), mock and FUT6 cells (lxl04) were seeded in 96-well microtitration 
plates 24 h before exposure to various concentrations of 5-FluoroUracile (5-FU) (0.1 to 100 
µM) for 72h. Drug sensitivity was determined by MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide)] cytotoxicity assay (Promega) for 4h. After exchange of MTT 
with DMSO and incubation for 30 min at 37˚C, sample were analysed. Each concentration was 
performed in four replicate wells. Untreated cells were used as the control. The colorimeter test 
was measured at Absorbance 497 nm. The average growth inhibition rates compared with the 
control were calculated from the result with at least three independent experiments. The 5-FU 
concentrations causing a 50% growth inhibition compared with the controls (IC-50) were 
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calculated from a semilogarithmic dose-response curve by linear interpolation, using GraphPad 
Prism 7 Software. 
 
2.1.6 Transduction of LS174T cell line with lentivirus 
 
A three-plasmid system was used that contemplates a lentiviral construct with the cDNA 
sequence of interest, an expression vector with the vesicular stomatitis virus G envelope 
glycoprotein gene (VSV-G) and a packing vector. They also have present truncated long-
terminal residues (LTR) for self-inactivation. Firefly luciferase cDNA-LUC1(Photinus 
pyralis) is a 1,6kb fragment that codes for 550 amino acids residues and a 61kDa protein. 
Firefly luciferase (Photinus pyralis) genes were before amplified by polymerase chain reaction 
(PCR) and cloned into different the pLenti6/V5 Directional TOPO cloning vector containing 
the CMV promoter. Lentiviral particles were generated by co-transfection of HEK 293 T cells 
with the three plasmids, using pPACK Lentivector Packing Systems (Bioscience). 
5x105 cells per well were seeded with 106-109 TU/ml of virus to a concentration of 8 µg/ml of 
polybrene (Sigma-Aldrich) in 2 ml of medium. The plate was shaken and incubated overnight, 
37º, 5% CO2. After 24h the new culture medium was placed with 3,2 µg/ml of Blasticidin 
(Thermo Fisher) for two weeks. Cells that were already transduced (i.e. SW948/48 ST6Gal1) 
carrying the Blasticidin antibody selection gene, were selected manually/ To performed it, the 
cell cultures were kept growing until they could form visible and isolated colonies. Twenty-
four random colonies were then picked by small papers imbibed in trypsin that would detach 
them. The colonies were cultured in 24 well plates (Greiner Bio-One Cellstar) or in no-treated 
culture dish (Stemcell) for 3D culture. 
 
2.1.6.1 Luciferase assay 
 
The enzymatic reaction requires the substrates luciferin, with co-factors ATP, Mg2+ and O2: the 
reaction was performed using Luciferase Assay System Kit (Promega). 
Firefly luciferase emits a yellow-green light corresponding to a wavelength of 560nm.The 
luciferase assay offers a nearly instantaneous measure of total luciferase expression in the 
lysate; therefore, the emitted light is proportional to the luciferase concentration. Although the 
high efficiency of the assay, the luciferase half-life is less than three hours due to its low 
intrinsic stability, as a disadvantage. 
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24 hours before the detection assay, 105 cells per well were cultured in a 96 well plate (Oregon 
scientific). After 24h the medium was removed, and the cells were washed with 1X PBS. 1X 
Reporter Lysis Buffer (RLB) from the kit was added to each well and a single freeze-thaw 
cycle at -80˚C was performed to ensure the complete lysis. At room temperature, luciferase 
assay reagent was added, composed by luciferase assay buffer and luciferase assay substrate. 
Samples were read at ChemiDoc Touch (Biorad) to check for chemiluminescence.  
 
2.2 Antibodies and lectins 
 
The use of antibodies and lectin-chimeras was necessary in all the immunoassay experiments 
performed: flow cytometry (FC), immunofluorescence, Förster resonance energy transfer 
(FRET), immunoprecipitation (IP), immunohistochemistry (IHC), enzyme-linked 
immunosorbent assay (ELISA) and western blot (WB).), western blot (WB). Primary 
conjugated and not conjugated used are listed in the following Table 2.1. Secondary conjugated 
antibodies used are specified the appropriate technique section. In the table are listed three 
main categories of antibody used: specific for CRC classification experiments and glycoprotein 
and glycans used throughout the entire project development. 
 
Table.2.3 List of primary antibodies used in immunoassays. 
 ANTIBODY 
EPITOPE 
ANTIBODY 
NAME 
(lectin name) 
ANTI
- 
PRODUCED IN CLONE 
ISOTYP
E 
µg/
mL 
Brand 
C
R
C
 C
L
A
S
S
IF
IC
A
T
IO
N
 
5-
hydroxytryptamin
e receptor 2B 
HTRB2 human rabbit polyclonal  0.1 Sigma 
FERM domain 
containing 6 
FRMD6 
mouse
, 
human 
rabbit polyclonal  0.2 Sigma 
Caudal Type 
Homeobox 
Transcription 
Factor 2 
CDX2 human rabbit polyclonal IgG 1 
Novus 
biological 
Zinc finger E-box-
binding homeobox 
1 
ZEB1 human rabbit polyclonal  0.2 Sigma 
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Human epidermal 
keratin 
AE1/AE3 
Bovin
e, 
Chick
en, 
Huma
n, 
Mouse
, Non-
human 
primat
e, 
Rabbit
, Rat 
mouse monoclonal IgG1 0.2 Thermo 
G
L
Y
C
O
P
R
O
T
E
IN
S
 
CEA 
(CEACAM5) 
CD66e human mouse 3E10-3 
IgG1 
kappa 
1 
Immunotool
s 
CD13 CD13 human mouse 3D8 IgG2a 0.5 
BD 
Pharmigen 
CD44 CD44-APC human mouse P2A1 IgG2a,k 0.5 
USBiologica
ls 
CD44 CD44 
Mouse
, Rat, 
Huma
n 
rabbit polyclonal n.a. 0.1 AbCam 
CD44s Pan 
Specific 
CD44 human mouse 
2C5(monocl
onal) 
IgG2A 0.5 R&D 
G
L
Y
C
A
N
S
 
SLe x/a // CLA HECA 
Huma
n, 
Mouse 
rat 452 IgM, κ 0.5 Biolegend 
E-selectin ligands 
E-selectin /CD62E 
(lectin) 
human 
Mouse myeloma 
cell line 
X 
chimera 
IgG 
0.1 R&D 
SLe a CA19.9 human mouse CA19-9-203 IgG, µ 0.2 Abcam 
SLe x CD15s human mouse CSLEX1 IgM, κ 0.5 
Bd 
pharmigen 
Le x CD15 human mouse HI98 IgM, λ 0.5 Biolegend 
Lewis y A70/C-C8 human mouse 7le IgM 0.2 Santa Cruz 
sTn B72.3 human mouse monoclonal IgG1 n.a.  
sTn LA25 human mouse monoclonal IgM n.a.  
sTn 3F1 human mouse monoclonal IgG1 n.a.  
Tn 5F4 human mouse monoclonal IgM n.a.  
 
2.3 Immunoassays 
 
2.3.1 Flow Cytometry 
 
The expression at cell surface was analysed by flow cytometry. Approximately 3×105 cells 
were harvested per condition and resuspended in PBS buffer. Cells were washed and incubated 
for 30 min at 4˚C with primary conjugated and not-conjugated antibodies. Subsequent washing 
steps were performed at 1000/1500 RPM for 2 min, and not-conjugated primary antibodies 
were detected with FITC conjugated anti-mouse Ig (Dako, F0232; dilution 1µg/mL) or APC 
anti-rat Ig (BD Pharmingen, 1µg/mL) for 15 min in the dark. After washing at 1000/1500 RPM, 
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data acquisition was carried out using Attune Acoustic Focusing Cytometer (Applied 
Biosystems) in which 10 000 events, gated on forward scatter (FSC) vs. side scatter (SSC), 
were collected for each sample. Data were collected through BL1-A and RL1-A channels. 
After 1X PBS cell suspension aspiration, the density plot graph FSC-A vs SSC-A is generated 
and then the gate is drawn to cover the cell population within 10 000 events. This gate is used 
to generate a histogram graph of fluorescence channel vs count where the positive cells peak is 
counted from the end of the unstained peak. At this point the median fluorescence intensity 
(MFI) or % of positive cells is extrapolated.  
If required, the cells were fixed in 4% Paraformaldehyde (PFA) before to be analysed. Data 
was subsequently analysed using FlowJo vX 0.7 software.  
 
2.3.2 Antibodies blocking migration by wound scratch assay 
 
Cells were cultured in Culture-Insert 2 Well in µ-Dish 35 mm (Ibidi) inside 12-well plate 
(Invitrogen) until 100% confluence was reached; after silicon membrane removal, cell were 
maintained outside incubator in L-15 medium (Lonza) at 37˚C in gentle motion. Antibodies 
diluted at concentration of 0.5µg/mL were added every 3 days [SLewisx (CD15s -CSLEX1 
clone, BD Pharmigen), SLewisa (CA19.9-203 Abcam), CD44 (anti-CD44-pan 2C5, R&D)] 
and relative controls prepared. Pictures were taken every 24h with an inverted microscope 
equipped with a digital camera (Xerox). For analysis, a fixed area of the wound was defined. 
Every 24 hours, the area occupied by migratory cells was measured and discounted to the initial 
area until all the wound was filled by cells. 
The wounded area in the photographs was measured using ImageJ software and the percentage  
 
2.3.3 Immunofluorescence 
 
0,4 x 106 cells/mL cells were cultured on top of round coverslips inside 12 well plates (Orange 
Scientific) and cultivated for 24h. In case of intracellular staining, after 1X PBS wash, they 
were fixed and permeabilized with 200µl of Fixation/Permeabilization Solution (Kit from BD 
Biosciences) for 20 minutes at 4ºC. After three washes with 1X PBS for 5 min, cells were 
blocked with 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich) and washed three times 
again. In case of extracellular staining, the cells were directly incubated with 1 ml of 
Fixation/Permeabilization Solution (Kit from BD Biosciences) for 30 minutes. Dilution of 
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primary antibody was chosen with the same criteria of flow cytometry in 
Fixation/Permeabilization Solution (Kit from BD Biosciences); incubation for 30 min at room 
temperature (see paragraph 2.3.1). After x3 5 min wash with 1X PBS, cells were incubated 
with secondary antibodies with anti-rat IgM-FITC (1:50) (BD Pharmingen), anti-mouse IgG-
FITC (1:100) (Dako) or anti-mouse Ig-FITC (1:100). To stain the nucleus, To-Pro3-Alexa 
Fluor 633 (Invitrogen) or 4’,6-diamidino-2-phenylindole (DAPI) (1μg/mL) (ThermoFisher) 
were used by covering the cells for 15 minutes and then washed 3Xx3 with 1X PBS, 5 min. 
Finally, the coverslip sealed with mounting medium Mowiol (Dabco) and analysed in the 
Fluorescence Microscope. The microscope used is Axiolmager D2 – Zeiss, with a 40x 
objective and the laser filters of 358nm, 488 nm and 633 nm to excite FITC and Alexa Fluor 
633, respectively. The images obtained were processed by Fiji software.  
Fluorescence intensities from five randomly selected microscopic fields of cells were 
quantitatively analysed with ImageJ software using the Corrected Total Cell Fluorescence 
(CTCF) formula: 
 
CTCF = Integrated density – (Area of selected cell x Mean fluorescence of background 
readings) 
 
2.3.4 Immunohistochemistry 
 
A cohort of 40 clinical cases of colon and rectum cancer (adenocarcinomas and adenomas) 
were obtained from the Portuguese Institute for Oncology of Porto (IPO-Porto, Portugal), 
according to the local committee of ethics. All procedures involving tumour tissues have been 
authorized by the Portuguese Institute of Oncology of Porto ethics committee. Tissue 
comprehend a variety in stages and cancer location. All the tissue come from 5-fluorouracile 
(5-FU) treated patients. 
Formalin-fixed, paraffin embedded (FFPE) tissues were screened by immunohistochemistry 
using the biotin/streptavidin system. FFPE tissue sections were deparaffinized with xylene, 
rehydrated with a graded series of alcohol washes and subjected to heat-induced antigen 
retrieval using citrate buffer pH=6.0 (Vector Laboratories) for 15 min in the microwave, after 
pre-heating of the solution at maximum power rating for 5 min. Sections were incubated with 
0.3% hydrogen peroxide (Merck KGaA) for 25 min, blocked with UV Block® (Thermo 
Scientific, TL-060-HD) and incubated overnight at 4oC in a wet chamber for glycan antigens 
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[anti-CA19.9 1:100, anti- CD15s 1:100, anti-CD15 1:100, anti-Lewisy 1:75, HECA-452 
1:100], for glycoproteins [anti-CD44 polyclonal 1:4000, anti-CEA 1:50] for CSM-CRC 
markers [ anti-HTR2B 1:3000, anti-FRMD6 1:3000, anti-AE1/AE2 1:500, anti-ZEB 1:4000 
and anti-CDX2 1:2000]. 
After washing with PBS-Tween, biotinylated secondary antibody anti-mouse IgG (H+L) was 
added to tissue sections, before incubation with streptavidin (Thermo Scientific, 434301). 
Binding was detected by incubation with 3,3’-diaminobenzidine (ImmPACT™ DAB, Vector 
Laboratories, SK-4105) for 4 min. Nuclei were counterstained with hematoxylin for 1 min. 
Positive and negative control sections were tested in parallel. The negative control sections 
were performed devoid of primary antibody. Positive controls consisted of known positive 
tumour tissues for the antigen in study. Tumours were classified as positive when mAb 
immunoreactivity was observed by microscopic presence of brown chromogenic product in 
tumour cells. Staining was assessed double-blindly by two independent observers and validated 
by an experienced pathologist. Whenever there was a disagreement, the slides were reviewed, 
and consensus was reached.  
 
2.3.4.1 In situ proximity ligation assay 
 
In situ proximity ligation assay (PLA) was performed in FFPE sections selected with the best 
score of intensity for anti-CD44 polyclonal, anti-CD15s and anti-CA19.9 for detection of 
CD44-sLe
x/a 
glycoform using the Duolink in situ Detection Reagents (Olink Bioscience, 
Uppsala, Sweden). FFPE tissues were deparaffinized, rehydrated and submitted to acid and 
heat-induced antigen retrieval, followed by incubation with 3% hydrogen peroxide and 
blocking solution in a humidity chamber. The Duolink in situ Probemaker was used according 
to the manufacturer instructions to conjugate the PLA oligonucleotide arms directly to primary 
antibodies also used in immunohistochemistry. Conjugated mAbs to CD44 (1:50) and anti-
CA19.9 (1:100) or anti-CD15s
 
(1:100) (labelled with PLA probes) were diluted in PBS with 
5% BSA and with 1:20 of assay reagent (Olink Bioscience) and slides incubated for 1h at room 
temperature. Slides were then washed with wash buffer A (0.01 M Tris, 0.15 M NaCl, and 
0.05% Tween 20). For the ligation step, the two oligonucleotides (1:5) and the ligase (1:40) 
both diluted in pure water, was added to slides and incubated for 30 min at 37 °C. After 
washing, the amplification solution, consisting of nucleotides and fluorescently labelled 
oligonucleotides (1:5) together with polymerase (1:80) (both diluted in pure water), were added 
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to the samples. The oligonucleotide arm of one of the PLA probes acted as a primer for a 
rolling-circle amplification reaction using the ligated circle as a template, generating a repeated 
sequence product. The fluorescently labelled oligonucleotides were hybridized to the 
amplification product. The slides were washed with 0.2 M Tris and 0.1 M NaCl. To visualize 
the nuclei, cells were incubated DAPI (Sigma-Aldrich, 0.4 mg/ml). Samples were examined 
under a Zeiss Imager.Z1 Axio fluorescence microscope (Zeiss, Welwyn) PLA results were 
evaluated by two observers and validated by an experienced pathologist, who independently 
registered cytolocalization of staining. Negative controls included analysis without primary 
antibody and sialidase treated tissue sections.  
 
2.3.5 RT q-PCR 
 
Total Ribonucleic acid (RNA) was extracted using GenEluteTM Mammalian Total RNA 
Purification kit (Sigma-Aldrich), according to manufacturer’s instructions. Optional on-
column DNaseI digestion (Qiagen) was also performed. Next, 10 μL of purified RNA was 
reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). The conversion mix was prepared by adding, for each PCR tube (VWR), RT 
Buffer, RT Random Primers, deoxynucleotides (dNTPs), MultiScribe Reverse Transcriptase 
enzyme and RNase free water (NZYTech), following the manufacturer’s instructions. 
Complementary Deoxyribonucleic acid (cDNA) conversion was performed in a thermocycler 
(Programmable Thermal Controller PTC-100TM – MJ Research) with the following program: 
Step I -10 minutes at 25ºC, Step II - 120 minutes at 37ºC and Step III - 5 seconds at 85ºC. Real-
time PCR was performed starting with preparing the RT-PCR mix, adding for each RT-PCR 
tube (Simport), 2 μL of cDNA, 2 μL of diluted probe 1:4, 1 μL of RNase free water and 5 μL 
of the Master Mix Fast (Applied Biosystems). The probes used was St6GalNAc1(Applied 
Biosystems). All experiments were performed in duplicates and two endogenous controls were 
used, β-actin and Glyceraldehyde 3-phosphate dehydrogenase (GADPH). Samples were run in 
RotorGene 600 (Corbett) with the following program: Step I – 1 cycle, 20 seconds at 95ºC and 
Step II – 40-50 cycles, 3 seconds at 95ºC and 30 seconds at 60ºC. Finally, results were analysed 
by calculating the relative mRNA levels using the adapted formula (2.2), which infers the 
number of messenger RNA (mRNA) molecules of the interest gene per 1000 molecules of the 
endogenous controls291. GraphPad Prism 7 Software was also used. 
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(2.2) Relative mRNA level = 2-ΔCt x1000 
 
2.4 Biomarker isolation and study 
 
2.4.1 Protein extraction 
 
Total protein extraction: 5x106 cells/mL were lysed in IP Lysis/Wash buffer (Thermo 
Scientific) complemented with 1% Protein Inhibitors (Roche) and incubated for 20 min in ice. 
Incubation was interrupted every 5 min with vortexing for 1 min. Subsequently, cell debris 
were precipitated by centrifuged at 10000 x g for 10 min and protein concentration was 
quantified using Pierce BCA Protein Assay Kit (Thermo Scientific) following manufacturer’s 
instructions. 
Membrane protein extraction: membrane protein extraction was performed with the Mem-
PER™ Plus Membrane Protein Extraction Kit (Thermo scientific) following manufacturer’s 
instructions (Protocol 1: Adherent Mammalian Cells). 1% Protein Inhibitors (Roche) was 
added before the use of the permeabilization buffer. Regardless the instruction, cell 
concentration may depend on the density of the protein required. 
All the protein extracts were stored frozen at -80˚C, in order to reduce variables and to guaranty 
experiment continuity. 
 
2.4.2 Immunoprecipitation 
 
For protein isolation, 100-200 µg of cell membrane extracted from LS174T and HT29FUT6 
with Mem-PER™ Plus Membrane Protein Extraction Kit (Thermo scientific) were precleared 
with Protein G-agarose (Invitrogen). Precleared samples were incubated with 3µg of anti-
CD44 or HECA-452, or E-selectin-Ig (in presence of calcium) for 2h and then incubated with 
Protein G-agarose beads (pre-blocked with 1% BSA) overnight. Mix with beads was washed 
three times with lysis buffer and boiled in SDS-PAGE sample loading buffer for 5 minutes or 
precipitated with 0.1 M Glycine (stabilized with 5% 1M Tris-HCl pH 9.5). Then E-selectin-Ig 
immunoprecipitated (IP) is treated with PNGase F (Sigma-Aldrich) and Neuraminidase from 
Clostridium perfringens (Roche) enzymes as recommended by the manufacturer. Finally, 
samples of E-selectin-Ig IP and CD44 IP (non-treated or treated with PNGase F/ 
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Neuraminidase) were subjected to reducing 8% SDS-PAGE, transferred to PVDF membrane, 
and immunoblotted with mAb HECA-452, CD44-h-pan or E-selectin-Ig. 
 
2.4.3 SDS-PAGE and Western blot 
 
SDS-PAGE: Sample were loaded intoin 4% stacking gel (dH2O, 30% Acrylamide, 0.5 Tris 
pH6.8, 10% Sodium dodecyl sulphate (SDS) [Invitrogen], Tetramethylethylenediamine 
(TEMED) [Sigma-Aldrich], 10% Ammonium Persulfate (APS) [Sigma-Aldrich]) and 
separated into a 8% resolving gel (dH2O, 30% Acrylamide, 1.5 Tris pH8.8, 10% SDS 
[Invitrogen], TEMED [Sigma-Aldrich], 10% APS [Sigma-Aldrich]) in Running buffer) at 100 
V for 30 min followed by 120 V for 1h.  
Transfer: Proteins separated by SDS-PAGE proteins were transferred into a polyvinylidene 
fluoride (PVDF) membrane at 400 mA for 1 hour at 4ºC and using Transfer buffer (25 mM 
Tris, 192 mM glycine, pH 8.3, 20% methanol). Membranes were blocked with 7,5% non-fat 
milk powder dissolved in Tris-buffered saline- tween (TBST) 0.1% for 1 hour at RT. 
Membranes were incubated with HECA-542 mAb (1:1500), anti-CD44-h-pan-2C5(1:1500), 
anti-CEA – CD66e (1:500), anti-CD15s - CSLEX1(1:500), diluted in TBST 0.1%  and E-
selectin chimera (1:1000 overnight at 4ºC) TBST 0.1% and 2 mM CaCl2.  
Revealing: Primary antibodies were washed 3X for 10 min in TBST 0.1%. Next, membranes 
were incubated with appropriated Horseradish peroxidase (HRP)-conjugated secondary 
antibodies diluted in TBST 0.1% for 1 hour at RT (anti-mouse IgG 1:5000, Southern Biotech; 
anti-rat Ig, 1:1500, Southern Biotech). Chimera antibody, E-selectin was washed TBST 0.1% 
and 2 mM CaCl2 and stained with anti CD62E (1:1500) (anti-human, rat; clone 68-5H1, BD 
Pharmigen) for 1h at room temperature. After 3X washes of 10 min, was stained with anti-rat 
HRP IgG (H+L) (1:1000) (Southern Biotech), diluted TBST 0.1% and 2 mM CaCl2. 
Final 3X wash with TBS-t 0.1% was followed by staining with Lumi-light Western Blotting 
Substrate (Roche) for detection. Revelation was performed exposing the membranes to 
Amersham Hyperfilm ECL (GE Healthcare Life Sciences) and using Corestream® Kodac® 
autoradiography GBX developer and Corestream® Kodac® autoradiography GBX fixer 
(sigma).   
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2.5 Biomarker glycosylation characterization  
 
2.5.1 Enzyme treatment 
 
The sialidase treatment was performed to remove the sialic acid from structures according to 
the experimental case, once it had hydrolysed the α2-6 and α2-3 sialic acid linkage. After the 
first wash, 100µg/µL of immunoprecipitated from E-selectin-Ig (R&D) was mixed with 400 µl 
of sialidase buffer. A sialidase treated and non-treated control samples were prepared. Sialidase 
from Clostridium perfringes, (Roche) was added to a final concentration of 100 mU/ml. Both 
samples were incubated at 37ºC, for 90 minutes in continuous mixing.    
PNGase F treatment was performed on protein immunoprecipitated from E-selectin-Ig (R&D) 
to remove N-glycans. Samples and control samples were diluted in 3X denaturing buffer (New 
England, Biolabs) and denatured at 100˚C for 10 min. following PNGase F reaction was 
performed following manufacturer's instruction (New England, Biolabs) with 500U/µL at 37˚C 
in continuous mixing.  
Both enzyme reactions were tested by 8% SDS-PAGE and Western Blot analysis, described in 
section 2.3.3.  
 
2.5.2 Förster Resonance Energy transfer  
 
Förster/Frequency Resonance Energy transfer or FRET is a no-radioactive transfer from a 
suitable molecule donor to a suitable molecule acceptor. FRET happens when emission 
wavelength fluorophore of the donor overlaps with the excitation wavelength of the acceptor, 
and if the two molecules are at the max distance of 9 nm. For the FRET experiment were used 
three primary antibodies: anti-CD44, rabbit polyclonal (Abcam), anti-CD15s- CSLEX1 mouse 
(BD Pharmigen), anti-CA19.9-203 mouse (Abcam). Secondary conjugated antibodies were 
chosen in pairs for each different experiment, as shown below: 
1. anti-rabbit FITC IgG 495-519nm (Sigma, 1 µg/mL) --> anti-mouse IgG PE 566-576 nm 
(Sigma, 1µg/mL) 
2. anti-mouse IgG PE 566-576nm (Sigma, 1 µg/mL) --> anti-rabbit Cy5 IgG 649-666 nm 
(Abcam, 1µg/mL) -->  
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3. anti-rabbit Cy3 IgG 554-568nm (Abcam, 1 µg/mL) --> anti-mouse Alexa Fluor 633 IgG 
631-650 nm (Life Technologies, 1 µg/mL) 
Samples were analysed in a Attune Acoustic Focusing Cytometer (Applied Biosystems) with 
using (?) BL1, BL2 and RL1 channels. Data were analysed with FlowJo v10 and GraphPrims 
v7. 
 
2.5.3 Liquid Chromatography-MS-MS 
 
Proteins were in-gel digested with trypsin after reduction (dithiothreitol) and alkylation 
(iodoacetamide). Tryptic peptides were then extracted from the gel slices, lyophilized, 
dissolved in solvent A (water/0.1 formic acid (FA) v/v), and subsequently analysed by online 
C18 nano-HPLC MS/MS with a system consisting of an Easy nLC 1200 gradient HPLC system 
(Thermo, Bremen, Germany) and a LUMOS mass spectrometer (Thermo). Fractions were 
injected onto a homemade pre-column (100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm, Dr. 
Maisch, Ammerbuch, Germany) and eluted via a homemade analytical nano-HPLC column 
(20 cm × 75 μm; Reprosil-Pur C18-AQ 3 μm) using a gradient from 10 to 40% solvent B 
(20/80/0.1 water/acetonitrile/FA v/v/v) in 20 min. The nano-HPLC column was drawn to a tip 
of ∼5 μm and acted as the electrospray needle of the MS source. The LUMOS mass 
spectrometer was operated in data-dependent MS/MS mode (cycle time 3 seconds) with a 
normalised collision energy of 32 and recording of the MS2 spectrum in the Orbitrap. In the 
master scan (MS1) the resolution was 120 000, and the scan range was from m/z 400–1500 at 
an AGC target of 400 000 with maximum fill time of 50 ms. Dynamic exclusion after n = 1 
with exclusion duration of 10 s was applied. Charge states 2–5 were included for MS2. For 
this, precursors were isolated with the quadrupole with an isolation width of 1.2 Da. The MS2 
scan resolution was 30 000 with an AGC target of 50 000 with maximum fill time of 60 ms. 
MS/MS data were searched against a human protein database (Uniprot, 67915 entries) using 
the Mascot search algorithm (Matrix Science, London, UK; version 2.2.04). Trypsin was 
selected as enzyme (up to two missed cleavages were allowed) and the MS and MS/MS 
tolerance were 10 p.p.m. and 0.02 Da, respectively. Carbamidomethylation of cysteine was set 
as a fixed modification and oxidation of methionine was specified as a variable modification. 
Scaffold (version Scaffold_4.8.4, Proteome Software Inc., Portland, OR) was used to validate 
MS/MS based peptide and protein identifications applying an FDR of 1% at the peptide level.  
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2.6 Antibody production 
 
2.6.1 Antigen preparation and isolation 
 
Two different antigens preparations for immunization were made, membrane protein and 
immunoprecipitated proteins  
Membrane proteins were prepared by protein extraction of LS174T membrane proteins using 
the Mem-PER™ Plus Membrane Protein Extraction Kit (Thermo scientific). Second sample 
was prepared by isolation and purification of CD44 extracted from LS174T membrane protein 
lysate.  In this case, 500 µg of LS174T membrane protein were purified with 80µg of protein 
G beads (Invitrogen).  Precleared samples were incubated with 15µg of anti-CD44 for 2h and 
then incubated with Protein G-agarose beads (pre-blocked with 1% BSA) overnight (paragraph 
2.4.2) and precipitated with 0.1M Glycine precipitation in a volume of 200 µL. Sample was 
run in native acrylamide gel 8% (using paragraph methods 2.4.3, avoiding the use of SDS and 
2-Mercaptoethanol), in a unique well of 500 µL volume. Controls for western blot revealing 
were also prepared. Samples run for 100V 1.30h. At end of the run the gel was separated in 
two parts. One containing the sample designed for immunization (Part A) and the other 
destined for western blot developing (Part B). Bands from part A were cut following protein 
ladder (New England, BioLabs) standards and stored at 4˚C, while part B was transferred in 
PVDF membrane at constant 400 mA for 1h. Membranes were blocked with 7,5% non-fat milk 
powder dissolved in TBST 0.1% for 1 hour at RT. Membranes were incubated with anti-CD44-
h-pan-2C5(1:1500). Primary antibodies were 3X washed for 10 min in TBST 0.1%; and 
subsequentially membranes were incubated with appropriated Horseradish peroxidase (HRP)-
conjugated secondary antibodies diluted in TBST 0.1% for 1 hour at RT (anti-mouse IgG 
1:5000, Southern biotech). Final 3Xx3 wash with TBST 0.1% was followed by staining with 
Lumi-light Western Blotting Substrate (Roche) for detection. Revelation was performed 
exposing the membranes to Amersham Hyperfilm ECL (GE Healthcare Life Sciences) and 
using Corestream® Kodac® autoradiography GBX developer and Corestream® Kodac® 
autoradiography GBX fixer (Sigma).   
The band revealing CD44 in part B was selected among the stored bands of part A, diluted in 
PBS and send for immunization. Maximum yield possible achieved is 0.5 µg/µL.  
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2.6.2 Immunization 
 
Female Balb/c mice aged 6 weeks (Harlan UK) (Ref: 0421/000/000/2017) were used and fed 
ad libitum. Good animal handling practices as well as good laboratory practices used at 
IHMT/UNL animal room are according EU Directives (2000/54/CE Exposure to biological 
agents, 88/320/CE Good laboratory practices, 90/679/CE, 405/98/PT and 1036/98/PT). Efforts 
were made to minimize suffering, and at the completion of the study, the mice were euthanized 
by CO2 followed by cervical dislocation. 
MAb production was performed according to the hybridoma technology described by Köhler 
and colleagues. First group of six-week-old female Balb/c mice (Harlan UK) were immunized 
intraperitoneally with 100 µg of LS174T membrane extraction emulsified 1:1 (v/v) with 
complete Freund's adjuvant (Sigma, F5881) followed by 2 additional injections of LS174T 
membrane proteins emulsified with incomplete Freund's adjuvant (Sigma, F5506) with 
intervals of 21 days. Second group of six-week-old female Balb/c mice (Harlan UK) were 
immunized intraperitoneally with 100 µL (supposed 40µg) isolated CD44 from LS174T 
emulsified 1:1 (v/v) with complete Freund's adjuvant (Sigma, F5881) followed by 2 additional 
injections of isolated CD44 isolated from LS174T emulsified with incomplete Freund's 
adjuvant (Sigma, F5506) with intervals of 21 days. The acrylamide was kept in the sample (no 
extra purification needed) and was used has extra adjuvant. Blood samples were collected from 
the mice cheek throughout the immunization procedure and collected serum was screened by 
indirect ELISA, as described below. 
 
2.6.3 Hybridoma technology 
 
When the serum presented the desired and specific immune response, a final boost injection 
was performed three days before the animals were euthanized and subsequently the spleens 
were harvested. Splenocytes from the immunized mouse were mixed with Sp2/0-Ag14 
myeloma cells (ATCC® CRL-1581™) at a ratio of 3:1 and fused in the presence of 
polyethylene glycol/dimethylsulphoxide (PEG/DMSO, Hybri-max Sigma-Aldrich, P7306) 
using a standard protocol. Cells were plated into 96-well flat bottom micro plates (Orange 
Scientific) and maintained in selection medium, DMEM medium (Gibco) supplemented with 
HAT medium (1×10−4 M hypoxanthine, 4×10−7 M aminopterin, 1.6×10−5 M thymidine (Sigma), 
10% (v/v) FBS (Sigma), 2 mM L-glutamine, 0.2 mg/ml gentamycin (Sigma), 1 mM sodium 
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pyruvate (Gibco), 1% (v/v) non-essential amino acids (Gibco) and incubated at 37oC, 95% 
humidity containing 5% CO2 for 7-12 days. Hybridoma cells were expanded in HAT medium, 
screened by indirect ELISA and cloned by the limiting dilution method to obtain stable single 
clone cell lines. Selected hybridomas were further adapted to grow in medium without HAT 
supplementation. 
Two hybridoma series were created named miceLS174T (from immunization with membrane 
protein total lysate) and miceCD44 (from CD44 extracted from LS174T membrane proteins) 
The hybridoma cells were cultured and cloned to produce antibody against SLewis antigens 
and/or CD44. The hybridoma cells were mainly adherent and were maintained on T25 and/or 
T75 culture flasks (SARSTEDT) on an incubator at 37ºC, with a humidified atmosphere and 
5% CO2, and cultivated in complete DMEM medium (Gibco). The hybridoma cells were 
detached from the culture flasks with a scraper whenever their confluence was approximately 
of 80%. After centrifugation at 1200 RPM for 5 minutes, the supernatant was collected and 
stored for further analysis. The corresponding pellet was resuspended in complete medium for 
subculture or resuspended in fetal bovine serum (FBS) (Gibco) with 10% (v/v) of DMSO 
(Sigma) for storage in liquid nitrogen 
 
2.6.4 Cloning 
 
To select the stable hybridoma clone producing antibodies, 100 hybridoma cells diluted in 
60mL of DMEM with the same composition described in 2.1.2 were distributed by five 96-
well plates with 200μL each well (calculating 0.5 cell/well). When the cells were confluent the 
supernatant was collected, and the ELISA assay was performed as described in 2.6.6. The 
exceed clones were resuspended in complete medium for subculture or resuspended in fetal 
bovine serum (FBS) (Gibco) with 10% (v/v) of DMSO (Sigma) for storage in liquid nitrogen. 
 
2.6.5 Dot blot 
 
Dot blot using a dot microfiltration apparatus. A volume of 30µl of 5µg/µL of HT29 FUT6, 
LS174T and SW620 wt cell lysate was dotted on a nitrocellulose membrane (Bio-rad) and 
vacuum was applied. Next, the membrane was blocked using 3% milk-PBST solution for 1h 
at RT. After blocking the membrane was washed three times with PBST and further incubated 
with hybridomas supernatant total supernatant for 1h at RT. After 3X washes with PBST the 
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membrane was incubated for with anti-mouse IgG (Fc specific) HRP (Sigma-Aldrich) for an 
additional 1h at RT. 3X washes with PBST were followed by staining with Lumi-light Western 
Blotting Substrate (Roche) for detection. Revelation was performed exposing the membranes 
to Amersham Hyperfilm ECL (GE Healthcare Life Sciences) and using Corestream® Kodac® 
autoradiography GBX developer and Corestream® Kodac® autoradiography GBX fixer 
(Sigma-Aldrich). 
 
2.6.6 Enzyme-linked immunosorbent assay (ELISA) 
 
Mouse serum titrations and screening of hybridoma supernatants of miceLS174T (immunized 
with total lysate) were determined by indirect ELISA using as antigens; commercial against 
Bovine Submaxillary Mucin (BSM), Porcin Submaxillary Mucin (PSM), Sialyl Lewisa, or 
Sialyl Lewisx from Sigma, or recombinant 36 kDa CD44 (Abcam), or 5 µg/mL membrane 
lysates of LS174T, HT29FUT6, SW948wt [partially positive for CD44] and, or SW620 wt cell 
lines.  
Mouse serum titrations and screening of hybridoma supernatants of miceCD44 (immunized with 
recombinant human CD44) were determined by indirect ELISA using as antigens: CD44 
[Abcam, Recombinant human 36kDa], CEA [Abcam, Recombinant human 76kDa], Sialyl 
Lewisa [Sigma Aldrich], Sialyl Lewisx [Sigma Aldrich] and 5 µg/mL membrane lysates of 
LS174T, HT29FUT6, SW948wt and SW620 wt  
96-well polystyrene plates (Corning) were coated overnight at 4˚C with 50 µl of 5 µg/mL of 
cell lysates [LS174T, HT29 FUT6, SW948 wt, SW620 wt], dissolved in Carbonate-
Bicarbonate Buffer solution pH=9.2; no blocking was followed the coating.  
3µg/mL of CEA, sialyl Lewisx/a, BSM, PSM and 0.5 µg/mL of CD44 were coated overnight at 
4˚C with 50 µl in PBST 0.1%and incubated overnight at 4°C. Blocking was followed with 5% 
skim milk powder (VWR) in PBST 0.1% for 60 min. Next washing steps, diluted mouse sera 
or hybridoma supernatants were added to the wells and incubated for 90 min. Further washing 
steps were performed followed by incubation with HRP-conjugated goat anti-mouse Ig 
(1:1000) for 60 min. After three additional washing steps, 50 µl of 3,3',5,5'-
tetramethylbenzidine (TMB) (Thermo Scientific, 002023) substrate were added to each well, 
plates were incubated in the dark and the reaction was stopped by adding 50 µl of 1M HCl. 
Optical Density (OD) was measured at 450 nm on a microplate reader (SpectraMax 190 
Microplate Reader, Molecular Devices). The mouse producing the highest titre of antibodies 
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of interest was selected for splenocyte fusion. To screen the antibody production of hybridoma 
cells, the same procedure was implemented on the hybridoma cell culture supernatants. Unless 
otherwise mentioned, the incubation steps were performed at room temperature.  
 
2.6.6.1 Live cell ELISA 
 
Hybridoma supernatants were screened with freshly cultured LS174T and SW948 wt cell lines. 
Cells were grown in 96-well plates and incubated with mice serum or hybridoma culture 
supernatants at 25°C for one hour. Plates were washed 3 times in washing buffer PBST 0.05% 
and the bound antibodies were detected by incubation with HRP-conjugated anti—mouse IgG 
at 25°C for another hour. After careful washing, 3,3′,5,5′-tetramethylbenzydine (Sigma, 
Deisenhofen, Germany) was added as substrate. The colour reaction was measured at 450 nm 
with a Bio-Rad ELISA reader (Richmond, CA).  
 
2.6.7 Flowcytometry of hybridomas 
 
Hybridomas were tested using different cells supernatants against several colorectal cancer cell 
lines. Methods used followed the indications described in 2.4.1. No dilution of primary 
antibody was required.  
 
2.7 Statistical analysis 
 
The correlation between data was analysed using Spearman Correlation and unpaired student’s 
t-test was used for the comparison of features. 
Statistical analysis was performed using the Student’s T-test for paired samples. Differences 
were considered statistically significant when p< 0.05 (*), p< 0.01 (**) and p< 0.005 (***). 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc). 
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3.1 PART I: biomarker discovery 
 
The first part of the PhD project aimed to the identification of a potential and suitable biomarker 
for colorectal cancer diagnosis and/or treatment. First, we evaluated the cell surface expression 
in six colorectal cancer and normal colon cell lines, which were selected based on differences 
in stages and grades of the primary tumour (Table 3.1). Thoroughly, stages define tumour size 
and spreading and grades, the level of differentiation from primary cells, as already mentioned 
in chapter 1.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For aim of the project, we have also selected a series of existing antibodies against glycan 
antigens and glycoproteins for cell lines expression analysis (Table 3.2). The glycans antigens 
were chosen based on literature data regarding aberrant glycans in colorectal cancer199,250,258,292. 
The final selection included the major glycans overexpressed throughout all the stages of the 
cancer development, corresponding to Lewisa/x/y (Le a/x/y), sialyl Lewisa/x (sLea/x), Thomsen-
Friedenreich (T), Thomsen-nouvelle (Tn) and sialyl-Thomsen-nouvelle (sTn)153. Two major 
Cell lines Cancer Type GRADES STAGE 
CCD 841 CoN normal colon X X 
LS174T Colon Adenocarcinoma Grade I Stage 2 
HT29 Colon Adenocarcinoma Grade I Stage 3 
SW948 Colon Adenocarcinoma Grade III Stage 2 
SW48 Colon Adenocarcinoma Grade III to IV Stage 3 
SW620 
Metastasis 
Colon Adenocarcinoma 
Grade IV Stage 3 
Table 3.1 List of colon cell line selected for in vitro experiments. They differ for grades-level of differentiation 
from primary cell- and stages -level of invasiveness of tumour mass-. Normal colon was used as control cell 
line 
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glycoproteins have been selected for testing: carcinoembryonic antigen (CEA), used as 
prognostic factor in CRC, CD44, found overexpressed in CRC studies127. 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The selected material, cell lines and antibodies, was used in different immunoassays, in order 
to characterize CRC cells expression and new potential biomarkers. The immunoassay used 
includes flow cytometry, western blot, immunofluorescence and immunohistochemistry.  
 
3.1.1 Cell growth time glycan and cancer stage dependent 
 
In order to pursue study on glycosylation, four of the CRC cells lines available were transfected 
or transduced with genes that code two glycosyltransferases, respectively FUT6 and ST6Gal1. 
FUT6 (Alpha-(1,3)-fucosyltransferase) is a fucosyltransferases responsible for fucosylation of 
sLewisx antigen and was stably transfected in HT29 and SW620 cell lines (Table 1.2). ST6Gal1 
(Beta-galactoside alpha-2,6-sialyltransferase 1) is a sialyltransferase responsible for sialylation 
on terminal gal in α-2,6 of N-glycan and it was stably transduced in SW948 and SW48 cell 
lines (Figure 1.8). Rate of cellular growth, depending on glycosylation levels, was calculated 
by measuring the doubling time of the cell lines (Figure 3.13).  
Table 3.2 List of glycans and glycoprotein antigens chosen for cells and tissue screening and their 
respective names used in experiments 
ANTIGEN TYPE ANTIGENS 
ANTIBODY 
NAMES 
Glycoproteins 
CD44 anti-CD44-hpan 
CEA anti-CD66e 
Glycans 
Sialyl Lewisx/a 
HECA-425 or E-
selectin-Ig 
Sialyl Lewisa anti-CA19.9 
Sialyl Lewisx anti-CD15s 
Lewisx anti-CD15 
Lewisy anti-Ley (A70/C-C8) 
Sialyl Tn 
B.72.3 or LA25 or 
3F1 
Tn 5F4 
T HH8 or PNA 
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Scores obtained, revealed contrasting results. HT29 FUT6 shows differences in doubling times 
of almost 2fold compared to their wild type (wt) (Figure 3.13 A), yet almost no difference in 
doubling time was shown in SW620 cell lines analysis (Figure 3.13B). Results suggests no 
influence in cell growth rating from increase of sLex antigens.  
Increase in time for cell growth rating is also depicted from SW48 to SW48 ST6Gal1(Figure 
3.13C); nevertheless, doubling time for SW948 ST6Gal1 is shorter (<h) than SW948 wild type 
(Figure 3.13D), suggesting that even if increase of sialylation might influence cell growth, 
further analyses are required.   
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Figure 3.13 Colorectal cell lines calculation of doubling time, glycan dependent. Cell lines were equally distributed in culture and 
analysed at the same time of the day for 10 days. Dots represent day of harvest while continuous dotted lines show trend lines of 
growth. In A) HT29 and HT29 transfected with FUT6 gene shows an increase of almost 2x of doubling time, contrasted by results in 
B) were differences between SW620 and SW620 FUT6 are almost null. In C) increase of doubling time from SW48 to SW48 ST6Gal1 
is shown, while in D) decrease of cell growth between SW948 and SW948 St6Gal1 has been revealed. The growth curves are 
representative of n=3 experiment; the unpaired T test found significance in  delay of doubling time between SW620 WT/FUT6, and 
SW948 WT/ST6GAL1. 
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Differences of cells stage-dependent growth were also pursued. The five CRC cell lines 
selected (LS174T, HT29, SW948, SW48 and SW620; Table 3.1) were originated from 
adenocarcinomas of Caucasian patients, collected from differ stages and cancer grades. We 
investigated doubling cell times in order to analyse differences in cells behaviour stage/grade 
dependent (Figure 3.14). Comparisons shows a consistency in slower doubling time of LS174T 
and SW948, of stage II CRC, compared to HT29, SW48 and SW620, of stage III.  
 
 
 
The total analysis aimed to study differences in cell growth rate, in order to understand whether 
increase of glycosylation might influence tumour growth. Moreover, in order to guaranty 
consistency between cell culture and patient tumour cells, correlation between stage and 
growth was made. Stage associated cells analysis confirmed an increase of growth in higher 
staging, while contrasting results on glycosylation analysis on cells behaviour required further 
investigations with different immunoassays. 
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Figure 3.14 Comparing of CRC growth rating stage dependent. Analysis show that 
LS174T and SW948, of stage II, have a slower doubling time compared to HT29, 
SW48 and SW620 of stage III. The growth curves are representative of n=3 
experiment; the unpaired T test found significance in delay of doubling time 
between LS174T (grade 1) and SW48 (grade 3/4) 
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3.1.2 Glycan and protein expression -live cells- 
 
In order to find the most expressed and thus, most promising biomarker, a panel of 9 antibodies 
was selected for flow cytometry live cells analysis. The selected commercial antibodies 
comprehend 6 glycans cancer specific antigen (sLex/a, Ley, Lex, Tn, sTn), already proven to be 
Sl
e
x(
C
D
15
s)
SL
e
a(
C
a1
9.
9)
L
e
y 
(A
70
-8
0)
L
e
x 
(C
D
15
)
T
n
 (5
F4
)
sT
n 
(B
72
.3
)
C
E
A
 (
C
D
66
e)
SL
e
x/
a 
(H
E
C
A
)
C
D
44
0
10
20
30
40
100
150
Antigens
M
F
I 
 (
%
)
HT29 Wt
Mock
Fut6
Sl
e
x(
C
D
15
s)
SL
e
a(
C
a1
9.
9)
L
e
y 
(A
70
-8
0)
L
e
x 
(C
D
15
)
T
n
 (5
F4
)
sT
n 
(B
72
.3
)
C
E
A
 
(C
D
66
e)
SL
e
x/
a 
(H
E
C
A
)
C
D
44
0
5
20
30
40
Antigens
M
F
I 
 (
%
)
SW48
Wt
Mock
St6Gal1
Sl
e
x(
C
D
15
s)
SL
e
a(
C
a1
9.
9)
L
e
y 
(A
70
-8
0)
L
e
x 
(C
D
15
)
T
n
 (5
F4
)
sT
n 
(B
72
.3
)
C
E
A
 (
C
D
66
e)
SL
e
x/
a 
(H
E
C
A
)
C
D
44
0
10
20
200
400
Antigens
M
F
I 
 (
%
)
SW948
Wt
Mock
St6Gal1
sL
e
x(
C
D
15
s)
sL
e
a(
C
a1
9.
9)
L
e
y 
(A
70
-8
0)
sT
n 
(B
72
.3
)
C
E
A
 (
C
D
66
e)
SL
e
x/
a 
(H
E
C
A
)
C
D
44
0
5
10
15
20
200
400
600
800
Antigens
M
F
I 
 (
%
)
CCD 841 CoN normal colon wt
Sl
e
x(
C
D
15
s)
SL
e
a(
C
a1
9.
9)
L
e
y 
(A
70
-8
0)
L
e
x 
(C
D
15
)
T
n
 (5
F4
)
sT
n 
(B
72
.3
)
C
E
A
 (
C
D
66
e)
SL
e
x/
a 
(H
E
C
A
)
C
D
44
0
20
40
60
80
100
200
400
600
800
Antigens
M
F
I 
 (
%
)
LS174T wt
Sl
e
x(
C
D
15
s)
SL
e
a(
C
a1
9.
9)
L
e
y 
(A
70
-8
0)
L
e
x 
(C
D
15
)
T
n
 (5
F4
)
sT
n 
(B
72
.3
)
C
E
A
 (
C
D
66
e)
SL
e
x/
a 
(H
E
C
A
)
C
D
44
0
5
10
15
20
100
150
Antigens
M
F
I 
(%
)
SW620 Wt
Mock
Fut6
A
C
B
D
FE
Figure 3.15 Representation of median fluorescence intensity (MFI) of different antigens extracellular expression. The antigen tested are 
sLex/a, Ley, Lex, Tn, sTn, CEA and CD44. Different colon cell lines (A-F) have been tested in order to look for a potential biomarker and 
to find correlation between cancer grades and antigens expression.  In A) normal colon CCD841Con presents high expression of CD44 
but none of aberrant glycosylation. Grade 1 B) LS174T presents high level of CD44, of Tn and sLex/a antigens. In grade 1 C) HT29and its 
correlate FUT6 transfected cell lines, is maintained high expression in sLex/a antigens but a moderate expression of CD44 antigen. In 
grade 3 D) SW948 and its corresponding ST6Gal1 transduced cell lines, shows high expression in CD44, in Lex and a relative low 
expression in CEA and sLex/a antigens. In E) SW48 and the transduced ST6Gal1 maintain a low signal in Lex and relatively low CD44. In 
F) grade 4 SW620 and its relative FUT6 cell line displayed low CD44 expression contrasted by high sLex/a expression. The MFI obtained 
in flow cytometry experiments are representative of n=2 experiment; no statistical analysis was performed on the results. 
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overexpressed throughout all the stages of colorectal cancer153 and 2 glycoproteins. The 
glycoproteins selected were the carcinoembryonic antigen (CEA) and the protein CD44, with 
the intention to compare what is already in use as a prognostic biomarker with a new potential 
biomarker, highly discussed in the literature255,256. 
All the colon cell lines were screened including normal colon CCD841Con, grade 1 LS174T, 
grade 1 HT29 wt (including HT29 mock and HT29 FUT6), grade 2 SW948 wt (including 
SW948 mock and SW948 ST6Gal1), grade 3/4 SW48 wt (including SW48 mock and SW48 
ST6Gal1) and last grade 4 SW620 wt (including SW620 mock and SW620 FUT6) (Figure 
3.15).  
As result of the extracellular screening, the negative control CCD841Con showed no aberrant 
expression of glycans, no expression of CEA antigen but high expression in CD44 (Figure 
3.15A). Likewise, LS174T highly expresses CD44 glycoprotein, but increase in sLex/a and Tn 
antigens is also depicted (Fig. 3.3B). Similar conditions are found in the HT29 cell lines, with 
an overall considerate expression in sLex/a and CD44 antigens (Figure 3.15C). In SW948 and 
SW48 a common increase of Lex with reduction of sLex/a antigens is presented (Figure 3.15D). 
CD44 remains highly expressed in SW948 while in SW48 is detected reduction in signal, until 
almost completed lost in expression in SW620 cell lines, which shows high expression of sLex/a 
antigens (Figure 3.15F). 
Further analysis comparing the different stages related cell lines expression confirmed sLewis 
antigens as the most expressed, especially in the LS174T (Figure 3.16A). The sLewis antigens 
were studied either with the antibody HECA-452 specific for Cutaneous lymphocyte antigen 
(CLA, a carbohydrate epitope of sialic acid ligand for E-selectin, P-selectin, and L-selectin) or 
with sLex-antiCD15s and sLea-anti-CA19.9 carbohydrate specific antibodies. The antigens Lex 
and Ley tested with specific monoclonal antibodies, respectively anti-CD15 and anti-A70-80, 
did not reveal any unique nor intense MFI expression (Figure 3.16D-E). Therefore, sLewis 
antigens were selected as the main target for further downstream analysis. 
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After evaluation and selection of aberrant glycosylation, also the two-glycoprotein selected 
(CEA, CD44) were compared in different cancer stages (Figure 3.17). 
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Figure 3.16 Correlation of (s)Lewis antigen expression in different stage-correlated cell lines. A-C) High 
expression of sLex/a is presented in most of the cell line studied LS174T (stage 2), HT29 and SW620 (stage 
3). In D) lower expression of Lex is presented in SW948 (stage 2), while in E) no cell line responded to 
Ley signals. . The MFI obtained in flow cytometry experiments are representative of n=3 experiment; no 
significance was found with impaired T test. 
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Figure 3.17 Differences in glycoprotein expression in different cancer stages. In A) SW948 shows a moderate-low expression 
of the CEA protein, while in B) the expression of CD44 is very high in CCD 841 Con and stage 2, LS174T and SW948, and is 
reduced in stage 3, SW48-HT29- SW620, cell lines. The MFI obtained in flow cytometry experiments are representative of n=3 
experiment; no significance was found with impaired T test. 
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CEA analysis revealed expression of the glycoprotein in SW948 cell line but no presence in 
the other 5 cell lines, including normal colon, negative control, is shown (Figure 3.17A). On 
the contrary, CD44 appeared to be highly expressed in normal colon CCD 841 Con, with a 
progressive lost throughout the cancer staging (Figure 3.17 B). CD44 is an adhesion protein of 
different isoforms and highly glycosylated, and the results suggested possible implication of 
the protein in cancer progression.  
Moreover, an interesting correlation between increase of FUT6, thus in sLex antigens, and 
CD44 expression in HT29 cell lines has been revealed, suggesting a possible association 
between aberrant glycosylation in cancer progression and increase of protein expression 
(Figure 3.18). 
 
 
3.1.3 Glycan and protein expression -protein extraction- 
 
Following cells membrane expression analysis, cell total proteins were extracted and analysed 
by western blot. The analysis had the purpose to confirm observation made by flow cytometry, 
to characterize aberrant glycosylation and glycoprotein isoforms and to validate antibodies 
affinity. Four antibodies were selected for the screening:  
 
1. HECA-452: to confirm sLex/a as the most expressed in LS174T wt, in HT29 (wt, mock 
and FUT6) and in SW620 (wt, mock and FUT6) (Figure 3.19); 
2. anti-CD44-hpan: to confirm high CD44 expression in LS174T, in SW948 (wt, mock, 
ST6Gal1); change in expression between HT29 (wt, mock) and HT29 FUT6; lower 
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antigens expression correlated with 
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mock HT29, sLex/a antigens are 
moderately expressed while the 
protein CD44 is almost absent. In the 
HT29 FUT6 transfected cell line, an 
expected increase of SLex antigens is 
correlated to a substantial increase of 
CD44 expression.  The MFI obtained 
in flow cytometry experiment are 
representative of unique experiment; 
no statistical experiments have been 
performed on the results obtained 
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expression in SW48 (wt, mock, ST6Gal1) and almost no expression in SW620 (wt, 
mock and FUT6) (Figure 3.20); 
3. anti-CD66e: to compare expression of CEA protein to CD44, and verify its potential as 
biomarker at intramembrane and cytoplasmatic level (Figure 3.21); 
4.  anti-CD15: to compare at the intracellular level of CD15 antigens in the CRC cell lines 
level (Figure 3.22). 
Western blot analysis of HECA-452 (1:1000) of total lysate extraction, revealed to be in 
agreement with flow cytometry results. In detail, LS174T presents two major bands, at 
>245kDa and 180>x>135, with intensive signal for sLex/a antigens (Figure 3.19A); HT29 FUT6 
cell lines confirmed a substantial increase of sLex/a signal at ~135kDa and ~90 kDa, compared 
to the almost missing signals in wt and mock controls (Figure 3.19B). SW948 and 48 (wt, 
mock) present smaller signals at ~100 kDa, at 75>x>63 kDa; no increase in signals of ST6Gal1 
transduced cell lines has been noticed (Figure 3.19C-D). SW620 FUT6 presents increase of 
expression at ~200 kDa, ~170 kDa and at ~90 kDa, and disappear of bands present at 100 kDa 
in wt and mock.  
 
~ 
CD44 is a glycoprotein presenting alternative splicing that give origin to different isoforms. 
Eight isoforms have been already recognized; their molecular weight depends on the level of 
glycosylation of each correspondent exons and it could vary from 250 kDa, down to 16kDa 
(see paragraph 1.7.5 CD44)256.  
Western blot analysis revealed the most intense signals in LS174T, HT29 (wt, mock, FUT6) 
and SW948 (wt, mock, ST6Gal1). LS174T investigation presents two major bands at >135kDa 
Figure 3.19 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by HECA-452 (1:1000). In A) LS174T 
presents two major bands, at >245kDa and 180>x>135; in B) HT29 FUT6 present increase of sLex/a signal at ~135kDa and ~90 
kDa and no almost signals is detected in wt and mock controls; in C) SW948 and 48 (wt, mock,St6Gal1) present smaller signals 
at ~100 kDa and at 75>x>55 kDa; in D) SW 48 (wt, mock, ST6Gal1) present smaller signals at ~100 kDa, at 75>x>63 kDa; in 
E) SW620 wt and mock present the only band at ~100 kDa, while  FUT6 presents increase of expression at ~200 kDa, ~170 kDa 
and at ~90 kDa..Western blots shown are representative of 2 experiments. 
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(probably corresponding to glycosylated form of CD44v2-10/ CD44v3-10) and at ~90kDa 
(probably corresponding to glycosylated form of isoform CD44s); same bands are found with 
less intense signal in HT29 (wt, mock, FUT6) (Figure 3.20A). Of particular remark, is the 
appearance of new band at ~130kDa (probably corresponding to glycosylated form of CD44v2-
10/ CD44v3-10/CD44v8-10) that with the increase of sLex (as revealed in HECA-452 analysis- 
Figure 3.20B) could correspond to an increase or change in glycosylation.  
SW48 (mock, ST6Gal1) revealed only two bands at ~90kDa and ~75kDa (probably 
corresponding to glycosylated form of CD44s) (Figure 3.20 B); same pattern has been revealed 
in SW948 cells with the exception of a consistent isoform at ~135kDa (probably corresponding 
to glycosylated form of CD44v2-10/ CD44v3-10) in wt, mock and ST6Gal1 (Figure 3.20B). 
Although, the analysis of SW948 presents similarity with LS174T and HT29 (wt, mock, 
FUT6), there is no variation in molecular weight in SW948 ST6Gal1 cell line, suggesting that 
no modification of sialylation occurred on CD44 from the wt. 
SW620 (wt, mock) present only one band at ~50kDa (might corresponding to the glycosylated 
form of the isoform CD44v8-10 or CD44v10) (Figure 3.20C). 
 
 
CEA is a glycoprotein present in different isoforms. Glycosylation can influence greatly its 
molecular weight, with full-length CEA of 180–200kDa passing to 76.8 kDa when no-
glycosylated. New isoforms, no glycosylated, have also been detected at ~60 and ~40 kDa293. 
Figure 3.20 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by anti-CD44-hpan (1:1500. 
In A) LS174T presents two major bands at >135kDa and at ~90kDa, probably two glycosylated form. Same bands are 
found in HT29 wt, mock and FUT6. However, in HT29 FUT6 is presented a new band at ~130kDa, probably due to 
differences in glycosylation. In B) SW48 (wt, mock, ST6Gal1) reveal two bands at ~90kDa and ~75kDa, with lower 
signal intensity. Same pattern is revealed in SW948 (wt, mock, ST6Gal1) with the exception of a consistent isoform at 
~135kDa. In D) SW620 (wt, mock) presents a band at ~50kDa probably no glycosylated. No bands are revealed in 
SW620 FUT6. Western blots shown are representative of 2 experiments 
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Western blot screening presents two mayor band in LS174T (~200kDa) and in HT29 (wt, 
mock) (~180kDa), probably glycosylated (Figure 3.21A-B). Cell lines SW948 and 48 (wt, 
mock, ST6Gal1) present an almost identical pattern with double bands between ~48-40 kDa, 
suggesting the presence of no-glycosylated form of CEA (Figure 3.21 C-D). SW620 (wt, mock) 
present a major band ~60 kDa, but no signal was revealed in SW620 FUT6. 
 
 
CD15 (Lex) was also tested, as a tumour -associated glycan and being abundantly expressed in 
SW948 cell line. In analysis, contrasting to flow cytometry results, LS174T shows high 
intensity smeared band suggesting abundant presence of CD15 antigen in the protein lysate 
(Figure 3.22A). Same results were encountered in SW948 (wt, mock, ST6Gal1) cell lysates 
with evident smeared band at 250>x>100 kDa (Fig. 3.10C). However, HT29 wt and mock 
presented more defined bands <48 kDa. One band at ~48 kDa is shown in HT29 FUT6 (Figure 
3.22 B). SW48 cell lysates (wt, mock, ST6Gal1) at ~180kDa (Figure 3.22 D). No staining was 
found on SW620 cells lines (Figure 3.22 E) 
Figure 3.21 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by anti-CD66e (1:1000). In A) LS174T 
presents one major band at ~200kDa, probably glycosylated. In B) HT29 wt, mock one band at ~180kDa has been revealed 
but no signal is found in FUT6. In C) andD) SW948 and SW48 (wt, mock, ST6Gal1) reveal two bands between ~48-40 kDa, 
with lower signal intensity. In E) SW620 (wt, mock) presents a band at ~60kDa probably no glycosylated. No bands are 
revealed in SW620 FUT6. Western blots shown are representative of 2 experiments 
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In conclusion, two main glycan antigen, sLex/a and Lex, and two major glycoproteins, CD44 
and CEA, have been selected on previous studied of the cell membrane screening, obtained by 
flow cytometry. The total lysate analysis has been important for identification of specific 
targets and to test potential function of the commercial antibodies. CD44 and sLex/a have been 
revealed to be the most promising target because of the high molecular weight presented in 
LS174T, HT29 (wt, mock, FUT6) and SW948 (wt, mock, St6Gal1), suggesting elevated 
influence of post-translational modification. Moreover, increase in glycosylation of sLex in 
HT29 FUT6 correspond not only to an increase of HECA-452 signal at ~135kDa, but also to 
the formation of a different molecular weight of the protein CD44, suggesting a correlation 
between the two antigens. CEA analysis show abundancy in high molecular weight protein 
isoforms in LS174T and in HT29 (wt, mock), but lower molecular weight in other cell lines. 
Moreover, its glycosylation level did not seem dependent to variation of presence of 
glycotransferases. Lex, in contrast to flow cytometry results, showed intense signals not only 
in SW948 but also in LS174T cell lines. However, this might suggest higher presence at the 
intracellular level and for this reason was not selected as a good candidate as a biomarker and 
antibody production.  
 
 
 
 
Figure 3.22 western blots total lysate extraction of CRC cell lines (20µg/µL) analysed by anti-CD15 (1:1500). In A) LS174T presents smeared 
band from 180kDa down to ~50kDa. In B) HT29 (wt, mock) two bands at <48 kDa and one band at ~48kDa in found in FUT6. In C) SW948 
and smeared band at 250>x>100 kDa are presented, validating results obtained by flowcytometry. In D) SW48 (wt, mock, ST6Gal1) reveal 
two bands at ~180kDa and ~100kDa, with medium-high signal intensity. In E) SW620 (wt, mock, FUT6) no bands are revealed. Western blots 
shown are representative of 2 experiments 
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3.1.4 Glycan and protein expression -Colorectal cancer patients- 
 
In order to understand the diagnostic and therapeutic potential of the different glycosylated 
antigens, CRC tissues from a cohort of 40 patients were selected from different stages of CRC 
and different locations, to optimize variability. The analysis performed by 
immunohistochemistry served, also, for validation and translation of the results obtained by 
cell lines screening, previously described (paragraphs 3.1.1/3.1.3/3.1.4). 
 
The antibodies used for the screening and their relative antigens were the following:  
 CEA: anti-CD66e 
 CD44: anti-CD44-hpan (all isoforms) 
 Lex: anti-CD15 
 Ley: anti-A70/C-C80 
 sLex: anti-CD15s 
 sLea: anti-CA19.9 
 sLex/a: HECA-425  
 sTn: LA25 
 
Tissue staining in a cohort of 40 CRC patients, revealed a positive staining for all antibodies 
in approximately 90 to 95% of cases. Staining for sLex/a was detected in 90% to 98% of the 
cases, with similar lower intensity, independently of the antibodies used. Yet staining with 
HECA-452 antibody showed higher extension covered, as compared with the other antibodies 
(anti-CD15s and anti-CA19-9). 
The CEA protein, which is actually used in the clinics as a prognostic marker, was detected in 
nearly 90% of the samples, while the signal intensity was moderate to strong in almost 50% of 
the samples. On the other hand, CD44 was also detected in nearly 90% of the samples, showed 
a general homogeneous extension, and 62.5% of the cases gave moderate intensity of the 
signals (Table 3.3). 
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In detail, in normal cells, CD44 is found in leukocytes and nerve plexuses, but is not expressed 
in muscle and adipose tissue and the positive control used was the skin, which shows intense 
membrane marking. CD44 labelling is cytoplasmic and membrane. Its signal intensity was 
based on the strong membrane labelling present on the lymphocytes / leukocytes of each cut 
(internal control). Informative data (labelling site, positive normal tissues, among others) and 
optimizations of this antibody were based on the expression of this marker in the "The Human 
Protein Atlas" database. CD44 expression is found in the cytoplasm and membrane of tumour 
cells and normal colonic epithelial tissue has no labelling.  
CEA marking presents cases with low extension, that are located at the secretory pole of the 
tumour gland structures and is also present in the secretion outside the tumour cells. CEA mark 
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0% (white) up to 70% (red). On the left, it is presented the extension of signal, which is well distributed in the 
glycoprotein. On the contrary, glycan such as Lex showed high tumour extension, while SLex and SLea antibodies 
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different antibodies specificity for the same antigens. On the right, the intensity staining is homogeneously negative 
to weak in the glycans alone, but there is an increase of CD44 staining suggesting an improved the signal specificity. 
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on the secretion of the Lieberkühn crypts and is not expressed on any other structure that 
constitutes normal colon / rectal epithelial tissue. 
The expression of CD15s is mainly located in the secretory pole of the characteristic glandular 
structures of adenocarcinomas and in the secretion produced by the tumour. The type of 
labelling is variable and may be in both cytoplasm and membrane. In cases with normal 
epithelium representativeness, the existence of CD15s is not evident, except in some cases, 
marking in areas of mucus (not inside the cells that constitute Lieberkühn crypts). Even in some 
cases negative for CD15s, positive mucus is found for CD15s. 
The expression of CA19.9 is localized in the tumour cells and staining in secretion produced 
by the tumour is noticeable. In the normal epithelium, in some cases can be observed the 
presence of marking in the goblet cells (cytoplasmic) as well as in the mucus produced by the 
epithelium. CA19.9 labelling extends from the cytoplasm to the membrane. Even in cases 
negative for CA19.9 in tumour cells, we can verify the presence of positive secretion for 
CA19.9. The positive control used was a previously tested bladder cancer cut. 
HECA expression is found primarily in the cytoplasm of tumour cells, with few cases of 
membrane labelling. Additionally, it has been noticed presence of positive marking in the 
secretion produced by the mucus. Regarding normal tissue labelling, HECA marks on immune 
system cells (to be designated) and goblet cells that produce the mucus responsible for the 
protection of the colon. HECA expression is also found in some cells of the base of the colonic 
epithelium. Even in cases negative for HECA in tumour cells, we can observe positive 
secretion. The positive control used was the same cut as the CA19.9 immunohistochemistry. 
L2A5 expression is mostly cytoplasmic, with two or three cases of enhanced labeling in the 
cell membrane region. Staining on the secretion produced by the tumor was visible and it was 
also possible to see the L2A5 label on the goblet cells (mucus producing) that make up the 
normal mucosa. Even in negative cases (in the tumor cell) for L2A5, it is visible presence of 
STn positive mucus.  
CD15 expression is mostly cytoplasmic, with few cases of enhanced labeling in the cell 
membrane region. It is noticed in secretion produced by the tumor and mostly weak 
cytoplasmic labeling of CD15 in the enterocytes that make up the normal mucosa. The positive 
control used was the internal positive control given by leukocytes present in all cases. 
Intravascular or tissue leukocytes have strong membrane labeling for CD15. In 5 cases a very 
specific labeling pattern, revealed that cells with greater labeling intensity on membranes are 
located in front of tumor invasion. 
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Lewisy expression is exclusively cytoplasmic, mostly weak and exclusively tumoral. Lewis Y 
expression is not immunohistochemically visualized in immune system cells, muscle, blood 
vessels, as well as in most secretion products (mucus). The marking pattern is not defined in 
all cases, however, there seems to be a definite Lewis Y marking pattern in the globality of the 
analysis: sites on the invasion front have higher marking intensity. In normal epithelial tissue 
Lewisy appears weak in cytoplasmic of goblets cells and enterocytes. 
In general, all antibodies showed reactivity with CRC tissue. As represented in Figure 3.23A, 
it was possible to observe overlaps of positive signals of CEA and CD44 with (s)Lewis antigens 
which likely indicated the co-localization of the glycoproteins and the glycans. Lex, sLex and 
sLea showed higher extension of the staining (Figure 3.23B). Moreover, the presence of CD44 
in mucus was observed and taken a positive staining for a potential soluble biomarker (Figure 
3.23C). For this reason, a first attempt of proximity ligation assay (PLA) between anti-CD44 
and anti-CD15s/CA19.9 and HECA was tried. However, no remarkable signal was observed 
suggesting further optimization and better tissue selection was needed, before taking major 
conclusions.  
 
 
 
 
Figure 3.23 Example of immunohistochemistry staining with different antibodies tested on same tissue cut from CRC patient. 
In tissue section in A) CEA presents high intensity and extension andCD44 present an intense membranal staining. In tissue 
section in B) Lex, sLex and sLea presents high extension and intensity, overlapping signals in A). In B) Ley and HECA-452 
(sLex/a) present, respectively none and lower staining 
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 3.1.4.1 Correlations in immunohistochemistry results 
 
Further analysis of immunohistochemistry results had the purpose to reveal linkage between 
antigens expression. Correlation between antigens expression scorings have been performed 
(Figure 3.24). Interpolation of the data revealed main significant correlation between  
 CD15s and CA19.9 (**), HECA-452 (**) 
 CD15 and CD15s (**), HECA-452 (**) 
 CD44 and Ley (*) 
 CEA and CD15s (**), HECA-452 (**) 
 CA19.9 and CD15s (**), HECA-452 (**) 
 HECA and CD15s (**), CD15 (**) 
 sTn and CD15s (**), CD15 (**) 
 Ley and CD44(**) and HECA-452 (**) 
 
Figure 3.24 Antigens scoring inter-correlations obtained by immunohistochemistry results of cohort of 40 CRC patients. Main 
significant correlations are found among CD15s, CA19.9 and HECA (**) 
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Further analyses were performed in order to reveal correlation between antigens expression 
and cancer staging and invasion. Cancer staging, defined by I (early-stage cancer), II (cancer 
growth in tissues), III (lymph nodes invasion) and IV (metastasis)132, has been divided in 
mostly non-invasive profile (I-II) and invasive profile (III-IV) and correlated with antigens 
extensions/intensity. Analysis revealed a significative increase of CD44 protein expression 
(Figure 3.25A) and significative extension of Ley expression (Figure 3.25B) in invasive stages.  
Studies on antigen characterization in lymph node cancer invasion were also performed. In the 
actual analyses, invasion (defined in TNM system by the symbol N (node)) has been divided 
in N=0, no invasion, and N>1 if the cancer has spread to the lymph nodes. SLex (scored by 
anti-CD15s staining) shows a significative increase in expression in cancer cell invasion 
(Figure 3.26A). Likewise, Ley extension expression as a significant increase in lymph node 
invasion (Figure 3.26 B)  
 
Figure 3.25 Correlation studies between cancer staging and antigen expression. In A) increase in CD44 expression (extension 
x intensity) is correlated with significant (*) increase of cellular invasiveness (stages III/IV). Equally, in B) increase in Ley 
extension in expression is significantly (*) correlated with a more malignant phenotype. Immunochemistry antigen signals 
were measured by the pathologist and analysed with unpaired T-test. 
Figure 3.26 Correlation studies between cancer invasiveness (N) and antigen expression. In A) increase in 
CD15s (sLex) expression (extension x intensity) is correlated with significant (*) increase of cellular 
invasiveness (N>1). Equally, in B) increase in Ley extension in expression is significantly (**) correlated with 
a more malignant phenotype, in agreement with the aforementioned staging results. . Immunochemistry antigen 
signals were measured by the pathologist and analysed with unpaired T-test. 
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Crosstab analysis were also applied in order to understand correlation of antigen expression in  
ganglion metastasis (N=0 no invasive and N>0 invasive phenotype). HECA-452 (sLex/a) 
signals, defined as no-present by ",00" and present by "1,00", revealed to be highly expressed 
in ganglion metastasis (65,5%), while its absence has been correlated with a non-invasive 
cellular behaviour (72.7%) (Figure 3.27A). Equally, analysis with only CD15s (sLex) revealed 
that absence of antigen corresponds to the 81.8% of non-invasive tissue sections, while 
presence of the antigens increases ganglion metastasis up to 62.1% (Figure 3.27B). 
 
 
 
Overall survival (OS) patient’s percentage, dependent on different antigens expression, was 
also measured (Figure 3.28). Analysis revealed that the increase in CD15 expression (Lex) 
correspond to increase of 8-years OS, with a significance of p=0.013 (**) 
 
 
 
 
 
 
 
 
Figure 3.27 Crosstab correlation between antigen expression and percentage of ganglion metastasis. In A) HECA-452 signal, 
which recognize sLex/a, is associated with an increase of ganglion metastasis.  In B) analysis of CD15s (sLex) confirmed 
increases of invasive behaviour in 62.1% of the cases. Chi-square tested confirmed significance of the test with A) p=0.03 (*) 
and B) p=0.013 (**) 
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As a conclusion we have shown correlation in expression between sLex and sLea in different 
cancer staining, obtained with anti-CD15s, anti-CA19.9 and HECA-452. Moreover, studies of 
all the antigen revealed significant correlation among sLex/a, Ley and CD44 with invasiveness 
behaviour in tissue scoring. On the contrast, expression of Lex showed an increase of 8-years 
overall survival, suggesting that sialylation level of Lewis antigens is involved in malignancy 
profiles.  
Being the purpose of the project to find biomarkers that could detect CRC throughout the 
cancer staging and to build antibodies as diagnostic and therapeutic tool, sLex/a antigens, as 
aberrant glycans and CD44, as glycoprotein, were selected for further studies and biomarker 
characterization. 
 
3.1.5 Biomarkers anti-tumour effect 
 
In order to validate the potential anti-tumour effect of commercial antibodies in vitro and to 
validate the potential efficacy of sLewis and CD44 antigens as novel biomarkers, scratch 
wound assay was performed. The migration potential of the cells was measured in the presence 
or absence of antibody against CD44 and SLex, in order to see their potential in influencing 
cells migration, with both CD44 and sLex/a antigens involved in cells adhesion and 
Figure 3.28 8-years overall patient survival. Expression of CD15 increase chances of OS with a significance 
of p=0.013 (**) 
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migration222,294. Three cell lines were selected by their antigen expression levels: LS174T (high 
in sLex/a and CD44), SW48 (medium-low in sLex/a and CD44), SW620 ((medium-low in sLex/a 
and null in CD44). With the purpose to maintain low variability, the antibody selected were all 
mouse binding human IgG type: anti-mouse II, anti-CD15s and anti-CD44-hpan. Antibody 
were kept in motion with concentration of 0.5 µg/mL, renewed every 3 days, given the stability 
of antibodies in culture. Cells were cultivated in Ibidi culture insert and maintained in culture 
up to full wound closure of the negative control (anti-mouse II IgG) or cell death. 
In Figure 3.29 example of the scratch wound assay is shown. The positive control showed a 
confluency of more than 90% in the scratched fragment at day 7, while the cells stained with 
antibodies against SLex exhibited a delay in closure. Moreover, with sLex being more expressed 
than CD44, the sLex treatment resulted in less migration on day 7 than the anti-CD44 antibody. 
These preliminary results suggest the involvement of sLex antigens in cell migration and 
adhesion, and the effect of commercial antibodies on cell migration in vitro. 
 
 
 
Figure 3.29 Example of scratch wound assay performed with SW620 wt cell lines. The cells are positive for sLe antigens 
but have low expression of CD44 SW620 shows a most fully closure at the 7th day, while wounds maintained with anti-
CD15s show delayed in stability. CD44 being mostly not expressed by the SW620, show similar closure to the negative 
control 
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LS174T were maintained in culture for four days. Wounds with anti-CD15s and anti-CD44 
shows almost no closure, compared to the linear growth of the negative control (Figure 3.30 
A1-2). Delay in closure have been noticed in SW48 where, after 8 days, samples containing 
anti-CD15s and anti-CD44 appear to have substantial slower migration compared to the 
negative control (Figure 3.30 B1-2). On the contrary, SW620 maintained with anti-CD44 
revealed almost identical closure of the control, while samples co-cultivated with anti-CD15s 
shows differences in closure at the 7th day (Figure 3.30 C1-2). 
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Figure 3.30 Comparison of wound closure of LS174T, SW48 and SW620, co-cultured with anti-mouse II (Ctrl-), anti-CD15s (sLex) 
and anti-CD44-hpan (CD44). Antibodies were maintained in motion at 0.5µg/mL, until full wound closure or cell death.  In A) 
LS174T, high in sLe and CD44, at the 4th day show almost no closure compare to the negative control. In B) SW48 medium-low in 
sLex/a and CD44, show clear delay in closure after the 8th day. In C) SW620, low in sLe, has a delayed wound repair, compared not 
only to the negative control, but also to the samples co-cultured with anti-CD44. In fact, this antibody appears not to affect cell 
migration when CD44 is mostly absent from cell expression. The values obtained by the scratch wound assay experiment are 
representative of unique experiment; no statistical experiments have been performed on the results obtained 
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Further preliminary testing with LS174T co-cultured with anti-CA19.9 (sLea) and E-selectin-
Ig (chimera protein binding sLex/a) revealed similar behaviour in wound healing delay. In fact, 
not only the antibody anti-CA19.9 confirmed difference in closure at the 4th day, but also cells 
in contact with E-selectin -Ig increase cells distance (Figure 3.31 A-B).  
 
 
 
This preliminary result, suggest that E-selectin when used as decoy for sLex/a antigens, may 
participated in cancer cell toxicity. However, further experiments should be applied before any 
conclusion could be made. 
Thus, given the difference of antigen expression of the three cell lines, it is possible to notice 
a proportional delay in migration in all cell lines. Of particular interest is the cell behaviour of 
SW620 with anti-CD44, not only because wound closure is proportional to the control, but also 
because validates the antibody effects in LS174T and SW48 wound (Figure 3.30 C2). Increase 
in wound space in presence of E-selectin-Ig have also been considered. Data suggest that not 
only sLex and CD44 could play major in cell migration, but also the production of specific 
monoclonal antibody against sLex and/or CD44 might have good potential if used as 
therapeutic tool. For this reason, CD44 and sLex/a were selected as new potential biomarkers.  
 
A B
0 24 48 96
0.0
5.0×105
1.0×106
1.5×106
Time (h)
A
r
e
a
 m
m
2
Wound healing assay 
LS174T + anti-CA19.9
Ctrl- (anti-mouse IgG)
anti-CA19.9
0 24 48 96
0.0
5.0×105
1.0×106
1.5×106
Time (h)
A
r
e
a
 m
m
2
Wound healing assay 
LS174T + E-selectin-Ig
Ctrl- (anti-mouse IgG)
E-selectin-Ig
Figure 3.31 Preliminary results of wound closure of LS174T  co-cultured with anti-mouse II (Ctrl-), anti-CA19.9 (sLea) and 
E-selectin-Ig (sLea/x) antibodies were maintained in motion at 0.5µg/mL, until full wound closure or cell death.  In A) LS174T, 
high in sLe, at the 4th day show almost no closure compare to the negative control. In B) LS174T co-cultured with E-selectin 
--Ig revealed proportional increase in wound distance, suggesting an active role of E-selectin in blocking cell migration.The 
values obtained by the scratch wound assay experiment are representative of unique experiment; no statistical test have been 
performed on the results obtained. 
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3.2 PART II: biomarker isolation and characterization  
 
Biomarker discovery has been performed by cell lines screenings, by analysis cohort of 40 
CRC patients FFPE tissue and by antibody in vitro efficacy. Experiments confirmed 
overexpression of aberrant glycosylation compared to healthy tissue. Moreover, increase in 
CEA (used as a prognostic biomarker) and CD44 (adhesion protein involved in tumour 
malignancy) has also been observed. In detail, sLex/a revealed to be involved in most cancer 
stages, also when translated into cancer line analysis; it also shows to play major role in 
ganglion metastasis. On the other hand, CD44 have shown higher expression in HT29 when 
transfected with FUT6, glycotransferase involved in core-fucosylation of sLex, and in LS174T, 
which expresses high levels of sLex/a antigens. It has been also displayed its involvement in 
cell migration in tissue analysis and migration assay (wound scratch assay). For all these 
reasons, sLex/a antigens and CD44 glycoprotein have been selected for further characterization 
and eventual mice immunization (Figure 3.32). SLex/a and CD44 are also known as E-selectin 
ligands. The role of E-selectin in cancer progression and metastasis has been reinforced by a 
number of basic researches69,203, thus studies of E-selectin ligands behaviour could be of great 
utility in biomarker research. Furthermore, because an ideal biomarker should be cancer-
specific and that both, sLex/a and CD44, can be found in normal tissue, it has been decided to 
study specific change in glycosylation on CD44 surface. In fact, glycoprotein carrying a 
specific aberrant glycosylation could be the key for the selection of new cancer- specific 
biomarker. 
 
Figure 3.32 Representative funnelling structure 
for antigen selection. In yellow are represented the 
different aberrant cancer-related glycans, in blue 
the glycoproteins involved in cancer profiling. 
CRC cells were tested by flow cytometry, western 
blot, immunohistochemistry and wound scratch 
assay. SLex/a and CD44 have been selected as the 
most promising biomarkers involved throughout 
different cancer stages. 
 105 
 
3.2.1 Immunoprecipitation and isolation of antigens 
 
In order to further characterize CD44 and sLex/a as E-selectin ligands, we have performed 
protein isolation. Immunoprecipitation (IP) technique was selected and applied on LS174T and 
HT29 FUT6 membrane protein extraction, as both cell lines show high expression of CD44 
and sLex/a antigens (Fig 3.21).  
 
Two antibodies were selected for immunoprecipitation: anti-CD44-hpan and E-selectin-Ig 
chimera (3µg of antibodies for 100 µg of protein). Example of IP with HT29 FUT6 cell 
membrane extract is shown in figure (Figure 3.34 A-B). Both precipitate show positive staining 
for CD44 and E selectin ligands with major bands at ~135kDa. 
 
Figure 3.33 Schematic representation of immunoprecipitation (IP) technique. The different steps are described in figure. Final sample is 
recovered with glycine-low pH where both antibody and desired protein precipitate. In the final sample, pH is balanced by Tris-base solution 
at pH6.8  
Figure 3.34 Example of IP results for HT29 FUT6 membrane protein extract. 
In A) precipitate with anti-CD44-hpan revealed two major bands in ~135kDa. 
IP flow through shows did not occur that recovery of all CD44 proteins. In B) 
E-selectin IP revealed two major bands at ~135kDa and a minor at ~100 kDa. 
Western blots shown are representative of 18 experiments 
.  
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3.2.2 E-selectin ligands analysis 
 
Precipitate of LS174T and HT29 FUT6 (duplicate) by E-selectin-Ig were analysed through 
liquid chromatography- mass spectrometry (LC-MS/MS). Samples were separated in gel in 7 
bands each (Figure 3.35A) and proteins were in-gel digested for LC-MS/MS analysis. In the 
four sample (duplicates of both cell lines) CD44, backbone 82kDa, was identified with 100% 
confidence (Figure 3.35 B-C). Identification of the protein do not include post-translational 
modification thus the possible CD44 isoform might be CD44v2-10256, that could be found 
glycosylated up to 250 kDa. 
 
 
3.2.2.1 CD44 as E-selectin ligand in CRC  
 
Immunoprecipitation of HT29 FUT6 with anti-CD44-hpan and E-selectin-Ig were tested and 
compared in immunoblots. This experiment served as a validation of CD44 carrier of sLex/a.  
In Figure 3.36 is shown western blot revelation, presenting in sequence, positive and negative 
controls (HT29 FUT6 total membrane proteins, IP of CD44 flow through), IP of CD44 and 
positive control (IP of E-selectin ligands). Blot has been stained with E-selectin-Ig and one 
band appeared at the expected ~135kDa, confirming CD44 as carrier or E-selectin ligand. 
Figure 3.35 LC-MS/MS of LS174T and HT29FUT6 membrane protein E-selectin-Ig IP. In A) gel 
separation of the protein and division in 7 bands. In B) confidence of 100% CD44 human. Backbone 
of 82kDa. In C) correspondent sequence of peptides confidence. 
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Validating CD44 as glycoprotein carrying the sLex/a antigens, we have planned to produce 
antibody combining its double specificity for CD44 and sLex/a antigens, to increase specificity 
and sensitivity in biomarkers detection. 
 
The CD44 immunoprecipitated was also tested by enzyme-linked immunosorbent assay 
(ELISA). Plate were coated with a max yield of 3µg/mL and tested by anti-CD44-hpan 
(positive control) and HECA-452, as E-selectin substitute, recognizing sLex/a. Absorbance 
(450nm) revealed positive signal for sLex/a antigens for CD44 IP (Figure 3.37). Cross-testing 
was useful to confirm CD44 as a carrier of or/and E-selectin ligand.  
 
Figure 3.36 Validation of CD44 IP as E-selectin ligand. In A) blot is stained with E-selectin Ig, and both CD44 IP and E-
selectin-Ig IP presents signal at ~135 kDa. E-selectin-Ig IP has been used as a positive control. In B) qualitative signal 
intensity has been measured by imageJ. 135 kDa bands in IP CD44 and IP E-selectin, show similar intensity percentage. 
Western blots shown are representative of 2 experiments 
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Figure 3.37 ELISA testing of CD44 IP. Although weak signal is revealed in the 
positive control (anti-CD44-pan), positive signal for HECA-452 (sLex/a) is 
shown. Negative controls, respectively II anti-mouse-HRP IgG for anti-CD44 
and II anti-rat-HRP IgM, already subtracted from the absorbance intensity. The 
ELISA experiment is representative of a unique experiment. 
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3.2.3 Förster resonance energy transfer between CD44 and sLex/a 
 
Förster resonance energy transfer (FRET) is a mechanism that describes energy transfer 
between two fluorophores. Energy transfers happens when a donor molecule is at a max 
distance of 9nm from an acceptor molecule and the donor-emission-wavelength is overlapping 
with the excitation-wavelength of the acceptor. For this reason, the choice of the proper 
fluorophores was critical. FRET was performed by flow cytometer on LS174T cell lines. In 
case of positive FRET was expected median fluorescence intensity (MFI) increase in the 
acceptor channel. Three primary antibodies have been selected: anti-CD44 (rabbit polyclonal), 
anti-CD15s and anti CA19.9 (mouse monoclonal). Combination of secondary antibodies was 
chosen based on fluorophore qualities and on coupling: PE (anti-mouse) --> Cy5 (anti-rabbit) 
[glycan donors, CD44 acceptor] and FITC (anti-rabbit) --> PE (anti-mouse) [CD44 donor, 
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Figure 3.38 FRET representation between sLewis antigens and CD44 on LS174T cell line. In A) sLex donor-PE signal remained 
equal, while substantial increase is seen in CD44 Cy5-acceptor, suggesting presence of sLex on protein surface. In B) CD44-
PE (donor) and sLea-PE (acceptor), showed increase in MFI PE-acceptor channel, indicating presence of sLea on the 
glycoprotein. MFI is normalized. The MFI measurement obtained by flow cytometry experiment are representative of n=2 
expeeriments 
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glycans acceptors]. As a result of the combinations, visible increase of signal in CD44 (Cy5-
channel acceptor) from sLex donor suggest presence of the glycan on the protein surface 
(Figure 3.38A). Combination between CD44-FITC (donor) and sLea-PE (acceptor), showed 
increase in MFI PE-acceptor channel, indicating presence of sLea on the glycoprotein 
expressed on LS174T surface (Figure 3.38B). 
 
3.2.4 CD44 type of glycosylation 
 
Sialyl Lewisx/a can be found either as O- or N-glycans. Thus, in order to characterize the type 
of glycosylation, IP of E-selectin-Ig from HT29 FUT6 total membrane protein was treated with 
two enzymes. PNGase F is the most effective enzymatic method for removing almost all N-
linked oligosaccharides from glycoproteins; neuramidase (Sialidase) cleaves terminal sialic-
acid residues that are α2,3-, α2,6-, or α2,8-linked to Gal, GlcNAc, GalNAc, AcNeu, GlcNeu, 
oligosaccharides, glycolipids, or glycoproteins.  
PNGase F treatment of E-selectin-Ig IP was stained with anti-CD44-hpan and as E-selectin-Ig 
as cross-control. As a result, drop of signal and of molecular weight is visible in the blot A, 
from ~150 kDa down to ~120 kDa (Figure 3.39A) and lost in signal with E-Selectin-Ig (Figure 
Figure 3.39 PNGase treatment of E-selectin-Ig IP from HT29 FUT6. In A) blot 
is stained with anti-CD44-hpan and is possible to visualize a drop in signal and 
molecular weight from ~150 kDa to ~120 kDa. In B) twin blot is stained with 
E-selectin-Ig and lost in signal is visible, confirming the correct enzymatic 
reaction. In C) relative quantification of CD44 signal is visible. Drop in 
intensity may be due to loss of glycosylation and thus antibody affinity. Western 
blots shown are representative of  a unique experiment. 
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3.39B). Drop in intensity of signal may be due to glycan influencing anti-CD44-hpan antibody 
binding (Figure 3.39C) 
 
 
Neuramidase treatment of E-selectin-Ig IP was also stained with anti-CD44-hpan and as E-
selectin-Ig as cross-control. As a result, increase of signal of CD44 is visible in figure A and 
decrease in signal with E-Selectin-Ig in B (Figure 3.40). Increase of CD44 signal (Figure 
3.40C) may confirm a role of glycosylation in anti-CD44-hpan binding and affinity. Moreover, 
it suggests that the sialidase reaction was partially completed.   
 
 
Using enzymatic reaction, it was possible to prove that CD44 in HT29 FUT6 is decorated 
majorly with N-glycans and that E-selectin ligands (sLex/a) are bound to N-glycan chains. 
Reactions with neuramidase suggested partial removal of sialic acid and role of glycosylation 
in influencing anti-CD44-hpan binding and affinity. Since no enzyme for O-glycan cleavage 
with the same function of the PNGase F is available, it was no possible to study directly O-
type of glycosylation on CD44 on HT29 FUT6. 
Figure 3.40 Sialidase treatment of E-selectin-Ig IP from HT29 FUT6. In A) blot is 
stained with anti-CD44-hpan and is possible to increase in signal intensity. In B) twin 
blot is stained with E-selectin-Ig and decrease in signal is visible. In C) relative 
quantification of CD44 signal is showed. Increase in intensity may be due to loss of 
glycosylation and thus antibody affinity. Western blots shown are representative of  a 
unique experiment. 
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3.2.5 CD44 as a soluble biomarker 
 
Study of glycosylation of CD44 suggested its potential as a cancer-specific biomarker. 
However, a good biomarker should be detectable with the use of non-invasive techniques. For 
this reason, the next question raised was to discover if CD44 is soluble in the serum. The 
aforementioned IHC experiment revealed presence of CD44 in tumoral mucus. Nonetheless, 
further studies aimed to test the presence of CD44 in LS174T cell line supernatant. Being the 
presence or the concentration of free CD44 unknown, supernatant was concentrated 6x and 9x 
times. Western blot revealed proportional increase in signal of bands at ~150kDa and ~100 
kDa, in accordance with LS174T total membrane positive control (Figure 3.42). Results show 
that in CRC LS174T cell line culture, CD44 can be found as soluble form, increasing its 
potential as good biomarker. 
 
 
3.2.6 Antigen isolation and preparation 
 
As a consequence of the results obtained, CD44 and sLex/a were selected for mouse 
immunization. 
However, in order to increase antibody production specificity a certain purification of CD44 is 
required. LS174T was selected as cell line with highest expression of high molecular weight 
of CD44.  
Figure 3.41 Testing of LS174T supernatant for CD44 as soluble protein. Increase of 
supernatant concentration, correspond to a proportional increase in signal, correspondent 
to same molecular weight of the bands used as a control of total membrane protein LS174T. 
Bands are revealed at ~150 kDa and ~100 kDa.. Western blots shown are representative of  
a unique experiment. 
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IP of CD44 was performed and in order to separate the protein precipitate with the antibody 
anti-CD44-hpan (that co-precipitated during isolation), sample was subject to a native gel 
PAGE (Figure 3.42A) with the main). interest to stimulate antibody production against native 
form of the protein. 3/4 of native gel was then cut in different bands (A-D) and stored in PBS. 
1/4 of gel was used for western blot analysis of the protein bands. Protein ladder was used as 
standard and mark. 
After revelation, band containing CD44 (with maximum yield possible achieved is 0.5 µg/µL)  
was extracted and injected into the mice. Presence of polyacrylamide was used as an extra 
immunization adjuvant. Mice after immunization of CD44 will be named miceCD44.  
A second immunization series was performed in order to produce sLex/a specific antibodies. 
For this immunization was chosen to inject directly into the mice 10µg (per inoculation) of 
LS174T total membrane protein, high in sLex/a antigen expression (Figure 3.42B). These mice 
will be referred as miceLS174T. 
 
.
Figure 3.42Schematic representation of mice antigen immunizations. In A) CD44 IP of LS174T was run in native gel 8% in 
order to separate the protein from the antibody anti-CD44-hpan, co-precipitated. western blot revelation was needed for 
identification of the correct band containing CD44. samples in polyacrylamide, diluted in PBS 1x, were directly injected in 
the mice, afterwards named miceCD44 (n=3). in B) direct injection of LS174T total membrane lysate in the mice. antigen was 
selected based on the high expression of sLex/a glycans on Ls174T membrane. mice after immunization have been referred as 
miceLS174T(n=2) 
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3.3 PART III: immunization and serum testing 
 
CRC cells and tissue screening lead to the identification of CD44 glycoprotein and sLex/a 
antigens as a good potential therapeutic biomarker. Moreover, CD44 showed to be a soluble 
protein that could be useful in early CRC diagnosis. Thus, two series of mice were immunized 
with CD44 isolated from LS174T (miceCD44) and LS174T total membrane lysate high in sLex/a 
antigens (miceLS174T). This section is dedicated to immunization timelines and techniques 
adopted in order to check antibody serum titer and its antigen specificity. 
 
3.3.1 Immunization types and timeline  
 
Following the previous results, it was decided to pursue with immunizations of the mice with 
CD44 immunoprecipitated from LS174T cells or the LS174T total lysates. The 
immunoprecipitated containing CD44 glycoprotein was obtained by co-precipitation with the 
antibody anti-CD44-hpan and subsequently run on native gel for separation. The 
polyacrylamide band corresponding to CD44 protein was cut and dissolved in PBS. The mix 
was blended with adjuvants and directly injected into the mice. A theoretical yield (based on 
max antibody capture efficiency) was calculated, but because of the impossibility to quantify 
the protein, a total of 5 immunizations were performed (Figure 3.43A). A second type of 
injection in different mice was performed with LS174T total membrane extraction (Figure 
3.43B). 
Figure 3.43 Timeline representing the different injections performed on mice during the immunization 
protocol. Two parallel protocols were performed with CD44 (A) or total membrane protein LS174T 
cells (B). Mice were immunized with CD44 extracted from LS174T mixed with polyacrylamide and 
adjuvants or immunized with total membrane extraction protein from LS174T.  
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3.3.2 Serum testing by ELISA 
 
The antibody titre in serum of immunized mice was evaluated mainly by ELISA. It has been 
developed specific protocols to allow a more efficient screening that comprises ELISA plates 
coated with membrane proteins extracted from cell lines previously tested: LS174T (high 
expression of CD44 and sLex), SW620wt (not expressing CD44) and HT29 FUT6 (high 
expression of CD44). The coated wells were incubated with serum from immunized mice and 
a non-immunized mouse (negative control). Other controls were performed to test the 
performance of the method which included the anti-CD44-hpan antibody and HECA-452 
antibody positive for E-selectin ligands (Figure 3.44). The analysis of antibody titre was 
checked regularly after the 2nd immunization. 
The results showed high reactivity between HT29 FUT6 total lysate and serum from mice 
immunized with CD44 (MiceCD44). All three coatings (LS174T (high expression of CD44 and 
sLex), SW620wt (not expressing CD44) and HT29 FUT6 (high expression of CD44) showed 
high reactivity with serum of MiceLS174T. In order to prevent tolerance reactions with loss of 
antibodies titre, due to prolonged immunizations, the mice were sacrificed at the 5th 
immunization. The spleens from mice showing antigen reactivity were then used to obtain 
hybridoma cells by fusion with myeloma cells, as part of the workflow (Figure 3.44). 
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3.3.3 E-selectin testing by ELISA 
 
MiceLS174T serum presented clear positivity in signals by staining with three different CRC cell 
lines proteins. However, no specificity or difference in reaction was found among the three 
samples, probably due to the high titre of polyclonal produced by the immunization. Thus, in 
order to double-check specificity against E-selectin ligands, IP with E-selectin-Ig of LS174T 
total protein was tested against miceLS174T serum (Figure 3.45). Cross-control HECA-452 (anti-
sLex/a) was used to check IP reaction. Results shows a clear high binding in LS174T control, 
IP flow through (probably with specific proteins) and E-selectin-IP. Although, many non-
specific bounds are present, positive signal in E-selectin-IP wells were positive indicating the 
use of this mice to obtain hybridomas. 
Figure 3.44 Results of mice serum tested for reactivity against CRC cell lysates. The presence of antibody titres of mouse sera 
was tested against the antigens coated and evaluated by ELISA. During the immunization three mouse groups were tested: Mice- 
(control mice with no immunization), MiceCD44 obtained from the mice immunized with CD44 extracted from LS174T cell line, 
and MiceLS174T immunized with LS174T total membrane protein. The coating was performed with LS174T (high in CD44 and E 
Selectin ligands), HT29 FUT6 (high in CD44) and SW620 wt (negative for CD44). During the different immunizations a high 
affinity for sera of MiceCD44 with HT29FUt6 and high signals with MiceLS17T were detected for the three coatings. Mice were 
sacrificed after the 5th immunization. In A) serum check at day 30; in B) serum check at day 60; in C) serum check at day 75; in 
D) serum check at day 90 and sacrifice. ELISA experiment shown are representative of  n=5 experiment. No significance was 
found with one way ANOVA test.  
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3.3.4 Serum check on live cells 
 
In order to check whether mice CD44/LS174T could recognize antigen on live cells, flow cytometry 
against LS174T (high expression of CD44 and sLex) and HT29 FUT6 (high expression of 
CD44) was tested. Serum was checked at the 4th immunization (day 60). Results show low 
intensity signal recognition of both cell lines by serum of miceLS174 (Figure 3.46A+B), but no 
binding was detected in miceCD44 (Figure 3.46A). Although recognition on membrane of CD44 
have been preferable, antibody detecting CD44 in serum for diagnostic proposed was also 
desired. Thus, we decide to pursue flow cytometry experiments only with miceLS174T in order 
to obtain future hybridomas. 
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Figure 3.45 ELISA testing of miceLS174T on E-selectin IP of LS174T cell line. Signal 
show positive reactivity against LS174T total membrane lysate, protein flow 
through and IP, suggesting presence of polyclonal specificity and aspecificity for E-
selectin ligands. mice were sacrificed in order to detect monoclonal specific for E-
selectin ligands. ELISA experiment shown are representative of n=3 experiment. 
Significance was found with two way ANOVA test. 
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3.3.5 Serum check of miceCD44 by dot blot 
 
As a consequence of no specific binding of miceCD44, cross check with dot-blot analysis were 
required. Different concentrations of total membrane protein (1.5/3/6 µg/µL) of LS174T (high 
expression of CD44 and sLex), SW620wt (not expressing CD44) and HT29 FUT6 (high 
expression of CD44) were bound on nitrocellulose membrane. Dot-blot showed proportional 
reactivity for LS174T and HT29 FUT6, with increase of signal in LS174T samples. No staining 
was shown in SW620 cell lines, neither non-specific binding of secondary antibody was 
detected. Results suggested presence of specific antibody against CD44 present in serum of 
miceCD44. 
Figure 3.46 representation of flow cytometry analysis of HT29 FUT6 and LS174T 
cell lines by serum of miceLS174T/CD44. In A) relative MFI have been plotted and 
shows positive reactivity by miceLS174T, but no visible staining was noted by serum 
of miceCD44. In B) flow cytometry histogram representation of difference in signal 
intensity by serum of miceLS174T/CD44. only polyclonal serum of miceLS174T shows 
partial binding. Flow cytometry experiment shown are representative of  n=2 
experiment.  
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Figure 3.47 Dot blot of miceCD44 against 
different concentration of total membrane 
protein (1.5/3/6 µg/µL) of: LS174T (high 
expression of CD44 and sLex), SW620wt 
(not expressing CD44) and HT29 FUT6 
(high expression of CD44). Dot-blot 
showed proportional reactivity for LS174T 
and HT29 FUT6, with increase of signal in 
LS174T samples. Dot blot experiment is 
representative of n=4 experiments 
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3.4 PART IV: hybridomas cloning and antibody selection 
 
Two series of hybridomas were produced from spleen extracted from, respectively, 
miceCD44 and miceLS174T. As previously described in chapter 1.8.1.1, hybridomas are fusion 
cells obtained from fusion of collected B cells from immunized mice and myeloma cells 
producing each one a specific monoclonal antibody. Each clone is tested and selected against 
the desired antigen271,272,295. The cells of the two hybridomas lines produced were mainly tested 
by ELISA coated with total membrane lysate of different CRC cell lines or commercial antigen 
as coating for the plate ELISA well. The selection process of the two hybridoma lines will be 
discussed in different paragraphs. 
 
3.4.1 MiceCD44 clone’s selection process 
 
The hybridomas obtained from miceCD44 were cloned and a group of 5 different clones was 
evaluated. Cloning is the technique required to isolate each fused cell from the pool, in order 
to isolate B cell producing monoclonal antibody. Moreover, repetition of cloning helps to select 
the most stable hybridoma clone producing the antibody with the desired specificity and 
affinity.  
The supernatant was tested against wells coated with LS174T (high in CD44 and E selectin 
ligand) and SW948 (low in CD44 and moderate in E-selectin ligands by ELISA), as total 
membrane lysate or live cells. To confirm binding specificity, MiceCTRL, which had not been 
immunized, were also used (Figure 3.48). Results show that all clones have a low binding to 
LS174T and SW948 extracts like serum control. However, a higher binding to the LS174T live 
cells antigens was observed by the with clone CD44.4 supernatant relative to the other 4 clones, 
presenting simultaneously, a minimum signal against SW948 live cells antigens. Clone CD44.5 
supernatant show no binding to LS174 live cells antigens but with the highest binding to the 
SW948 relative to the other clones.  
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Thus, clone CD44.4 was selected for 2nd cloning of hybridomas, due to the signal intensity 
and specificity. In fact, SW948 wt is expressing minor isoforms of CD44 that might carry lower 
glycosylation levels, which would not be useful for the purpose. Rather, an antibody with high 
affinity for CD44 and detection of aberrant glycosylation, such as sLex/a antigens, is needed for 
diagnostic and treatment scopes. 
A secondary cloning was performed for CD44.4 (Figure 3.49). The sub-clones were tested 
against different cell membrane lysates: LS174T (high expression of CD44 and sLex), HT29 
FUT6 (high expression of CD44), SW948 (low in CD44 and moderate in E-selectin ligands) 
and SW620wt (not expressing CD44) (Figure 3.49A). Clones were also tested against 
commercial tetramers of sialyl Lewisx (sLex) and sialyl Lewisa (sLea) (Figure 3.49B). 
Figure 3.48 testing of 5 different clones obtained from miceCD44hybridoma fusion. The clones have been tested 
against LS174T (high in CD44 and E selectin ligand) and SW948 (low in CD44 and moderate in E-selectin ligands 
by ELISA). the wells were coated either by total membrane lysate (5 µg/mL) or with 90% confluency live cells. 
Membrane lysate were blocked 1% BSA; no blocking was performed on live cells. Results show higher binding of 
CD44.4 in LS174T and CD44.5 in SW948 live cells. ELISA experiment shown are representative of  n=2 experiment.  
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The results suggest that the supernatants of clones 2.15, 2.17, 2.24, 3.3 and 3.5 show higher 
signal against LS174T membrane lysate extracts (high expression of CD44 and sLex) rather 
the almost absent binding with the other cell lines. Signals towards signals HT29 FUT6 (high 
expression of CD44) and SW620 (not expressing CD44) was low, suggesting that clones 2.15, 
2.17, 2.24, 3.3 and 3.5 do not recognize CD44 but probably sLex or other proteins. 
On the other hand, screening of all 10 clones against commercial sLex/a/ Figure 3.497) suggest 
that clones 2.3, 2.4, 2.14, 2.15, 3.3 and 3.5 displayed binding with sLex and sLea.  
Clones3.3 and 3.5, having in common binding with LS174T and sLex/a antigens, were selected 
for further expansion and analysis. Clones 2.3, 2.4 (positive for sLex/a) and 2.15, 2.17 and 2.24 
(positive for LS174T) were also selected for further validation. 
After expansion, supernatants were tested against the same antigens and the recombinant form 
of CD44 (36 kDa), produced in human cell lines. However, after expansion most of the signals 
were lost exception made for clones 2.17, 2.24 and 3.3 for LS174T (Figure 3.50A) and 2.3 for 
sLex (Figure 3.50B). Moreover, almost no signal was detected from the clones against CD44. 
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Figure 3.49 testing of the 10 more stable clones against membrane protein lysates and commercial sLex/a/. 
In A) cell membrane lysates LS174T (high expression of CD44 and sLex), HT29 FUT6 (high expression of 
CD44), SW948 (low in CD44 and moderate in E-selectin ligands) and SW620wt (not expressing CD44) 
have been tested. Clones 2.15, 2.17, 2.24, 3.3, 3.5 show higher signal on LS174T membrane lysate coating 
rather the almost absent binding with the other cell lines. In B) clones 2.3, 2.4, 2.14, 2.15, 3.3, 3.5 clones 
displayed binding with sLex and sLea.. ELISA experiment shown are representative of  n=4  experiment. 
No significance was found with one way ANOVA test. 
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Although the use of a minor isoform (instead of 82 kDa) does not guaranty the presence of the 
CD44 epitope against which the antibodies were produced, no clones gave inter-crossing 
positive signals. Moreover, signal intensity was overall low, suggesting little hybridomas 
stability.  
 
 
For this reason, we took the decision to proceed with a new mice immunization with CD44 
extracted. From new immunization miceCD44, a 2nd hybridoma generation was obtained. 
MiceCD44 serum mice tested against the cell membrane lysates LS174T (high expression of 
CD44 and sLex/a), HT29 FUT6 (high expression of CD44), SW948 (low in CD44 and moderate 
in E-selectin ligands) and SW620wt (not expressing CD44) (Fig.3.40). Serum was also tested 
against commercial tetramers of sialyl Lewisx (sLex) and sialyl Lewisa (sLea) (Figure 3.51). 
Results showed high binding of the serum against LS174T, HT29 FUT6 and SW948 and a 
lower signal towards SW620 cell membrane lysates. Moreover, the serum resulted positive for 
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Figure 3.50 Expansion in vitro of the selected clones: 2.15, 2.17, 2.24, 3.3, 3.5 positive for LS174T and .3, 2.4, 2.14, 
2.15, 3.3, 3.5 positive for sLex/a.  In A) cell membrane lysates LS174T (high expression of CD44 and sLex), HT29 
FUT6 (high expression of CD44), SW948 (low in CD44 and moderate in E-selectin ligands) and SW620wt (not 
expressing CD44) have been tested. clones 2.17, 2.24, 3.3 displayed specificity for LS174T. 3.5 show binding for 
HT29 FUT6. In B) only 2.3 clone show binding for sLex. In C) no clone show affinity for CD44 36kDa recombinant 
compared to the control used with anti-CD44-hpan. ELISA experiment shown are representative of  n=2 experiment. 
No statistical test was performed 
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both sLex and sLea. Low binding to all the cell membrane lysates were observed for control 
serum (miceCTRL) (non-immunized) as expected. 
 
   
Given the positive results obtained, a 2nd fusion was done and cloned in 20 different clones. 
Selection of positive clones was done using as antigens: commercial CD44 recombinant (36 
kDa), membrane total lysate LS174T and commercial sLex and sLea (Figure 3.52). The serum 
from miceCD44-2nd generation- was used as positive control. From the 20 clones, only clone 
2C2 for CD44 and clone2B1 for LS174T gave a positive reaction (Figure 3.52A). No binding 
was detected for sLex/a (Figure 3.52 B). 
 
Figure 3.51 testing of the serum of miceCD44-2 generation. On the left, cell membrane lysates LS174T (high expression of 
CD44 and sLex), HT29 FUT6 (high expression of CD44), SW948 (low in CD44 and moderate in E-selectin ligands) and 
SW620wt (not expressing CD44) have been tested. Proportional binding of the serum is matching with CD44 expression in 
each cell lines. Morover, negative control miceCTRL serum shows no binding. On the right, serumt show intense binding with 
sLex and higher for sLea. Negative control miceCTRL serum shows no binding ELISA experiment shown are representative of  
n=3 experiment. No statistical test was performed 
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Although, the low signal obtained and the no recognition of sLex/a antigens, clones 2C2 and 
2B1 were selected for cells expansion and further testing against all the antigens used up to the 
moment: cell lysates membrane proteins (LS174T, HT29 FUT6, SW948, SW620), commercial 
sLex/a and human recombinant CD44 (36kDa) (Figure 3.53) 
ELISA shows interesting binding of 2B1 supernatant for LS174T (confirming results obtained 
in Figure 3.52), sLex and minor binding for sLea and CD44 recombinant. On the other hand, 
Figure 3.52 Testing of clones obtained from miceCD44 -generation 2- towards CD44 and sLex/a. In A) clone 2C2 show positive 
reaction for CD44 human recombinant (36 kDa) and clone 2B1 for LS174T (high in CD44 [82kDa in the no glycosylated 
form]). In B) almost no recognition of sLex/a is showed. ELISA experiment shown are representative of  n=2 experiment. No 
statistical test was performed 
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clones 2C2, revealed minor binding for sLex and CD44 recombinant. Thus, clone 2B1 has been 
selected for further antibody characterization.  
 
  
 
3.4.2 MiceLS174T clone’s selection process 
 
The second series of hybridomas produced with the injection of total membrane lysate of 
LS174T cell lines presented two main focuses. The first objective had the purpose to select 
hybridomas producing antibodies against sLex/a antigens. For this reason, hybridomas were 
tested against LS174T (high expression of sLex/a), HT29 FUT6 (moderate expression of sLex/a), 
SW948 (low/moderate in E-selectin ligands) and SW620wt (moderate expression of sLex/a); 
supernatants were also tested directly against commercial tetramers of sialyl Lewisx (sLex) and 
sialyl Lewisa (sLea). Moreover, given the difference in sialic acid expression, clones were also 
tested against Mucin from bovine submaxillary glands (BSM), highly O-glycosylated and high 
in sialic acid, and mucin from porcine stomach (PSM), with a content of bound sialic acid 
between 0.5-1.5%. The combo BSM-PSM was used to validate specific recognition against 
sialic acid, that was very important as a first step selection of clones recognising sLex/a. The 
Figure 3.53 ELISA assay for 2B1 and 2C2 clones, against all the antigens previously tested. 2B1 shows recognition of LS174T, 
sLex/a and CD44 recombinant (36kDa). Clone 2C2, show minor binding for sLex and CD44 recombinant. 2B1have been 
selected for further characterization. ELISA experiment shown are representative of  unique experiment of triplicates. No 
statistical test was performed 
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second aim of this hybridoma series was to check for antibodies recognizing the two mains 
glycoprotein studied, CEA and CD44. 
Firstly, the serum was tested against wells coated with LS174T (moderate in CEA, high in 
CD44 and E selectin ligand) and SW948 (high in CEA, low in CD44 and moderate in E-selectin 
ligands by ELISA), as total membrane lysate or live cells. HECA-452 was used as a positive 
control of sLex/a on the antigen surfaces, while to confirm binding specificity MiceCTRL serum 
which had not been immunized, was also used (Figure 3.54) 
Results show serum recognition of LS174T cell membrane lysate as well as live cell of LS174T 
and SW948, suggesting a successful immunization.  
 
 
High binding to live cells compared to the HECA-452, sLex/a positive control, suggested 
presence of no-specific antibodies in the serum. In order to prove the presence of specific 
antibodies against sLex/a or sialic acid, serum was tested again in different dilution against 
LS174T and BSM (Figure 3.55A). As cross control, ELISA against BSM and PSM was also 
tested (Figure 3.55B). Staining HECA-452 is used as positive control and MiceCTRL as 
negative. As a result, the serum displayed proportional binding to both LS174T and BSM, 
suggesting the presence of specific antibodies against sLex/a and O-glycans. Cross control, 
depicted highest binding for BSM rather than PSM, confirm production of antibodies specific 
for O-glycans and/or sialic acid. 
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Figure 3.54 testing of serum obtained from miceLS174Thybridoma fusion. The serum has 
been tested against LS174T (moderate in CEA, high in CD44 and E selectin ligand) and 
SW948 (high in CEA, low in CD44 and moderate in E-selectin ligands by ELISA). The 
wells were coated either with total membrane lysate (5 µg/mL) or with 90% confluency 
live cells. Membrane lysate were blocked 1% BSA; no blocking was performed on live 
cells. Results show serum recognition of LS174T cell membrane lysate as well as live cell 
of LS174T and SW948. ELISA experiment shown are representative of n=3 experiment. 
No significance was found with one way ANOVA test. 
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The supernatants of hybridoma clones obtained by fusion of this mice have been tested against 
all the antigens described at the beginning of this paragraph: LS174T, HT29 FUT6, SW948, 
SW620wt (total membrane cell lysates), commercial tetramers of sialyl Lewisx (sLex) and sialyl 
Lewisa (sLea), BSM, PSM CEA (Fig. 3.45). No CD44 recombinant was available at the time 
of the cells cloning. 
The results showed that clone 23 presents the highest binding for LS174T, HT29 FUT6, 
SW948, moderate for SW620 (Figure 3.56A);; moreover, it showed highest affinity for BSM 
and PSM, with preference of binding for BSM(Figure 3.56C), and for CEA(Figure 3.56D).. 
On the other hand, clone 13 showed preference in binding for sLex/a (Figure 3.56B). For this 
reason, clones 13 and 23 were chosen for cloning. 
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Figure 3.55 The serum of miceLS174T series testing affinity for specific glycosylation. HECA-452 is used as positive control and miceCTRL as 
negative for sLex/a and sialic acid. In A) both reactions show proportional reduction in signal intensity, suggesting the presence of specific 
antibodies against sLex/a and/or sialic acid. In B) miceLS174T serum displayed highest intensity signal for BSM, confirming presence of antibodies 
specific for O-glycans and or/ sialic acid. ELISA experiment shown are representative of  n=3 experiment. Significance was found performing 
two way ANOVA test 
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The supernatant of  
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Figure 3.56 ELISA testing of the 30 clones obtained from the fusion of miceLS174T. In A) clone 23 followed by weaker signals 
of clones 2, 29, 30 show high binding of LS174T (high expression of sLex/a), HT29 FUT6 (moderate expression of sLex/a), 
SW948 (low/moderate in E-selectin ligands) and low signals against SW620wt (moderate expression of sLex/a). In B) clone 13 
depicted intense binding of sLex/a. weaker signals of clones 5,23,25, 28 show binding for sLea. In C) clone 23 show preferential 
binding for BSM rather than PSM. weaker binding is also displayed by clones 2, 29,30. In D) CEA binding with clone 23 is 
visible. weaker signals are also obtained with clones 29 and 30. ELISA experiment shown are representative of n=4 
experiment. No statistical test was performed 
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Clones 13 and 23 were tested against all the aforementioned antigens, in order to pursue 
validation consistency: LS174T, HT29 FUT6, SW948, SW620wt (total membrane cell 
lysates), commercial tetramers of sialyl Lewisx (sLex) and sialyl Lewisa (sLea), BSM, PSM 
CEA (Figure 3.57). No CD44 recombinant was available at the time of the assay. 
Supernatants of the clones 13 and 23, show a marked decreased in signals probably due to 
hybridoma instability may have occurred during the cloning and maintenance of the cells. 
However, two clones 23.2 and 23.11 tested against total membrane lysate depicted moderate 
binding against LS174T, HT29 FUT6 and SW948 (Figure 3.57A). All the other antigens 
showed almost no signal for sLex and sLea (Figure 3.57B) or BSM, PSM (Figure 3.57C), 
exception made for clone 13.29 which showed binding for CEA (Figure 3.57D). However, no 
correspondent signal is detected against sLex/a. Being detection of glycosylation of the antibody 
produced as the first purpose, we decide to proceed with a 3rd subcloning only of clones 23.2 
and 23.11, in order to check hybridoma stability and to increase antibody production. 
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Figure 3.57 ELISA testing of the clones obtained from the 2nd cloning of clones 13 and 23 of miceLS174T. In A) clone 23.2 and 
23.11 depicted moderate binding against LS174T (high expression of sLex/a), HT29 FUT6 (moderate expression of sLex/a), 
SW948 (low/moderate in E-selectin ligands) and no signals against SW620wt (moderate expression of sLex/a). In B) clone 23. 
3, 23.29, 23.30 13 depicted low binding of sLex/a. In C) almost no clone binding for BSM rather than PSM. In D) CEA binding 
with clone 13.29. ELISA experiment shown are representative of  n=3 experiments. No statistical test was performed 
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The 2rd cloning of clones 23.2 and 23.11 was performed against all the aforementioned 
antigens, in order to pursue testing consistency: LS174T, HT29 FUT6, SW948, SW620wt 
(total membrane cell lysates), commercial tetramers of sialyl Lewisx (sLex) and sialyl Lewisa 
(sLea), BSM, PSM CEA and CD44 (Figure 3.58).  
Subclones 2A4 and 3A1, showed the highest binding for all the antigens tested, suggesting the 
presence of antibody binding specific glycosylation. However, positive signal also for PSM, 
CEA and CD44 may suggest presence of polyclonal production in the supernatant. In order to 
better understand antibody binding, we have decided to test clones 2A4 and 3A1 on live cells, 
using flow cytometry technique (Figure 3.59). Clones were tested against HT29 wt (negative 
control), HT29 FUT6 and LS174T (Figure 3.59A). Results showed only binding of the clone 
3A1. Moreover, the clone showed specific binding only on HT29 FUT6, although also in 
LS174T was expected.  
Thus, clone have been now sent for sequencing and we are waiting for results. In fact, antibody 
sequencing and cloning, will be useful for further characterize potentiality of this novel 
antibody. 
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Figure 3.58ELISA testing of the clones obtained from the 3rd cloning of clones23.2 and 23.11 of miceLS174T. In A) 
clone 2/3A4 and 2/3A1 show highest binding against LS174T (high expression of sLex/a), HT29 FUT6 (moderate 
expression of sLex/a), SW948 (low/moderate in E-selectin ligands) and SW620wt (moderate expression of sLex/a).  
In B) 2/3A4 and 2/3A1 depicted the highest binding of sLex/a. In C) almost all clones show preference in binding 
of PSM rather than BSM. 2/3A4 and 2/3A1 depicted the highest binding In D) CD44 and CEA are recognized by 
most of clones, however 2/3A4 and 2/3A1 depicted the highest binding of CD44 and CEA. ELISA experiment 
shown are representative of  n=3 experiments. No statistical test was performed 
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Figure 3.59 Flow cytometry staining of the depicted clones 23.2/ 2A4 and 23.2/ 3A1. In A) clones were tested against HT29 wt 
(negative control), HT29 FUT6 and LS174T. Flow cytometry intensity are represented. Only clone 3A1 show staining with HT29 
FUT6. In B) histogram MFI intensity of clone 3A1, shows only binding for HT29 FUT6 cell line. The MFI obtained in flow cytometry 
experiments are representative of n=2 experiment; no statistical analysis was performed on the results. 
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3.5 PART V: side experiments 
 
In this paragraph are listed all the preliminary side experiments performed during the PhD 
project development. Although incomplete works, the following experiments shows promising 
results that could be deepened in future projects. 
 
3.5.1 Cell confluency influencing glycosylation expression  
 
Reliability of glycosylation in cell culture is and has been a central focus. Although working 
with cell lines is fundamental to understand glycosylation behaviour and expression, it remains 
hard to completely rely on consistency of the results. In order to reduce the variables at the 
minimum, two cell lines expressing different glycans and glycoprotein were selected for further 
study on cell membrane expression. Being cell-to-cell communication an important influencer 
of cellular behaviour, LS174T (high in sLex/a and CD44) and SW948 (moderately high in Lex 
and high in CD44) were tested at 20%, 40%, 60%, 80% and 100% confluency. The cells were 
then harvested and analysed at the same time, in order to see if confluency could induce 
changes in glycan and/or glycoprotein expression. As results, in LS174T (Figure 3.60A) CD44 
expression increases at high cellular confluency while sLex/a expression with HECA-452, anti-
CD15s and anti-CA19.9 diminish from 20% confluency and remains lower but stable from 
60% to100% confluency. 
Consequently, cells analysis and protein extractions have been performed following the results. 
For instance, if sLewisx/a antigen were to be analysed, cells would have been harvested at low 
cellular density, while for analysis of CD44 proteins were extracted at 80-100% confluency. 
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On the other hand, analysis of SW948 did not show changes neither in glycan nor CD44 
expression, exception made for the antigen sTn which and Tn which starts their expression at 
100% confluency (Figure 3.61).  
Although, the confluence related expression experiment may not appear crucial for cell 
analysis, results suggest that it could serve as cellular behaviour standardization, very important 
to reduce variables and to work at the best cellular potential. 
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Figure 3.60 LS174T expression variability, confluency dependent. In A) comparing of CD44 and HECA-
452 signals, showing a substantial increase in CD44 expression and decrease in sLex/a antigens from 20%-
100% confluency. In B) sLex, Lex, sLea, sTn and Tn antigen were tested. separated analysis of sLex and a 
confirm decreasing in expression from 20%, previously reported with HECA-452 antibody. no signal of 
sTn nor Tn has been observed. The MFI obtained in flow cytometry experiments are representative of n=2 
experiment; no statistical analysis was performed on the results. 
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3.5.2 Colorectal cancer CMS  
 
In the paragraph 1.3.4, it was explained how Guinney et al. (2015) regrouped data on CRC by 
forming four consensus molecular subtypes (CMS) and how Trinh et al. (2016) validated the 
prognostic value of CRC subtyping by identifying a robust IHM assay for different markers, 
that help to identify molecular CRC subtypes. Five markers (CDX2, FRMD6, HTR2B, ZEB1 
and KER) were used. CSM1 was selected by the MSI status and the CSM2/3 by CDX2, a 
marker highly expressed in epithelial-like tumour. CSM4 were selected with HTR2B and 
FRMD6 expressed in mesenchymal like cells. To confirm the ETM transition, the marker 
ZEB1 and an anti-cytokeratin (AE1/AE3) was used to normalize for epithelial content. The 
Figure 3.61 SW948 expression variability, confluency dependent. In A) comparing MFI at different 
confluency of CD44 do not show particular changes in expression. In B) sLex, Lex, sLea, sTn and 
Tn antigen were tested. Lea confirm higher stable expression, as in sLex/a. Signal of sTn nor Tn 
appear at 100% confluency. The MFI obtained in flow cytometry experiments are representative 
of n=2 experiment; no statistical analysis was performed on the results. 
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experiment permitted to confirm the stratification of CRC groups and verify the therapeutic 
benefit for each subtype135.  
For this reason, we decided to reproduce the experiment on the 40 patient’s cohort CRC tissue, 
in order to pave the way for a possible association between each CSM and altered glycosylation 
(Table 3.3). However, no MSI of the cohort was traceable and in order to obtained significant 
results, more sample were needed. Nonetheless, preliminary results showed consistency with 
results obtained by Trinh et al. (2016) and we were able to show high tissue diversity used for 
IHC experiment. Prediction probability, showed in table 3.3, was calculated by the online mini-
IHC-classifier based on the automated image analysis of Trinh et al. (2016) which uses a 
random forest classifier to determine patient subtypes. Comparison between the automated and 
(online) semiquantitative classifiers showed strong concordance, highlighting that the 
simplified classifier can assign subtype classes in the absence of continuous quantitative 
information. Further IHC testing on CRC tissue is highly recommended. 
 
Table 3.3 Representation of the subtypes and prediction probability of CSM for the cohort of 40 patients’ tissue IHC, following 
online mini-IHC-classifier based on the automated image analysis of Trinh et al. (2016) 
CASES SUBTYPE 
PREDICTION  
PROBABILITY 
MICROSATELLITE  
INSTABILITY 
2042/12 A5 Mesenchymal 74.0% Without information 
2064/07 A3 Epithelial 86.4% Without information 
3813/11 C5 Mesenchymal 50.6% Negative 
5183/11 A6 Mesenchymal 61.8% Without information 
3716/11 A1 Epithelial 87.4% Without information 
3041/12 B5 Mesenchymal 59.0% Without information 
6381/08 3 Epithelial 87.4% Without information 
3038/12 A4 Mesenchymal 61.4% Without information 
5894/06 B2 Mesenchymal 55.8% Without information 
4199/12 C5 Epithelial 82.8% Without information 
4900/08 B5 Epithelial 94.8% Without information 
6963/12 B5 Epithelial 89.6% Negative 
4139/09 3 Mesenchymal 67.6% Without information 
1224/12 A5 Epithelial 87.6% Negative 
7104/10 A4 Epithelial 87.0% Without information 
6474/12 D6 Epithelial 99.4% Negative 
4590/09 C3 Epithelial 87.2% Without information 
7253/12 B5 Epithelial 87.4% Without information 
11621/11 A5 Epithelial 87.4% Without information 
2461/12 A4 Epithelial 63.6% Without information 
3410/11 A7 Mesenchymal 64.8% Negative 
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11024/09 A2 Epithelial 86.4% Without information 
10552/10 8 Epithelial 82.2% Negative 
11260/11 A4 Mesenchymal 60.8% Without information 
5317/11 C3 Mesenchymal 65.4% Without information 
11166/09 3 Epithelial 86.4% Without information 
5581/09 B4 Epithelial 98.0% Negative 
9201/06 1 Epithelial 99.8% Without information 
10160/12 A3 Mesenchymal 57.0% Without information 
10086/12 A3 Mesenchymal 60.0% Without information 
11987/10 A2 Epithelial 99.2% Without information 
6016/12 A7 Epithelial 87.4% Without information 
9638/07 3 Epithelial 85.8% Without information 
11315/08 A2 Epithelial 74.4% Without information 
4968/06 1 Mesenchymal 58.8% Without information 
9989/10 B3 Epithelial 83.2% Negative 
7030/08 1 Epithelial 63.6% Without information 
2500/12 4 Epithelial 74.4% Without information 
1033/11 A6 Epithelial 84.6% Without information 
2344/05 C3 Epithelial 95.4% Without information 
 
3.5.3 5FU IC50 in highly glycosylated cells 
 
Biomarker research have been applied on CRC cell lines and CRC tissue (cohort of 40 patients) 
All the CRC tissue originates from patients treated with chemotherapeutic and in particular all 
treated by 5fluorouracile (5FU). Thus, we decided that it would have been interesting to create 
continuity on the cell lines available, by testing the half maximal inhibitory concentration 
(IC50) on CRC cell lines; moreover, we wanted to see if glycosylation may influence on drug 
absorption and thus drug efficiency. Preliminary results were obtained by testing SW620 cell 
line (wt, mock and FUT6) with different concentration of 5FU. Cell viability was then 
measured by MTT reaction (Figure 3.62). Results show that SW620 FUT6 (thus higher 
expressing sLex) has half maximal inhibitory concentration (IC50) ~50% lower when 
compared to the wt and mock (low in sLex). This suggest that presence of sLex glycans can 
increase absorption and efficacy of 5FU and thus, reinforcing the idea that study of aberrant 
glycosylation can be useful as prognostic and predictive marker. 
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3.5.4 Luciferase assay 
 
The final goal of antibody production was to test in vivo antibody efficacy by creating 
xenografts of human cell expressing the luciferase gene in mice. The luciferase expression is 
fundamental for cell tracking and antibody efficacy quantification. Two cell lines have been 
chosen. HT29 (mock and FUT6) and SW948 (mock and ST6GAL1) were the mock were used 
as negatives and the transfected/transduced have higher expression of respectively, sLex and 
α-2,6-sialic acid. Lentiviral transduction with Luciferase gene was performed on cell lines 
and cells were tested for Luciferase expression through bioluminescence emission after cell 
lysis and substrates addition. The lysates were tested in Chemidoc with a 50 seconds exposition 
period in a 96 well plate where the previous cells. 
However, as aforementioned, stability of glycosylation in vitro can be variable and subject to 
changes, especially after further transduction with Luciferase gene. For this reason, antigen 
screening has been performed of both cell lines with main antigens CD44 and sLex/a. 
Cells were harvested at same confluency rates; however, results show differences in antigens 
expression before and after luciferase lentiviral transduction (Fig. 3.52).  
In detail, SW948 mock and SW948 mock luciferase, do not show any changes in antigens 
expression, while the ST6GAL1 shows block of expression for both antigens. 
Figure 3.62 IC50 of 5FU concentrations on SW620 wt, mock and FUT6 Results show that SW620 FUT6 (thus higher 
expressing sLex) has half maximal inhibitory concentration (IC50) of ~50% less when compared to the wt and 
mock (low in sLex). The cytotoxic assay is representative of n=3 experiments. 
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On the other hand, HT29 mock luciferase when compared to mock, show a general decrease 
in both antigens. No remarkable changes are instead noticed between HT29 FUT6 and HT29 
FUT6 luciferase. In general, change in antigen expression is noticed, and while HT29 FUT6 
cells show almost no difference, SW948 ST6GAL1 must be newly transduced with the 
luciferase gen. 
Figure 3.63 screening of cell lines SW948 mock and ST6GAL1 and HT29 mock and FUT6, before 
and after luciferase transduction. The MFI obtained in flow cytometry experiments are 
representative of n=2 experiment; no statistical analysis was performed on the results. 
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DISCUSSION & CONCLUSION 
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4.1 Biomarker research and material selection 
 
The first part of the project aimed to the identification of the most promising biomarker for 
colorectal cancer detection, among aberrant glycans and overexpressed glycoproteins. The 
determination of the possible new biomarker was necessary to produce novel monoclonal 
antibodies. Thus, we were looking for biomarkers with specific characteristics. Initially, the 
biomarker should detect most of the stages of cancer, with preference for CRC early stages 
detection. Indeed, as introduced in chapter 1.3.1, tracing cancer at first stages can raise 5 years 
survival probability up to 90%145.  
Secondly, a good biomarker should be identified with no-invasive techniques. Blood sampling 
is considered a minimal invasive technique, yet it is generally considered less invasive than 
colonoscopy and tissue specimen collection128. Thus, a biomarker detectable in patients' serum 
would be of easier access both for patient and clinician.  
In addition, a good biomarker should be cancer specific. Alterated glycosylation have been 
largely proven to be present specifically in cancer tissue; for instance sTn has been found overly 
expressed in bladder cancer and on the mucin 1 type (MUC1) surface211,296. More studies, on 
aberrant glycosylation on CRC cancer, revealed the overall presence of aberrantly expressed 
sialyl Lewis (sLe) antigens, throughout all the stages of tumour formation.  
Lastly, the biomarker should be stable, in order to reduce false positive or negative during 
serum testing. Proteins, among all the biomarker in use have been shown to be highly stable 
and to function as good diagnostic and prognostic biomarkers236,249,253. For instance, 
carcinoembryonic antigen (CEA) is in use as a prognostic biomarker after surgery resection, 
where scoring is expecting to lower in case of a successful operation138,139. On top of that, 
glycosylation covers the surface of glycoproteins and it is possible to trace aberrant 
glycosylation presence by studying the different carrier,  
For all this reason, we have decided to screen for two types of antigens: aberrant glycans and 
glycoproteins, already proven to be overexpressed in cancer or in colorectal cancer. 
To increase the translational power of this project, we have chosen to screen both for cell lines 
and patients' tissue specimens. The use of cell lines in translational project has been very 
discussed, as very useful for experimental set up and protocols optimizations, but unsure in 
human specimen reproducibility. To aggravate, as briefly mentioned in paragraph 3.5.1, 
glycosylation pathways may be lost or altered in cell lines, as a consequence of the 
immortalization process and cell lines passages in culture.  
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However, the use of cell lines remains crucial in the first steps of the project and the possibility 
to transduce/transfect cell lines with glycoenzymes, helps defining roles and function of 
aberrant glycosylation in cancer development.  
For project consistency, we have chosen cell lines harvested form colorectal patients in 
different stages and grades of the cancer (Table 3.1). The cell lines were tested for differences 
in doubling times, with first stages having higher doubling time of the last stages, as expected 
(Fig. 3.2). Alteration in cell growth, depending on differences in glycosylation expression, was 
also studied: we tested enzyme FUT6 expression, translated in HT29 and SW620 cell lines and 
enzyme ST6GAL1 expression, transfected in SW948 and SW48 cell lines. In detail, FUT6 is 
responsible of fucosylation of sLex antigens and ST6GAL1 for increase of α-2,6- sialic 
acid. Contrasting results show that modification in glycosylation may influence cells growth, 
yet it has not been possible to define how doubling time is dependent from increase sLex nor 
sialic acid expression (Fig. 3.1). Nonetheless, we have decided to pursue with the screening for 
antigen expression of all cell lines wt, mock and transfected/transduced, in order to study 
similarities and differences in expression. 
 
4.2 Colorectal cancer cells lines overexpressing CD44 and sLex/a 
 
Different immunoassays were planned in order to screen for antigen expression and to test 
commercial antibody specificity, by using different antibodies clones against the same antigens 
(Table 3.2).  
Firstly, live cell screening was performed by flow cytometry technique and as a results two 
major antigens have shown major expression: sLex/a and the glycoprotein CD44. In order to 
validate the results obtained, screening has been performed not only on CRC cell lines, but also 
in normal colon CCD 841 Con. sLex/a showed the maximum expression in LS174T, stage 2 and 
grade I, followed by HT29 and SW620, respectively, stage 3 grade I and stage 3 grade IV. The 
antigen Lex have been also taken under consideration, given the expression in cell line SW948, 
stage 2 grade III. 
CD44 was highly expressed, revealing a progressive lost in expression from normal colon 
down to grade IV in CRC lines. The CD44 antigen is a cell-surface glycoprotein involved in 
cell–cell interactions, cell adhesion and migration thus expression in normal colon was 
expected. However, studies of alteration in isoform expression and/or glycosylation suggests 
CD44 as suitable biomarker candidate. In fact, further analysis on HT29 FUT6 cell lines, did 
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not only show an increase of sLex, but also an important increase in CD44 expression, 
suggesting a correlation between the antigens (Fig. 3.6). On the other hand, unanticipated 
results revealed lower expression of the CEA antigen only in SW948.  In fact, CEA is used a 
prognostic factor for CRC in clinics and it was expected to show an overall higher expression 
in cancer cell lines297. 
In the second part of biomarker discovery, we aimed to study the stability of the proteins and 
glycans after extraction from the membrane. Western blot technique was applied in order to 
validate results previously obtained by flow cytometry, to characterized molecular weight 
expression of the antigens and to analyse antibody sensitivity on antigen detection. SLex/a, Lex, 
CEA and CD44 were selected (see paragraph 3.1.4). In general, blots run with the total 
membrane lysate of all cells in analyses, revealed high expression in sLex/a and CD44 antigens. 
Moreover, increase of CD44 correlated to increase of sLex in HT29 FUT6 cell was also noticed. 
Curiously, blot revelation with HECA-452 (sLex/a) and anti-CD44hpan depicted increase of 
signal in both staining of a band at 135 kDa in HT29 FUT6. CEA isoforms were mainly 
detected at low molecular weight, suggesting low presence of post-translational modifications 
while Lex revealed increase in signals, compared to live cells analyses. However, because of 
the difficulty in obtaining specific molecular weight for Lex and complete absence of the 
antigen in SW620 cell lines, we decided to not consider further Lex for future experiments. 
Thus studies obtained on cell lines, highly suggested to consider sLex/a and CD44 glycoprotein 
as potential future biomarker, supporting others literature results153,255,298.  
 
4.3 CD44 and sLex/a involved in ganglion metastasis 
 
Validation of the translational potential of the results obtained required further analysis on 
human specimen. Therefore, we have decided to screen human specimens by 
immunohistochemistry (IHC) (paragraph 3.1.5). A cohort of 40 CRC patients was selected to 
ensure significant results of the screening. Analyses showed an overall presence of aberrant 
glycosylation on tissues and high intense staining of the marker CD44 (Table 3.3). 
SLex/a and CD44 were also stained on colon cell mucus, suggesting its potential as no-invasive 
detection biomarker (Fig. 3.11) Moreover, further analyses depicted high correlation among 
the antigen’s expression, suggesting that in tumoral environments, glycotransferase disfunction 
may influence other expression pathways. In general, CD44 and Ley are found more expressed 
in cancer stages III/IV and sLex and Ley highly expressed in tissue with ganglionic metastasis 
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(Fig. 3.13/3.14). Values were confirmed by crosstabs obtained by CD15s and HECA-452 
antibodies scoring, that revealed higher expression of the antigens sLex (and maybe sLea) in 
ganglion metastasis (Fig.3.15). Nonetheless, overall survival (OS) analysis revealed that 
presence of Lex is associated with an increase of the OS. This support the idea that the level of 
sialylation may play a central role in cancer invasion and metastasis153. Consequently, we 
managed to validate the results obtained in cell culture screening and to choose sLex/a as new 
potential target.  
In tissue analyses CEA shows higher expression than the results obtained in cell lines analyses 
(Table 3.3). However, CD44 not only show higher intensity signals, but also correlation with 
staging progression and tissue metastasis. Thus, we have confirmed CD44 as glycoprotein 
candidate biomarker. 
Lastly, in order to understand the role of sLex and CD44 in cell migration and to validate the 
potential of antibodies against these antigens, we have performed the scratch wound assay. 
Thoroughly, cells were cultivated in inserts at 90% confluence or higher and after insert 
removal, we kept the cells in gentle motion in presence of anti-CD15s (sLex) and anti-CD44-
Hpan (Fig. 3.18). To study cell migration, we compared the closure timing of the gap. Results 
shows a general delay in closure in presence of anti-CD15s (sLex) of the three cell lines selected 
[LS174T (high in sLex/a and CD44), SW48 (medium-low in sLex/a and CD44), SW620 
(medium-low in sLex/a and null in CD44)]. The results confirm that sLex/a play a role in cell 
migration. Moreover, LS174T, maintained in culture with anti-CD44-hpan, display almost no 
cell migration and SW48 show delay in closure, while SW620 in presence of anti-CD44-hpan 
depicted no differences in migration of the control sample. The results not only confirmed the 
probable role of sLex and CD44 in cell invasion, but the effect of the antibody revealed a 
potential beneficial use of antibodies in preventing migration. 
 
4.2 CD44 as E-selectin ligand 
 
CD44 and sLex/a have been selected as possible candidates for CRC biomarkers. Moreover, 
both antigens are considered E-selectin ligand. E-selectin, also known as CD62 antigen-like 
family member E (CD62E), is a selectin cell adhesion molecule expressed only on endothelial 
cells activated by cytokines69. E-selectin studies have showed that E-selectin binding to colon 
cancer cells correlates with increasing metastatic potential, and that cancer cells bind E-selectin 
using glycoprotein or glycolipid ligands normally expressed on immune cells69. Therefore, we 
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decided to further characterize CD44 glycosylation, by extraction from LS174T and HT29 
FUT6 cell lines. In fact, LS174T presented high expression of high molecular weight of CD44 
(>135 kDa), while HT29 FUT6 showed a parallel increase of expression of sLex and CD44 
antigen, suggesting correlation between the two antigens. Moreover, as presented by Azevedo 
et al. (2018)256, CD44 presents different isoforms and on the spliced sites are presented many 
O- and N-glycosylation sites. This may support the theory, that a less un-spliced form of CD44 
presents a higher post-translational modification and thus, in cancer cell, could express higher 
aberrant glycosylation on its surface256. The highest isoform back bone not glycosylated 
correspond to 82 kDa that can be found glycosylated up to 250 kDa. In order to identify the 
backbone of CD44 expressed by the two cell lines, we immunoprecipitated the sample with E-
selectin-Ig chimera and sent to analyse through liquid chromatography mass spectrometry (LC 
MS/MS). Four separated samples (duplicated for each cell lines) confirmed the 
immunoprecipitation of CD44 82 kDa as E-selectin ligand (Fig. 3.23). Samples were also cross 
analysed in western blot by precipitating E-selectin ligands and CD44 (with anti-CD44-hpan) 
of HT29 FUT6. Both signals were revealed at 135 kDa and resulted positive for E-selectin-Ig 
in blot staining, confirming the presence of sLex/a on CD44 immunoprecipitated.  
At this point, it was important to understand whether CD44 was preferentially glycosylated by 
sLex or/and sLea. Thus, foster resonance energy transfer (FRET) of CD44/sLex and CD44/sLea 
was applied. Energy transfers happens when a donor molecule is at a max distance of 9nm 
from an acceptor molecule and the donor-emission-wavelength is overlapping with the 
excitation-wavelength of the acceptor. For this reason, the choice of the proper fluorophores 
was critical. FRET was performed by flow cytometer on LS174T cell lines. In case of positive 
FRET was expected median fluorescence intensity (MFI) increase in the acceptor channel. 
Using different fluorophore combinations, we revealed positive fret for both antigens, although 
sLex seem to have higher expression when compare to sLea (Fig. 3.26). Nonetheless, both sLex 
and sLea can be present as O- and N- glycosylation, and in order to understand the type of 
glycosylation, we have used two enzymes to cleavage N-glycans or sialic acid, respectively 
with PNGase F and neuramidase. The reaction with PNGase F depicted a successful result, 
with CD44 protein losing signal against E-selectin-Ig and reducing its molecular weight from 
150 kDa to 120 kDa with anti-CD44-hpan (Fig 3.27). This confirmed the presence of N-glycans 
on CD44 surface. Treatment with neuramidase results in increase of signal of CD44 and 
decrease of E-selectin Ig staining. This suggested the role that glycosylation have in influencing 
antibody binding and affinity. 
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All the results obtained on CD44 glycosylation, imply that even though CD44 may be found 
expressed on normal tissue, the use of CD44 aberrantly glycosylated can be used as cancer 
specific biomarker. However, before proceeding to antigen isolation, we have decided to check 
the presence of CD44 as a soluble marker on LS174T supernatant. In fact, both CD44 and 
sLex/a have been found in the cancer cell mucus on IHC staining and we aimed to compare the 
result in cell culture. Being the presence or quantity of CD44 in the cell culture supernatant 
unknown, we have used different concentration of supernatant and compared to the positive 
control total membrane lysate of LS174T. Two bands at ~150 and ~100 kDa, match the positive 
control signals with increase in intensity (Fig. 3.29). The results suggest, that not only CD44 
can be found soluble, but also the major glycosylated forms can be release outside the cell, 
probably after cell death. 
Therefore, we decided to isolate CD44 from LS174T and we injected in the mice for 
immunization. Being the extraction of CD44 a difficult process (Fig. 3.30) were most of the 
immunoprecipitant can be lost, we have also decided to immunize a second series of mice with 
LS174T total membrane protein, having a high concentration of sLex/a and CD44 antigen. 
 
4.3 Serum testing and antibody specificity 
 
The final aim of the project was to obtain antibody that could recognize CD44/sLex/a either as 
soluble marker in blood analysis or in live cells, to be used as therapeutic tool. Initially, testing 
of mice serum have been conducted mainly by enzyme-linked immunosorbent assay (ELISA). 
We performed a total of 5 immunizations and while we were aware of the concentration of 
LS174T total membrane lysate injections, we had calculated the quantity of CD44 isolated by 
theoretic best yield of extraction. The calculation in based on the maximum efficiency of 
antibody of protein pulled down. Serum titer was checked using membrane lysate of different 
cell lines expressing CD44 and sLex/a in different concentrations. For this we have used 
LS174T (high expression of CD44 and sLex), SW620wt (not expressing CD44, moderate in 
sLex/a) and HT29 FUT6 (high expression of CD44, moderate in sLex/a). Controls were selected 
as HECA-452 (anti-sLex/a) anti-CD44-hpan and miceCTRL, not immunized serum.  
Mice series immunized by CD44 (MiceCD44), shows from the second immunization preferential 
binding for HT29 FUT6 and a reduce signals for LS174T and SW620. Although we were 
expecting major signals in also in LS174T cell lines, specificity of binding for HT29 FUT6 
suggested recognition of a particular CD44 glycosylated form, and thus we proceed to mice 
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sacrifice (Fig 3.33). On the other hand, mice immunized with LS174T total membrane lysate 
(miceLS174T), shows high intense signals for the three cell lines. Being immunized with total 
membrane lysate, many aspecific signal were expected (Fig. 3.33). Thus, we decided to 
proceed with mice sacrifice and to select the monoclonal after hybridomas creation. Further 
analyses of serum mice on flow cytometry, revealed the recognition of cells membrane cells of 
LS174T and HT29 FUT6 by serum miceLS174T. On the contrary miceCD44 did not show any 
signal, thus we proceed to hybridoma formation, with purpose to look for a monoclonal 
antibody that can be used for detection techniques (i.e. diagnostic testing). 
 
4.4 Hybridoma maintenance and clones' selection 
 
Both hybridomas series, were selected mainly by ELISA screening. Being the immunizations 
coming from cells products, hybridomas often results difficult to select. In fact, hybridoma 
cells are highly sensitive to culture conditions and can lack of stability: thus, the selection 
process was hard to handle with the many antigens needed for selection. For instance, the 
coating of ELISAs well with total membrane lysate could not guaranty repetition of antigen 
pool variation in each well and each clone tested may differ in antibodies production from week 
to week. However, antigen signals were often positive for more than one antigen which, added 
to different replicant, have often cross-validated antibody affinity. For instance, in the second 
cloning of miceCD44 hybridoma (Fig. 3.38) both clones 3.3 and 3.5 were positive for LS174T 
(high in E-selectin ligands) and commercial sLex/a tetramers. The result suggested probable 
clone specificity for E-selectin ligands.  
Cloning process was used to select hybridoma clones, to expand them and increase specificity 
and titre of antibody produced. Cloning was also advantageous by increasing the selection of 
stable hybridomas. Mycoplasma contamination have affected also clones selection, with loss 
of positive clones during the selection procedure299. Although, mycoplasma infection is often 
a burden in mammalian cells culture, most of the clones were treated on time by mycoplasma-
antibiotic treatment300. This led to a temporary loss of antibody production induced both by 
mycoplasma and antibiotic. Thus, it is very important to establish routine mycoplasma tests 
until final clones are selected and kept at -80˚C. 
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4.5 Clone 2B1 from miceCD44 
 
The aim of monoclonal production of miceCD44 was to obtain a monoclonal antibody recognize 
CD44 82 kDa in its cancer glycosylated form. Contrasting results were obtained with the 
recognition of the polyclonal titre against live cells. In fact, while from a side, there was not 
recognition of serum miceCD44, of HT29 FUT6 nor LS174T cell lines (Fig. 3.35), from the other 
side hybridomas CD44.4 showed positive reactivity against live cell ELISA of LS174T and 
SW948 (Fig. 3.37). Nonetheless, negative results of the mice serum on flow cytometry 
narrowed the initial production to a possible monoclonal for protein detection tests. Selection 
occurred mainly by ELISA against different membrane protein of the CRC cell lines [LS174T 
(high expression of CD44 and sLex), HT29 FUT6 (high expression of CD44), SW948 (low in 
CD44 and moderate in E-selectin ligands) and SW620wt (not expressing CD44)] and sLex/a 
commercial tetramers. Commercial CD44 protein was used as final testing, because the only 
human recombinant version available was of a 36 kDa and it was probably missing most of the 
post-translational modification required (Fig. 3.39). Loss of signal at the 3rd cloning ???,, 
especially of sLex/a antigens and no signal found on CD44, pushed towards the creation of a 
second generation miceCD44. The second generation showed since the beginning more 
consistency with the signal expectations, with strong recognition of LS174T, HT29 FUT6, 
sLex/a antigens and lower signal in SW620 (Fig. 3.40). However, on the second cloning, most 
of the signals were lost exception made for clones 2C2 recognizing CD44 and 2B1 recognizing 
LS174T. At the end of expansion 2B1 revealed an interesting positive signal for LS174T, sLex/a 
and CD44, while 2C2 lost most of the signals (Fig. 3.42). Thus, it has been selected for 
sequencing and further characterization in vitro and future in vivo. 
 
4.6 Clone 2 3A1 from miceLS174T 
 
miceLS174T was created with the intention to produce antibodies mainly against sLex/a, but we 
have also decided to screen for the two main glycoproteins that we have analysed: CEA and 
CD44. Hybridomas were tested mainly by ELISA against LS174T ( high expression of sLex/a), 
HT29 FUT6 (moderate expression of sLex/a), SW948 (low/moderate in E-selectin ligands) and 
SW620wt (moderate expression of sLex/a); against commercial tetramers of sLex and sLea; 
against Mucin from bovine submaxillary glands (BSM), highly O-glycosylated and high in 
sialic acid, and mucin from porcine stomach (PSM), with bound sialic acid only at 0.5-1.5%. 
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Thus, while miceCD44 went straight forward to specific anti-CD44 monoclonal production 
(from protein to antibody), miceLS174T aimed to broad antigenic reaction, and attempt clones’ 
selections after hybridomas formation (from CRC cells to best antigenic reaction). However, 
as shown in serum of the miceLS174T tested, high levels of aspecific bound (for our final 
purpose) revealed intense signal in LS174T, HT29 FUT6 and SW620 (Fig. 3.33). Therefore, 
firstly we analysed the level of specificity against sialic acid and probable sLex/a specific 
recognition by serials dilution of the hybridomas against LS174T and BSM; we have also tested 
the hybridomas against BSM and PSM to check preference in sialic acid binding (Fig. 3.44). 
Both results suggest the presence of monoclonal specify and affinity for sialic acid. 
Hybridomas were then cloned three times and clones 2.2A4 and 2.3A1 have been selected as 
showing highest binding against most of the antigens tested; however, the high positive signals 
for most of the antigens suggests that more than one clone is present in 2.2A4 and 2.3A1 
cultures and further cloning is needed. Moreover, in the 3rd cloning most of the clones were 
more positive for PSM than to BSM, suggesting antibody preference for mucin sequences 
rather than the glycosylation on their surface (Fig. 3.48).  
Great reactivity against CD44 was taken into consideration and we have selected clones 2.2A4 
and 2.3A1 for further characterization on live cells. Flow cytometry performed against HT29 
wt (control) HT29 FUT6 and LS174T revealed binding of the antibody(ies) on HT29 FUT6 
surface. Although binding on LS174T was also expected, we have decided to select clone 
2.3A1 for antibody sequencing and further characterization in vitro and in vivo. 
 
4.7 Importance of glycosylation standardization 
 
All the side works presented in chapter 3.5, aimed to understand how glycosylation may 
influence or be influenced in different condition.  
Glycosylation is affected by many factors in cell culture301 and although many advances in 
research have been made by analysing glycans with different techniques (including 
immunoassay and mass spectrometry153), research should be able to standardize culture 
condition and glycosylation expression. Thus, as a first attempt, we have tried to see how much 
cell confluency can affect glycosylation expression. Two cell lines were chosen with the most 
diverse antigens expression, LS174T and SW948. Results shows that sLex/a antigens are highly 
expressed during low confluency (20%) while the adhesion protein CD44 is mostly expressed 
at high confluency (Fig. 3.49). Moreover, SW948 start expressing sTn only at 100% 
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confluency (Fig. 3.50). Thus, although in most of the cases glycan expression is maintained, 
we think that standardization of screening procedure in experiment that involves glycosylation 
expression would be highly desirable. Following the same concept, we tested glycosylation 
levels variation after transduction of luciferase gene into the cell lines. General variation of 
signal is noticed, however SW948 ST6GAL1 luciferase lost signals in CD44 and sLex/a 
antigens. Thus, during transduction, the gene could have been inserted in critical transcribing 
sequences interfering with main pathways of expression. Thus, new transduction is necessary 
to perform experiments glycan related in vivo. 
In paragraph 3.5.2, we have tried to validate the classifier proposed by Trinh et al. (2016)134,302. 
Comparison between the automated and (online) semiquantitative classifiers showed strong 
concordance, highlighting that the simplified classifier can assign subtype classes in the 
absence of continuous quantitative information. However, in order to associate to each CSM 
glycan expression, it is necessary to test a higher patient’s cohort in order to guaranty 
significant results. Moreover, all the tissues were treated with 5FU and in order to understand 
glycan influence on the treatment, we performed a half maximal inhibitory concentration 
(IC50) between SW620 wt and FUT6 transfected. As a result, higher expression of sLex antigen 
show lower IC50 of 5FU absorption when compare to the wt and mock (low in sLex). This 
suggest that most of the tissue tested, may have a lower glycan expression, when compared to 
the tumour before 5FU treatment. This study should be continued for further mechanism 
comprehension.  
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5.1 Conclusions  
 
Colorectal is considered the second deathliest cancer-type and one of the most common human 
malignant diseases. Due to its localization in the body, it is still very difficult to be detected in 
the early stages, when treatment is more effective. CRC detected at late stages is more likely 
to develop recurrences, even after treatment, leading to the necessity to create a new system to 
early stages detection. Glycosylation is one of the most common and important post-
translational modification that involves key biology processes such as cell-cell interaction, cell 
growth, cell adhesion etc. Several studies on cancer-associated glycosylation revealed that 
aberrant glycosylation is a universal feature in various steps of malignant transformation and 
tumour progression.   
Thus, the current project aimed to the identification of aberrant glycans as new possible 
biomarkers and to the production of specific monoclonal antibodies for their recognition. The 
work has been divided in two main part: biomarker discovery and antibody production. 
Colorectal cancer cell lines and patients’ tissue have been screened for different glycans 
overexpressed in tumour and for carcinoembryonic antigen (CEA) and CD44 glycoproteins. 
As a result of the overall screening performed with immunoassay techniques, sialyl Lewisx/a 
(sLex/a) and CD44 are the most expressed antigen. Data suggest that not only sLex and CD44 
could play major in cell migration, but also the production of specific monoclonal antibody 
against sLex and/or CD44 might have good potential if used as therapeutic tool.  
Moreover, correlation with increase of sLex and CD44 expression have been found. Both 
antigens are E-selectin ligands, where E-selectin is a selectin cell adhesion molecule expressed 
only on endothelial cells activated by cytokines69. The role of E-selectin in cancer progression 
and metastasis has been reinforced by a number of basic researches69,203. Therefore, E-selectin 
ligands have been precipitated from LS174T and HT29 FUT6 and analysed by LC-MS/MS 
and enzymatic reactions.69. The role of E-selectin in cancer progression and metastasis has 
been reinforced by a number of basic researches69,203. Therefore, E-selectin ligands have been 
precipitated from LS174T and HT29 FUT6, and analysed by LC-MS/MS and enzymatic 
reactions. CD44 expressed from both cell line is an e-selectin ligand, presenting sLex/a on its 
surface. Thus, in order to obtain the best hybridomas clones, we decided to perform two 
different immunization. The first immunization preparation was obtained by isolation of CD44 
by LS174T (miceCD44), while the second by total membrane protein of LS174T (miceLS174T). 
LS174T cell lines was selected because of their high expression of both antigens.  
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Immunization titer have been tested mainly by ELISA using different extract from cell lines 
[(LS174T (high expression of CD44 and sLex), SW620wt (not expressing CD44, moderate 
expression of sLex/a) and HT29 FUT6 (high expression of CD44, moderate expression of 
sLex/a)]. Flow cytometry experiments have also been performed on LS174T and HT29 FUT6 
with the serum of the two mice series. However, only miceLS174T serum was able to bind both 
cell lines. Thus, hybridomas from miceCD44 were tested only for antibody serving a purpose in 
immunoassay testing, while miceLS174T were also tested for live cell binding, and thus for 
potential therapeutic tool. 
From miceCD44, clone 2B1 has been selected as positive for CD44 and sLex/a commercial 
antigens; from miceLS174T, clone 2.3A1 has been selected not only for positive binding against 
most of the antigen tested, but also for binding of HT29 FUT6 in flow cytometry. Both clones 
will be sequenced and further characterized and validated as potential clinical tools.  
 
5.2 Future work 
 
The project presents an important experiment set up, from cell lines screening to antibody 
production. Cell line expression and translation on human specimen is still to be defined and 
for this reason different side experiment have shown good preliminary results. 
Glycosylation can be influenced in culture by many factor, and as future work, standardization 
of material handling is fundamental. On the same line, translation between cell lines and human 
specimen remains very important, and would be interesting to continue validating the IC50 of 
5FU in different cell lines overexpressing different aberrant glycans; in fact, most of the tissue 
are harvested after 5FU treatment and further analyses of glycans influencing 5FU absorption 
would help understanding better the samples and the results obtained. For the same reason, we 
find very interesting the correlation study between glycan expression and the four consensus 
molecular subtypes (CMS) classification, proposed by Guinney et al. (2015). 
Biomarker research in cell line and tissues showed mostly agreement in antigens expression. 
However, further testing of glycoprotein expression in serum of CRC patients’ needs to be 
validated before taking major conclusions. 
Monoclonal clones produced show promising recognition of CD44 and sLex/a antigens, thus it 
is necessary to characterize the antibody isotype and sequence the variable fragments in order 
to work with more stable products. Glycans microarray and affinity binding will be very 
important testing. 
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Abstract  
Colorectal cancer remains the second deadliest type of cancer with many causes resulting in a 
severe outcome. It is well recognized the higher level of cellular heterogeneity of colorectal 
cancer respect to any other type of cancer, which plays a big role in colorectal diagnosis, 
prognosis and treatment.  
Colorectal cancer is a curable disease when detected in early phases, up to 90% when detected 
in stage I, but the absence of symptoms makes the diagnosis a difficult process. Thus, the 
understanding of the tumor dynamics, cancer genetics and the expression of specific tumour 
biomarkers is crucial for the cancer early detection. Furthermore, parallel studies demonstrated 
the determinant role of post-translational modification in cancer formation and progression. 
The aim of this review is to resume and combine all the different aspects involved in colorectal 
cancer malignancy, important for clinicians and researchers to understand where we currently 
stand, and which improvements are required.  
1.Introduction  
Cancer is still considered one of the major death-related problem worldwide.  
In 2015, in Europe, out of the 5,217,376 deaths registered, 1,062,112 were caused by cancer, 
reaching roughly the 20% of the population.  
Colorectal cancer (CRC) dwells from the second to the third position as the most diagnosed 
malignancy and leading cancer related-death, in both sexes. In 2012, just in Europe, 447,000 
new cases have been registered with 215,000 deaths 1. It has been considered a major public 
concern in the Western world (Fig.1), but its incidence is also highly increasing in the 
developing countries. Genetic mutations, comprehensive of previous or family history of 
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polyps-formation, and environmentally-induced epigenetic factors derived from food habits, 
physical activity and/or smoking  are the main responsible of CRC incidence and increase 2–6.  
In the advanced stages, current therapies are not curative,  with the necessity of continuous 
treatments, which is becoming an important burden in the society7.  
At the metastatic stages, chemo-radiotherapy is the main therapy, which improves the treatment 
for the local advanced staged cancer, but is not curative 1,8. 
Thus, the greatest challenge of CRC, is the necessity to early stage detection methods. The 
identification of adenomas (benign tumour) before carcinomas formation (malignant tumour) 
can help treatment, thus reducing cancer incidence and increasing overall survival (OS)7.  
 
 
2. The role of CRC heterogeneity in the clinical decision  
Investigating cancer heterogeneity has been one of the central focus in the last two decades. 
Cellular heterogeneity is often responsible of misleading diagnosis and/or prognosis associated 
with inefficient classification and reduced treatment efficacy9. 
CRC displays a high level of heterogeneity and thus of high molecular complexity. 
From the pathological point of view, CRC histological analysis is essential for a correct 
diagnosis and prognosis. As shown in the table 1,  carcinomas account for 99.5% of all CRC 
of which 92% are adenocarcinomas, originated from the normal epithelium of colorectal 
Figure 4 Comparison of all cancer incidences (transparent), excluding non-melanoma skin cancer with 
colorectal cancer incidence in males (blue) and females (red) on different continents. Western countries 
resulted in both cancer incidence and CRC formation, as a consequence of a consumerism life style. The data 
are retrieved from project GLOBOCAN 2012. 
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mucosa 6,7. In the remaining 8%, in a highly heterogenous population, sarcomas, originating 
from the connective tissue, and other specific or unspecific carcinomas could be identified 
(Table 1).  
The study of the tissues by histological analysis is also essential for determination of the stage 
and the grade of the tumour. The stages determine the level of extension of the tumour resulted 
from the uncontrolled growth, while the grade measures the level of differentiation of the 
tumour cells and is a stage-independent measurement10,11.  
Two of the staging classifiers in use aim to classify tumour progression in different groups: i) 
in situ or stage 0, defines the presence of abnormal tissue, ii) localized or stage I where the 
cancer is present, iii) regional or stages -II /-III with the tumour spreading and distant or stage 
IV with a spread into distant parts of the body. On the other hand, the TNM staging helps to 
define the tumour in greater detail and is useful to determine the grade of the cancer, with T 
describing the size of the tumour, N the nearby lymph nodes and M eventual metastasis 
present5. Although the identification of the correct cancer stage and grade is fundamental to 
assign the correct therapy, the full understanding of the origin of CRC heterogeneity remains 
crucial for choosing the most efficient and effective treatment. Many theories have been 
postulated to explain the role, the origin and the function of the molecular heterogeneity in the 
tumour microenvironment 12. 
In the first theory, the cancer stem model, it is proposed that a minor group of cells, called 
stem-cells, is responsible of tumour initiation and progression, since they often carry specific 
proteins capable of inducing metastasis and tumour progression. In the second model of clonal 
evolution, a more classical Darwinian model has been pursued, where the mutations are 
acquired upon previous mutations and  
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the fittest survives upon the other clones. Finally, in the third model of the big bang, the 
mutations responsible for cancer development and progression happen mainly in early CRC 
formation13. 
These models have been theorised for a better comprehension of tumour progression and 
instead of been contradictory, they can be considered complementary solutions to the problem. 
Adenocarcinoma 92.10% 
Adenocarcinoma, 
NOS 
63.20% 
Adenocarcinoma 
in adenomatous 
polyps 
8.80% 
Mucinous 
adenocarcinoma 
6.30% 
Adenocarcinoma 
in villous 
adenoma 
1.90% 
Signet ring 
adenocarcinoma 
1.10% 
Mucin-producing 
adenocarcinoma 
0.70% 
Other 
adenocarcinomas 
10.20% 
Other specific 
carcinomas 
5.90% 
Neuroendocrine 
carcinoid 
4.40% 
Others 1.50% 
Epidermoid 
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0.70% 
Squamous cell 
carcinoma 
0.70% 
Unspecified, 
Carcinoma, NOS 
0.80% 
Table 1 Percent Distribution by Histology among Histologically Confirmed Cases, both sexes, USA, 
from 2011-2015.Different types (highlighted in darker-grey) and respective subtypes (light grey) of 
CRC carcinoma. Data collected by SEER 18 areas, adapted from SEER Cancer Statistics Review 
1975-2015 
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In general, heterogeneity can be subdivided in inter-tumours variety, among different primary 
tumours of the same type in the same patient, or intra-tumour variety within the same tumours. 
It can also be sub grouped into spatial and temporal heterogeneity, defining respectively, the 
diversity derived from different areas of the same neoplasm and the variability occurred 
throughout the time14.  
CRC among all cancers is considered one of the most heterogeneous, with differences in 
molecular expression, cellular subtypes and cancer location. Diversities among left, right colon 
and rectum have been investigated underlying genetic and immunological differences of 
colorectum in metastatic colorectal cancer15.  As consequence, the creation of a new 
classification, including all the variables that contributes to diversity, has become fundamental 
for impact on colorectal cancer screening and therapy.13. 
 
3. Factors inducing heterogeneity and new classification  
The origin of the complex heterogenetic tumour environment can be related both to genetic 
and to epigenetic factors, such as post-translational modifications, epigenetic regulation and 
differential tumour environment.  
Among the various genetic modifications, chromosomal instability (CIN), microsatellite 
instability (MSI), CpG island methylator phenotype (CIMP) and somatic copy number 
alterations (SCNAs) are considered the major cause for alterations in signalling pathways 
involved in CRC. In particular, the Adenomatous polyposis coli (APC) tumour suppressor 
protein, activator of the WNT protooncogene pathway, the RAS-MAPK cascade (with NRAS, 
BRAF and PIK3), the MYC transcription factor, the transforming growth factor (TGF)- and 
the p53 pathways, are  all responsible for cells proliferation and uncontrolled growth 6,16,17. For 
instance, the cause for around the 90% of sporadic colon cancers is the aberrant activation of 
the Wnt/-catenin signalling pathway led by APC mutations. On the other hand, mutations in 
the epidermal growth factor receptor (EGFR) is responsible for upregulating the oncogenic 
PTEN/PI3K/Akt and RAS/RAF/MEK/ERK signalling pathways. However, the upregulated 
genes may differ between tumour types, underlying the need for mutation profiling for all CRC 
tumours7. Moreover, heterogeneity cannot be explained just by cell alteration pathways since 
it is well known that other aspects of host-tumour interaction are crucial for the tumour 
microenvironment progression such as extracellular matrix, supporting stromal cells, 
metabolism and immune cells interactions6,18. As a consequence, the predictive value of the 
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staging, has resulted limited for estimation of the outcome and implementation of precision 
was needed. 
Guinney et.al. (2015) after evaluating six subtyping algorithms, that combined all the factors 
contributing to cancer heterogeneity, suggested a new sub classification for CRC cancer types, 
denominated consensus molecular subtypes (CSM). It is consisted of 4 defined sub groups:  
CSM1 (14%), MSI immune, characterized by an overexpression of genes involved with 
immune infiltrate combined with a strong activation of immune evasion pathways associated 
with higher MSI.  
 CSM2 (37%), the canonical, shows an elevated SCNA with an upregulation of WNT and 
MYC protooncogenes activation.  
CSM3 (13%), the metabolic, with mutations in KRAS, presents an heterogenous MSI 
associated with high metabolic activity.  
CSM4  (23%), the mesenchymal, with the worst outcome, presents activation of TGF-, 
angiogenesis  and an upregulation of factors involved in the epithelial-to-mesenchymal 
transition (EMT) necessary for migration and infiltration19. The CSM classification is 
recognized as an important tool, that combines the different variables for a better understanding 
of the complex tumour dynamics. Nevertheless, a 5th subgroup containing the 13% of 
unclassified cases of CRC was later identified, suggesting the necessity of ulterior refinement 
of the CRC-CSMs, including new variables such as post-transcriptional and epigenetic 
factors19.  
 
4. CRC detection  
The current diagnostic and prognostic process of CRC involve very complex procedures that 
involves patients’ symptoms, colonoscopy (on the left or right colon) and biomarkers 20.  
It remains therefore a major burden for the health system and patient quality of life. 
One major problem is the identification of early symptoms, since lower pain can be a result of 
many intestinal diseases, most of the time not being cancer related. As presented in the review 
by Vega et al.20, many meta data analysis have been performed in order to find some 
implications between symptoms and CRC. Among the different signs and symptoms, 
correlation is very poor. Yet, in some cases some signs and symptoms show high specificity 
but low sensitivity, such as weight loss, iron deficiency anaemia and all bleeding (dark blood) 
(85%-92%), in other cases, age ( >50) family history and faecal occult blood test appeared 
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more sensitive (75%-91%) than any other symptoms.  However, the presence of one or another 
symptoms could not be directly correlated to CRC20–23. Moreover, left-colon (LC) and the right 
colon (RC) have disclosed different behaviour in the symptoms, microbiome, clinical-, 
chromosomal- and molecular characteristics, with RC having a worse prognosis and suggesting 
different tumour entities15,24. In case of symptoms suspect of CRC, many screening programs 
have been developed, especially in the western countries, to help early diagnosis20. The main 
instrument used for CRC is colonoscopy, an endoscope used not only to detect polyps 
formation in the intestine, but also to cut the abnormal mass in situ for tissue biopsy and 
diagnosis. In particular sigmoidoscopy is a colonoscopy that is performed only in the lower 
part of the colon, including the rectum, and is less complicated of a full colonoscopy, with no 
need for sedation. Besides being an invasive technique,  the availability of the instruments for 
colonoscopy is limited and it has  associated complications such as bleeding, perforation and 
bacterial infections including antibiotic-resistant bacteria such as Escherichia coli and 
Klebsiella25. Additionally, CRC endoscopy has shown to have a limited value as diagnostic 
tool in symptomatic patience, having high sensitivity but lacking specificity in recognizing 
cancer cells20. Therefore, great efforts have been put in the investigation and funding of 
biomarkers accessible by non-invasive techniques, as blood and stools. These biomarkers 
include genetic, proteomic and cellular fragments that can be release into the circulation of the 
patient by the cancer cells. They can be detected through tests like the faecal 
immunohistochemistry test (FIT) and blood or faecal haemoglobin (FOBT)7. Current detection 
of liquid biomarkers, found in no-solid biological tissue, include also micro-RNA (miRNA), 
circulating tumour DNA (ctDNA) and protein such as the carcinoembryonic antigen (CEA)26. 
Liquid biomarkers used for diagnostic and prognostic purposes are indeed contributing to the 
development of the personalized treatment and targeted therapy. 
 
5. Improving CRC screening  
One of the greatest challenges is to find a good screening program, accessible and less invasive, 
with different diagnostic tools that would allow physicians to detect the disease at early stages. 
Advanced stages are not curable and as shown in figure 2A, with data obtained by the 
Surveillance, Epidemiology, and End Results (SEER) US cancer program: early diagnosis of 
CRC increases the chances of survival, from 90% when detected in stage I or local, with a drop 
to 14% when detected in metastasis, or distant phase 7,27. However, data retrieved by the 
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International Agency for Research on Cancer and the project CONCORD-2, show that up to 
2009 the screening programs were not able to improve the 5-years survival rate, suggesting 
that instruments and biomarkers for early detections were still lacking sensitivity or specificity 
(Fig. 2B) 28,29. Moreover, as researched in the statistical study of 2014, the invasiveness feature 
of the CRC screening, it is not well accepted by the population, who avoid volunteering for the 
test. The study, entitled “self-reported last colorectal cancer screening test” showed that more 
of than 50% of the population enquired, in-between 25 and 64 years, did not performed any 
colorectal cancer screening test up to this date30(Fig.2C). Concerning data result also from a 
meta-analysis performed on clinical trials acquired from ClinicalTrials.gov: the analysis 
showed that from 1971 to 2018 most of the trials presented, focused on the different treatments 
for CRC but few efforts were made on the discovery of new tools for diagnosis, prognosis, 
prevention and screening (Fig. 2D). Although finding the cure is and still remains a very 
important objective, we must not forget the impact that prevention and early diagnosis would 
have in colorectal cancer treatment and statistics.  
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Figure 2 Statistical analysis of CRC in clinics. A) Cancer of the Colon and Rectum 5-Year SEER Conditional Relative Survival and 95% Confidence Intervals 
Probability of surviving the next 5 years given the cohort has already survived 0, 1, or 3 years 1998-2014 by stage at diagnosis. B) Correlation between 
colorectal cancer program screening and colon cancer five-year net survival worldwide 2005-2009 C) Self-reported last colorectal cancer screening test by 
sex, age and educational attainment level.2014. Data by Eurostat. D) Trends of CRC clinical trials research types: From 1971 to 2018, most of the efforts 
throughout the 4 clinical trial phases have been put on treatment investigation. Study for new methods of prevention, diagnosis, screening and prognosis 
has slightly increase in the last 15 years. Data retrieved from ClinicalTrials.gov on the 28th October of 2018: presented 2331 of the 4911 cases downloaded.    
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6. Biomarkers in use  
Nowadays, the discovery of new biomarkers and the validation of the existing ones is crucial 
to facilitate the diagnostic process that leads to the understanding of a correct prognosis and 
treatment. Biomarkers or tumour markers can be genetic (DNA, RNA and miRNA), proteins 
(such as antibodies or glycoproteins) or may be the results of epigenetic factor (i.e. 
glycosylation and aberrant carbohydrate formation)31. In general, they are referred as tumour 
associated antigens (TAAs) and are expressed by the cancer cells in quantity proportionated to 
the number or mass of the neoplasm formation. The concentration of the TAAs in the body 
fluids can help in early diagnosis stages, but also to monitor the treatment and to help during 
the follow-ups32. 
Among the different biomarkers, DNA, RNA and proteins have been mainly tested. Common 
DNA markers used for detection are KRAS, TP53, APC and MSI. Faecal and serum testing, 
such as the BEAMing technology, have  
shown high specificity in CRC detection, in detecting circulating tumour DNA (ctDNA), up to 
98%32,33. RNA and micro RNA (miRNA, non-coding oligonucleotides) have been investigated 
as stool and blood biomarkers: MMP7, PTGS2,TP53 and MYBL2 (cancer specific genes) 
isolated from colonocytes are lacking of sensitivity for CRC detection, due to the fact that RNA 
is particularly subjected to degradation in the stool34.  
Protein biomarkers are more stable and seem to be a more promising approach. However, on 
date, only few protein biomarkers are in use. Carcinoembryonic antigen (CEA), a glycoprotein 
overexpressed in many tumours, cannot distinguish malignant form benign neoplasm but is in 
use as a prognostic tool: its centration after R0 resection surgery, the complete removal of the 
tumour mass, is useful for understand the success of the treatment, since its level decline after 
6 weeks. In case of continuous high concentrations post-surgery, suggests metastasis and 
infiltration 32,35. CA19.9 is a carbohydrate antigen, often associated with mucins, high 
molecular weight glycoproteins, and is also used as a prognostic factor: high levels determine 
a poor prognosis. However, it is less sensitive of CEA. Further studies, that combined an 
algorithm with CA19.9, CEA and other two carbohydrates antigens, CA72-4 and CA242, 
showed and improved diagnostic power36. 
Further promising marker are the circulating tumour cells (CTCs). It is known that tumour cells 
detach from the primary tumour into the blood stream in the early phases of progression. It 
could become a significant prognostic factor detecting the gravity of tumour stage. Until now, 
CTCs are isolated through positive selection for an epithelial cell surface marker—, epithelial 
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cell adhesion marker (EpCAM), overexpressed in cancer cells. However, when the cells 
undergo to epithelial to mesenchymal (ETM) the EpCAM expression drops and the sensitivity 
of the detection, decreases. 26,37,38. 
Nevertheless, as presented in a study of Neves et al. (2019), CTCs can also present another 
specific tumour antigen, named STn (sialylated Thomsen-nuovelle antigen) which is an 
aberrant O-glycan. It decorates glycoproteins and has been recognized to be overexpressed in 
advanced bladder and colon cancer. Using a size-based microfluidic device, they have shown 
that the majority of CTCs from blood of patients with metastatic bladder and colorectal cancers 
(>90%) are correlated with high sTn expression39.  
Tumour markers other than diagnostic and prognostic tools can be used as predictive tools. 
While with prognosis determines the overall outcome of the disease, independent of the 
treatment, the predictive marker allows to distinguish between different therapies that will be 
effective40,41. The role of the predictive biomarkers has gained importance for personalized 
treatment and targeted therapy. MSI, chromosome 18q loss of heterozygosity (18qLOH), p53, 
KRAS, BRAF, NRAS, PIK3CA mutations, PTEN expression were all studied in combination 
with Adjuvant therapy that may include chemotherapy (5-fluorouracil, oxaliplatin or 
irinotecan),radiation therapy, hormone therapy, targeted therapy (anti-VEGF or anti-EGFR: 
cetuximab, panitumumab, or bevacizumab) or biological therapy42.. 
It has been described the role of RASmut as negative predictive biomarker for anti-EGFR 
treatment, and the reduced efficiency of the therapy with RASwt/BRAFmut patients.  
BRAFmut, near always mutated in position V600E, is mostly located in the right-side colon and 
are negative prognostic for metastatic CRC (mCRC). MSI has a predictive values in immune 
checkpoint therapies1. MSI or microsatellite stability (MSS) and  the presence or absence of 
18q chromosome deletion are needed to be tested for therapies based on 5-FU32. 
However, most of the studies showed contradictory results, excluding few established cases, 
such as the role of KRAS gene in anti-EGFR therapy. Further work on function definition and 
adequate validation remains to be done (Table 2)42. 
 
 
 
 
MARKER FUNCTION MUTATION CONSEQUENCE 
COLORECTAL 
LOCATION 
PROGNOSTIC AND 
PREDICTIVE VALUE 
KRAS/NRAS 
proto-oncogene 
encodes a 
KRAS: exon 2 
(codons 12 and 13) 
or exon 3 o 
permanent 
activation of the 
RAS 
NRAS more 
present in 
the left-side 
Resistance to 
anti-EGFR 
Table 2 Genetic tumour markers original function, mutation and consequences of alterated pathway. Preferences of colon 
location and predictive potential are also listed. Data adapted from different publications, mainly the reviews of G.Zarkavelis et 
al. and M.E. Salem et al. 25,80–86. 
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GTPase protein 
(KRAS) 
NRAS: exons 2, 3 
and 4 of 
(RAS/RAF/MAPK) 
pathway 
BRAF 
encodes serine 
threonine kinase 
proteins 
8% of CRC carry the 
distinct BRAF V600E 
mutation 
direct downstream 
target of KRAS 
More 
present in 
the right 
side 
associated 
with high 
MSI 
resistance to 
BRAF inhibitors 
DNA MMR 
(mismatch 
repair) genes 
/MSI 
Microsatellites 
instability 
 MMR gene 
ability to fix DNA 
errors occurring 
during 
replication 
inactivated as a 
result of sporadic 
MLH1 promoter 
hypermethylation or 
germline mutations 
in MLH1, MSH2, 
MSH6 and PMS2 
genes 
MSI are originated 
from MMR deficient 
or proficient 
tumours and thus 
genomic instability 
Higher in 
right-side of 
the colon 
High MSI doesn’t 
benefit of 5FU 
but have better 
outcomes in 
stage II 
CpG island 
methylator 
phenotype 
(CIMP) 
CpG island are 
regions with a 
high frequency of 
CpG site (i.e., 
cytosine residues 
preceding 
guanines) 
Aberrant 
methylation of CpG 
islands 
hypermethylated 
genes, such as 
SLC5A8, ITGA4, 
SFRP2, CDKN2A, 
HLTF, and MGMT 
High in the 
right side 
associated 
with KRAS 
wt and BRAF 
mut 
Worse survival 
outcomes and 
poorer response 
to anti-EGFR 
EGFR/HER 
family EGFR 
Receptor of 
epidermal growth 
factor (EGF) that 
stimulates cell 
growth and 
differentiation 
Increased gene 
copies 
Uncontrolled cell 
growth when 
constantly activated 
Mostly Right 
sided 
HER2 could be 
responsible for 
EGFR resistant 
pathway 
TP53 
TP53 protein has 
role in cells 
growth 
arrest DNA 
repair 
 
Point mutation in 
codon 72 
Promotes malignant 
process and 
carcinogenesis 
Mostly rectal 
TP53 high 
mutation suggest 
worse survival 
APC/β-catenin 
APC 
(adenomatous 
polyposis) 
tumour 
suppressor 
protein 
promoter 
hypermethylation 
and somatic 
mutations 
Mutations of APC 
activates the Wnt 
pathway and 
inactivates  glycogen 
synthase-kinase-3β 
and β-catenin 
Mostly rectal 
APC 
hypermethylation 
for early 
diagnosis 
miRNA 
 
microRNA are 
highly stable 
structures with a 
hairpin-loop 
shape and small 
size 
Expression 
associated with 
different mutations 
of other markers 
microRNAs, play a 
key role in tumour 
suppression or 
growth 
Depends on 
miRNAs. i.e. 
miRNA146a 
and 147b 
higher in the 
left side 
1. miR-31: 
present with 
BRAFmt. potential 
predictive 
biomarker 
2. miR-99a and 
miR-125b: good 
prognosis with 
KRASwt 
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responding to 
EGFR therapies 
3. miR-181 poor 
prognosis with 
KRAS wt 
responding to 
EGFR therapies 
 4. miR-622: poor 
responders to 
radiation therapy 
in rectal cancer 
18qLOH Chromosome loci 
Loss of 
heterozygosis 
At D18S58 and 
D18S61 loci 
 
Allelic imbalance 
Distal colon, 
Left sided 
 
greater survival 
rate when 
treated with 
capecitabin 
 
PIK3CA 
 
Encodes for 
human p110α 
protein is 
encoded by 
the PIK3CA gene 
 
GLU542, GLU545, 
and HIS1047 
 
Highly oncogenic 
Decreasing 
mutation 
from right to 
left to rectal 
Implications with 
anti-EGFR 
treatment 
resistance and 
increased benefit 
from aspirin 
therapy 
PTEN 
Phosphatase and 
tensin homolog 
(PTEN) 
Is a tumor 
suppressor 
protein 
 
Mutation and 
deletion of PTEN 
Increase cell 
proliferation and 
reduce cell death 
Rectal 
tumour 
mainly but 
also right 
and left side 
Loss of 
expression may 
induce anti-EGFR 
resistance 
MYC protooncogene 
Constitutively 
expressed 
Cell proliferation Left sided 
Unfavourable 
prognostic 
WNT 
Group on signal 
pathways 
protooncogene 
Overexpression of 
WNT ligands 
Involved with ETM Left sided 
Early stages of 
carcinogenesis 
TGF- 
Transforming 
growth factor 
cytokine, stop 
cell cicle at G1 
Inhibition of TGF-
beta 
Proliferation, 
angiogenesis and 
immunosuppression 
Left sided 
TGF-beta activity 
can induce High 
risk of CRC 
relapse upon 
treatment 
 
 
7. The role of CSM classification in prognosis and 
treatment  
At the present, the only curative treatment is surgery with the R0 resection that consist of the 
complete removal of the tumour mass, to be distinguished from the R1 or R2 tumour-positive 
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residual resections43. Nevertheless, the CSM classification is becoming the most important tool 
for researchers and clinician to combine and correlate the role of the different tumour marker 
for a correct CRC prognosis and treatment. The classification takes into account the different 
outcomes of the therapies and the proper therapies are associated with the biomarker’s 
expression: ESMO guidelines have already adopted and adapted the therapies indication 
following the genetic, epigenetic and proteomic profile, associated to the different CSM 
classification1,19.  
Trinh et al.44 validated the prognostic value of CRC subtyping using five additional markers 
(CDX2, FRMD6, HTR2B, ZEB1 and KER). 
Using immunohistochemistry technique on four independent CRC patients’ cohorts, they have 
created a tool for CRC classification based on semi-quantitative pathology scoring. The CSM1 
subtype is identified by the MSI status, the CSM2/3 were selecting by CDX2 a marker highly 
expressed in epithelial-like tumour. CSM4 subtype is selected with HTR2B and FRMD6 
expressed in mesenchymal like cells.  
To confirm the ETM transition, of each subtype, the marker ZEB1 and an anti-cytokeratin 
(AE1/AE3) ware used to normalize for epithelial content. The experiment permitted to confirm 
the stratification of CRC groups and verify the therapeutic benefit for each subtype45. It was 
proven an increase of OS of epithelial like tumour KRASwt/BRAFwt patients in treatment of 
anti-EGFR (cetuximab) to a standard regimen of capecitabine, oxaliplatin and anti-VEGF 
(bevacizumab), in advanced CRC patients. Same therapy on CSM4 mesenchymal-like, with 
KRASmt/BRAFmt was not beneficial. On the down side this robust IHC classifier can be used 
more as a tool for the stratification than a prognostic or predictive marker with a missing marker 
that allows to distinguish CSM2 from CSM3 epithelial-like tumour. 
 
8. Glycosylation as the missing link  
Genomic studies and their correlation with tumour development and treatment success has 
been the major focus of the last decade. The significance of these studies in colorectal cancer 
research is undeniable in diagnosis and prognosis. However, as previously discussed, the 
heterogeneity of CRC is still responsible of misleading diagnosis. For this reason, more studies 
on tumour microenvironment have been equally in-depth, for understanding of cancer 
dynamics. The importance of epigenetic factors influencing post-translational modification 
cells mechanisms has emerged. Among these, aberrant glycosylation has shown to be highly 
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correlated with CRC phenotype and the translation from bench to clinic may results in new 
improvement not only in treatment but also in diagnosis and in discovering new 
biomarkers31,46. 
Glycosylation is one of the most common and important post-translational modification 
that involves key biology processes such as cell-cell interaction, cell growth, cell adhesion 
etc47.  
Glycosylation occurs both on proteins and  lipids: on the former, the sugar structures can be 
borne on asparagine (N-Glycans) or on serine/threonine (O-Glycans) residues while on the 
latter, the major class is recognized mostly in the glycosphingolipids class (GLS)48. Glycans 
are not encoded by the genome and their biosynthesis depends on metabolism signal 
transduction and the cellular status49. Several studies on cancer-associated glycosylation 
revealed that aberrant glycosylation is a universal feature in various steps of malignant 
transformation and tumour progression50. Aberrant glycosylation leads to dysregulation of 
essential cellular processes Additionally, it induce the novel biomarkers that can distinguish 
healthy from malignant tissue, characteristic very important in therapeutic approach51. For 
instance, the expression of the STn antigen, has been validated as promising tumour marker. 
In bladder cancer it is expressed specifically in tumour tissue and it has been reported 
overexpressed in 75% of high-grade bladder tumours presenting elevated proliferation rates 
and high risk of recurrence/progression expressed STn. Thus, targeting sTn could be the new 
valid therapy approach52. Likewise, aberrant glycosylation in CRC stages have been shown. 
General increase in N-glycan β1,6-branching, (poly-)N-acetyllactosamine extensions and 
(truncated) high-mannose has been proven, as well as, higher levels of core 1 glycans, (sialyl) 
T-antigen, (sialyl) Tn-antigen, and a generally higher density of O-glycans. Increase in 
sialylation and fucosylation results in a high expression of Lewis antigens and their sialylated 
derivates31. All these alterations can be considered a valid target for personalized therapy, being 
involved in main tumour cell functions such as tumorigenesis, metastasis, modulation of 
immunity, and resistance to antitumor therapy. 
Two are the main mechanisms involved in glycan structure changes: incomplete 
synthesis and neosynthesis48. Examples of incomplete synthesis can be attributed to the 
misregulation or silencing of glycosyltransferases and glycosidases, key enzymes responsible 
for the glycosylation processes, which occur in the formation and accumulation of aberrant O-
glycans such as SLewis X and STn(sialylated-Thomsen-nouvelle antigen)53. Neosynthesis can 
originate from altered expression of enzymes involved in the glycosylation pathways, possibly 
related to hypoxic conditions in tumors48. A normal colon mucosa presents bisecting N-
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acetylglucosamines (GlcNAc) on N-glycans as well as core 3 and core 4 O-glycans, globo-type 
glycosphingolipid (GSL) glycans, and disialylated gangliosides31. 
 Many modifications have been found and investigated throughout the stages of CRC. Lewis 
antigens and its sialylated derivatives (Lex/sLex and Lea/sLea) are the most prominent cancer-
associated epitopes on both glycoproteins and glycolipids, since overexpression is related to 
CRC malignant transformations and may lead to increased tumour cell adhesion and motility, 
thereby resulting in metastasis54. Some alterations, such as gangliosides GD3 and GM2 as well 
as the globo-type GSL Gb3 are specifically related to angiogenesis55. Many carriers, such as 
the mucin MUC1, CD44v6, and CEA have been identified carrying T- sT- 
(sialylated/Thomsen-Friedenreich (T)-antigen) and sTn-antigens (sialylated-Thomsen-
nouvelle (Tn)-antigen), tumour specific antigens31. Mucins, for instance, are major secretory 
products of the colon and are hyper glycosylated in colorectal cancer, due to the overexpression 
of the β1,3-galactosyltransferase. This aberrant glycosylation is associated with poor survival, 
cancer progression, and metastasis56.  
Nowadays, the glycoproteins carcinoembryonic antigen (CEA) and carbohydrate 
antigen sLea (CA19.9), as already mentioned, are the most widely applied serum biomarkers in 
clinics. Increased serum level of CEA or sLea indicates the presence of CRC57. Other 
biomarkers such as, highly fucosylated haptoglobin (Fuc-Hpt) are elevated in certain colorectal 
cancer patients, in relation to the proximity of the tumour to the liver and distance metastasis. 
The study of  combination of  Fuc-Hpt and CEA, has shown to be a promising  novel prognostic 
marker in colorectal cancer58. 
A different approach was adopted by Rho et al (2014). With a novel microarray paired with 
specific antibodies anti- sLex/sLea, it was possible to discover new biomarkers that can 
distinguish between stages III, IV and healthy control in CRC 59. Croce et al.(2005) have also 
investigated the 1-acid glycoprotein (AGP) which has been identified as a putative carrier of 
sLex antigen in colorectal carcinoma60. 
The role of aberrant glycosylation has shown to have an effective correlation with colorectal 
cancer cells formation and has disclosed a great potential in non-invasive biomarker discovery. 
However, a characterisation between aberrant glycosylation and cancer stages is still needed 
in order to depict the right candidates for early diagnosis. 
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9.The role of glycosylation in therapy 
 
The tumour-associated carbohydrate antigens (TACAs) are identified among the 
altered glycans expression, frequently associated with cancer results. The absence in normal 
healthy tissues, facilitates TACAs to be disease-specific immunotherapeutic targets and,  
thereby, reduce the potential risk of side effects, playing critical roles in cancer cell biology48. 
Due to this, many monoclonal antibodies (mAbs) have been and are being produced against 
these type of antigens, employing phage display and monoclonal antibodies techniques47. 
Important characteristics of mAbs are affinity, which measures the strength of interaction 
between an epitope and an antibody’s antigen binding site and the avidity, which gives a 
measure of the overall strength of an antibody-antigen complex: these two parameters are often 
exploited to selectively target tumours. IgG mAbs production is generally preferred because of 
their high affinity, but also IgMs isotype is used as a strong inducer of complement-dependent 
cytotoxicity (CDC). Antibody-dependent cell cytotoxicity (ADCC) and CDC mechanisms 
have been proved to be very important in the clinical efficacy of antiganglioside mAbs48. 
  Sterner et al. (2016) generated a database for Anti-Glycan Reagent (DAGR) where 
currently, 1120 unique monoclonal antibody entries have been classified61. Many mAbs have 
been produced for Lewis antigen detection, in particular of Lewisy (Ley). They have been 
created with different degrees of specificity and cross reaction with other closely related Lewis 
antigens and tested either alone or as a targeting agent coupled to a toxin or drugs62. 
 Among these are BR96, a mouse or chimeric human anti-Ley/x and B3, a mouse anti-Ley mAb: 
the former has been studied coupled either to toxins or chemotherapeutic agents, while the 
latter has been tested coupled to Pseudomonas aeruginosa exotoxin A. BR96 resulted as a 
powerful immunoconjugate with high efficiency in CRC xenograft studies63. Also B3, showed 
significant clinical activity, with responses in colon cancer64. Durrant et al. (2006) produced 
SC104, a mouse IgG1 that recognizes sialyltetraosylceramide, that can cause tumour cell death 
by ADCC, CDC and apoptosis. In vivo, it induced potent tumour rejection in colorectal 
xenograft models65. Other two mAbs anti sLea (5B1, IgG1 and 7E3, IgM) kill target cells by 
CDC and/or ADCC, thereby prolonging the survival of mice in a colorectal xenograft model66. 
 RAV12, a chimeric IgG1 mAb which recognize a sugar, RAAG12, overexpressed on 
adenocarcinomas of colorectal has been taken into account as a targeting approach. RAV12 
has demonstrated to be cytotoxic in vitro against the colorectal cell line COLO205 and induced 
antitumor activity in vivo in athymic mice bearing human colon67.  
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Other immune-conjugates have been created against protein biomarkers in CRC 
investigation. For instance PR1A3, a humanized IgG1 mAb anti-CEA linked to the 
immunotoxin n-succinimidyl-3-(2-pyridyldithio)-propionate was demonstrated to be equally 
effective in the treatment of CRC68. Edrecolomab, is a murine monoclonal antibody against 
EpCAM, which is a pan-epithelial differentiation antigen that is expressed in 90% of CRC 
cases. It is considered to be a potential alternative of 5-FU-based chemotherapy  as it shows 
quantitative expression differences between normal and cancerous tissues in CRC69. CD24 is 
also expressed in ~ 90% of colorectal adenomas and adenocarcinomas, and  anti-CD24 mAb 
(SWA11)  has been not-covalently linked to the immunotoxin ZZ-PE38; this immunoconjugate 
showed improved cytotoxity in vitro70. 
Loureiro et al. (2018) developed a monoclonal antibody against sTn-antigen, by 
hybridoma technique. The antibody, named LA25, has shown high affinity and specificity anti-
sTn and additional ability to bind 2–6-linked sialyl core-1 probes. This shows its great potential 
as therapeutic and diagnostic tool in clinics, being sTn a cancer specific aberrant glycan 71. 
Conventional mAbs however can be recognized as ‘non-self’ molecules by the immune 
system and can be carrier of risk of immune reactions such as acute anaphylaxis and serum 
sickness. Hence, in order to minimize the possibility of these events, antibody technology 
researcher have generated single-chain variable fragments: these engineered antibodies 
conserve the function of the variable part (Fv) but lack the constant  Fc region, that is 
considered to be highly immunogenic72. Lutterbuese et al. (2009), have constructed a series of 
bispecific single-chain antibodies (bscAb) that combine various single-chain variable 
fragments, recognizing human CEA and human CD3, a T-cell co-receptor that helps to activate 
the cytotoxic T-Cell. Treatment with CEA/CD3-bscAbs showed human T cell killings of 
tumour and prevented the growth of human CRC cell lines in a severe combined 
immunodeficiency mouse73.  
In this contest, existing monoclonal antibodies gained attention for the production of bscAb, 
where the bi-specificity can be directed simultaneously against both protein biomarkers, such 
as CEA and TACAs.  
10. Glycosylation and new therapies 
The urge for innovative treatments has led many research groups to investigate new 
ways to exploit aberrant glycosylation in cancer. 
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A promising approach is the carbohydrate-based anticancer vaccine, which have been 
ongoing under clinical trials. The idea is based on breaking the immune self-tolerance for 
tumour associate glycans, since many aberrant glycans are recognized as ‘self’ molecules: the 
rare immunogenicity is due to the presence in embryonic tissues or low expression levels in 
normal tissues74. The anticancer vaccines link multiple copies of the aberrant glycan to the 
immunogenic carrier protein keyhole limpet hemocyanin (KLH)74. Theratone, a phase III 
KLH-STn conjugate, tested in metastatic breast cancer has shown to increase the OS of the 
patients if injected with hormone therapy.  However, this vaccine fails in its efficacy when 
administered alone as it fails to activate T-cell-mediated immune response 75. 
Further studies have tried to mimic the cell surface to stimulate B-cell and T-cell-mediate 
immune responses. A tri-genic vaccine containing globo H, Ley and Tn was produced from 
Danieshefky et al. (2000) and showed to recruit the T-cell help against each of the aberrant 
glycan76. Finally, higher immunogenic vaccines have been produced by incorporating 
chemically modified sialic acid residues with unnatural N-acyl side chains51 into KLH 
conjugates. 
Esko et al.(2005) proposed to use decoys as anti-metastatic drugs though metabolic 
inhibition of sLex in metastasis77. In a parallel, Shirota et al. investigated the GSC-150 an 
analogue of sLex that binds to selectin, adhesion receptors which promote interactions of 
tumour cells with host platelets, leukocytes and endothelial cells. The data suggested that the 
sLex –selectin interaction is a contributing factor to metastasis with selectin inhibitors having 
a potential role in  cancer treatment78. In addition to this theory the clinically approved 
anticoagulant drug heparin as a selectin inhibitor, resulted in the suppression of tumour 
metastasis in experimental animal models and has shown beneficial effects in human clinical 
trials of colon cancer79. 
Posey et al. (2016) used genetically modified T cells that express chimeric antigen 
receptor (CARs) targeting cancer-associated Tn glycoform of MUC1. The CARs displayed 
target-specific cytotoxicity and could successfully control tumour growth in xenografts models 
of T cell leukaemia and pancreatic cancer80. 
Finally, important developments have been made in the field of nano-glycomics. For 
instance, glyconanoparticles (GNP) have been designed to mimic the carbohydrates present in 
target cells. These glyco-decoy control the biological adhesion processes and competing with 
interactions at the host cell surface. Nanoparticles (NPs) could be functionalized to deliver 
glycan-based galectin inhibitors or glycan ligands to sites of tumour growth, as already shown 
in pancreatic cancer tissue81.  
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Danhier et al.(2015) have performed local administration of chitosan lipid Nano capsules 
(LNCs) containing the anti-epidermal growth factor receptor (EGFR) and anti-GAL-1 siRNAs, 
which prolonged survival of nude mice bearing orthotropic U87MG glioblastoma cells82. 
11.  Conclusion  
In the last 10 years, many advances have been made in CRC research and many new 
technologies have been developed helping the clinics to increase the average of the overall 
survival of CRC and mCRC patients. High cancer heterogeneity makes the progression towards 
a personalized treatment more difficult. Early diagnosis can improve the OS of CRC patients 
but the absence of symptoms and of specific early stages liquid biomarkers leads to late 
detection. Most of the screening program proposed did not result correlated with overall 5 years 
of survival, suggesting the urge to improve the existing program with different and more 
specific test. Moreover, in the last 30 years the clinical trials have been focused to find the most 
effective treatment, but few efforts have been put in looking for new early diagnostic methods. 
Genetic biomarkers have been studied in order to understand their role as diagnostic, 
prognostic and predictive biomarkers. Except for some established cases such as such the role 
of KRAS in anti-EGFR therapies, further validation of other biomarkers has to be improved. 
The classification of the sub molecular consensus type (CSM) in colorectal cancer, contributed 
to the understanding of cancer heterogeneity by considering other aspects of host-tumour 
interaction, i.e. the immune system. Besides the DNA- and Protein-based therapies, also post-
translational modifications, such as glycosylation, has been proven to play a crucial role in 
tumour microenvironment and for this, it has been investigated. Aberrant glycans expressed 
mainly on protein surfaces suggested high potential as diagnostic tool in liquid biopsy; the 
same targets could be exploited in future targeted therapies.  
Antibodies and related products are the fastest growing class of therapeutic agents. 
Monoclonal and bispecific short fragments antibodies have been demonstrated to have 
promising effects in specific cancer cytotoxicity. However, the presence of side effects requires 
new ideas to combine functionality of monoclonal antibodies, epitopes and stealth ‘self’ 
molecular behaviour. As alternative techniques cancer-based vaccines and CAR-T cells have 
been proposed and studied. 
In conclusion, colorectal cancer still remains the second deadliest kind of cancer and although 
the many steps forward made in understanding cancer heterogeneity and improving 
personalized treatment, it is still missing a focus on early diagnosis. The field of glycobiology 
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appears interesting for the creation of new therapeutic and diagnostic target, where the 
challenge is the understanding of the biological context of the glycoprotein and glycolipid 
targets on cancer cells.  
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 Colorectal cancer (CRC) is considered the second deathliest cancer-type and one of the 
most common human malignant diseases. Due to its localization in the body, it is still very 
difficult to be detected in the early stages and it is essential to develop new sensitive, low cost, 
minimally invasive and accurate test to improve CRC early detection, prognosis and treatment 
(1).  
Several studies revealed that aberrant glycosylation is a universal feature in various steps of 
malignant transformation and tumour progression (2). Among all the tumoral glycans, the 
Lewis antigens, the Tn antigens and their sialylated derivates are probably the most prominent 
cancer-associated epitopes in CRC, since their overexpression is related to malignant 
transformations and may lead to increased tumour cell adhesion and motility and, thereby, 
result in metastasis (3).  
 This project aims to the development of novel antibodies against -CRC associated 
glycans, for improve of CRC detection. To achieve this, an initial validation of glycans and 
candidate protein scaffolding the glycans has been performed using existing antibodies. 
Secondly, protein extracts enriched from CRC cell lines expressing the identified 
glycan/protein were used in immunization schedule to develop novel antibodies, which are 
now being characterized for their fine specificity. 
Three main screening methods have been adopted in order to look for new CRC biomarkers: 
flowcytometry, western blot and immunohistochemistry. All the screenings have been 
conducted in comparison with a panel of different existing antibodies mainly against Sialyl 
Lewis antigens and glycoproteins. 
  As a result of the screening, using existing antibodies, CD44 and Sialyl Lewisx/a have 
been selected has potential antigens for new antibodies productions. We then immunized mice 
with protein extracts of cancer cell line LS174T high in sLewis antigens or with CD44 
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immunoprecipitated from cell lysate of HT29 transfected with FUT6, responsible for sLewisx 
expression increase. Following immunization and hybridoma technology, different hybridoma 
clones were tested for production of antibodies against, Slewis and/or CD44, The first 
hybridomas show reactivity against CRC total lysates, CRC live cells and protein rich in O-
glycan such as bovine serum mucin, further screening are ongoing. 
The selected clones will be tested on a cohort of 300 tissues of CRC patient, comprehensive of 
all the different stages of the cancer and finally tested in vivo experiment, in order to see they 
interaction with colon cancer cells in the microenvironment of xenograft mice. 
 Antibody/ies produced will be expected to help improving the clinical diagnosis and prognosis 
of CRC, with a high potential to be used also as treatment tools.   
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Cancer is one of the most prevalent diseases worldwide and its metastasization is a major cause 
of cancer related deaths.  
Some carbohydrates attached to proteins or lipids, i.e. glycans, are aberrantly expressed in 
cancer cells and this altered glycosylation pattern is highly associated with cancer malignancy 
and tumour progression what makes them promising candidates as novel cancer biomarkers 
and therapeutic targets. Overexpression of certain glycosyltransferases (e.g. sialyltransferase 
and fucosyltransferases) is the main mechanism behind tumour associated glycans(1). Our 
group is especially interested in the role of sTn, Tn, sLex, sLea and Ley antigens as cancer 
specific glycans, with absent or minimal expression in normal cells (2). 
Colorectal cancer (CRC) is the second most common cancer type and it is also correlated with 
an altered glycosylation pattern. Although this correlation is well known, none of the proposed 
glycan biomarkers has already reached clinical application. This can be ascribed to the scarce 
understanding of the molecular mechanisms and the lack of relevant in vitro and in vivo models 
to address them. 
Therefore, the main goal of this study is to establish experimental models based on CRC cell 
lines expressing altered glycans and to evaluate their behaviour in vitro and in vivo. 
To assess it, we analysed CRC cell lines, SW48, SW948, SW620 and HT29 that express 
relevant glycans and that were previously transfected and transduced with sialyl and 
fucosyltransferases, the ST6GalI responsible for increased alpha 2-6 sialylation, and FUT VI 
responsible for increased sialyl Lewis X/A/Y expression. These cell lines were genetically 
modified to express luciferase (luc) gene as a tracking mechanism by bioluminescence.  
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After a successful transduction with pLenti6/V5 directional TOPOvector containing the luc 
gene and an antibiotic selection, the luciferase expression was tested by bioluminescence and 
the cell lines were characterized in terms of glycosylation profiles, comparing them with their 
negative controls, MOCK cell lines, once previous studies showed that it’s no differences 
between MOCK and WT. 
At present, we are analysing tumour growth of the newly transduced cells lines. In the future 
progression and metastasis formation in animal models, will be also assessed. 
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